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INTRODUCTION
The liver is a unique multifunctional organ, historically known for its exceptional 
regenerative capacity. The liver is strategically located regarding nutrient processing and 
detoxification, receiving blood from the portal venous system, which include veins from 
the intestinal tract, spleen, pancreas, and gall bladder. This allows the liver to function 
in the storage and metabolism of nutrients, the synthesis of plasma proteins, and the 
clearance of endogenous and exogenous molecules entering the human body.(1) 
 In advanced chronic liver disease, characterized by extensive nodular scarring (cirrhosis) 
and loss of functional cell mass, liver function and the regenerative capacity become 
progressively impaired. During the natural course several stages can be distinguished. 
In the first stage – compensated advanced liver disease – patients are clinically often 
asymptomatic and have an excellent prognosis with a 1-year mortality of 1.0 – 3.4%.
(2) Transition into the second stage – decompensated advanced liver disease – occurs 
reportedly at an annual rate of 20 – 57%.(2) In this stage numerous complications involving 
all organ systems may develop, the most frequent being ascites, variceal bleeding, hepatic 
encephalopathy, infections, renal failure, pulmonary hypertension, hepato-pulmonary 
syndrome, and malnutrition. This thesis focuses on patients with this stage of disease, i.e. 
decompensated advanced chronic liver disease.
Aetiology
The most common causes of advanced liver disease include excess alcohol intake, 
viral hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, autoimmune 
hepatitis, non alcoholic steatohepatitis, and exposure to toxins including medication.(1, 
3, 4) Although liver disease may originate from a single cause, the disease is often caused 
by interacting causes and influenced by coexistent factors. The presence of potential 
cofactors, such as advanced age, male gender, obesity, high daily alcohol consumption, 
smoking, altered immunological status and genetic factors, could explain why certain 
individuals are more at risk to develop advanced chronic liver disease.(1, 5)
Pathophysiology
Many complications of advanced chronic liver disease are due to the development of 
portal hypertension.(6) Portal hypertension is most often caused by cirrhosis, but can 
have non-cirrhotic causes such as portal venous thrombosis, congenital liver fibrosis and 
nodular regenerative hyperplasia, however these aetiologies are outside the scope of 
this thesis.(7) Portal hypertension is defined by a sustained increase of the pressure in 
the portal venous system. According to the hemodynamic application of Ohm’s law of 
fluid (ΔP = Q x R), the venous pressure gradient in the portal system (ΔP) is the result 
of blood flow volume (Q) multiplied by the resistance opposing this blood flow (R).(8) 
In advanced liver disease, intrahepatic mechanical and dynamic changes increase blood 
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flow resistance, resulting in an increased portal venous pressure. Examples of mechanical 
changes include anatomical distortion of the liver by fibrosis and nodule formation, and 
vascular occlusion by thrombosis; dynamic changes include an increased hepatic vascular 
tone and sinusoidal endothelial dysfunction. When portal pressure is increased above a 
hepatic venous pressure gradient of 10 mmHg, vascular pathways bypassing the liver may 
develop, a mechanism that can be regarded as a natural adaptation to increased portal 
resistance and pressure. Part of these portosystemic collateral vessels develop superficially 
in the gastrointestinal tract, in particular near the gastro-esophageal junction and in 
the distal rectum, where anatomic communications between the portal and systemic 
venous circulation are pre-existent or may easily develop, and are called varices.(1, 9, 10) 
As a response to a diminished blood flow to the liver due to the collateral circulation, 
endogenous vasodilators (such as nitric oxide and calcitonin gene-related peptide) induce 
vasodilatation of the splanchnic vasculature. Leakage of these vasodilators to the systemic 
circulation, due to portosystemic shunting or reduced degradation in hepatocytes, is 
considered to be the cause of a decrease in systemic vascular resistance, characterized by 
a reduced effective arterial blood pressure and volume. In response the renin-angiotensin-
aldosterone system is activated, resulting initially in an increase in cardiac output, heart 
rate, and plasma volume, resulting in sodium and water retention. This phenomenon is 
named ‘hyperkinetic or hyperdynamic circulation’ and results in an increased splanchnic 
blood flow contributing and further aggravating portal hypertension in a vicious circle.(9)
Complications of advanced chronic liver disease
Patients with advanced chronic liver disease are susceptible to develop any of the many 
potential complications, such as ascites, variceal bleeding, hepatic encephalopathy, 
bacterial infections, jaundice, hepatorenal syndrome, hyponatriaemia, hepatopulmonary 
syndrome, hepatic hydrothorax, malnutrition and cardiac failure.(1, 11) In most patients 
multiple complications occur that may manifest simultaneously or subsequently.(12) 
Further, complications often develop secondary to other complications, e,g, spontaneous 
bacterial peritonitis, hepatic hydrothorax and umbilical hernias may complicate ascites 
and variceal hemorrhage may precipitate encephalopathy and renal failure. 
Ascites and spontaneous bacterial peritonitis
Ascites, an accumulation of free fluid in the peritoneal cavity, is the most frequent 
first decompensating event in patients with advanced liver disease. Sinusoidal portal 
hypertension leads to fluid effusion from the vessels into the peritoneum. Due to the 
hyperkinetic circulation, splanchnic dilatation and renal sodium and water retention, the 
intravascular volume is expanded allowing the maintenance of ascites formation.(13) The 
prognosis of ascites formation is co-dependent on the development of ascites infection, 
denoted as spontaneous bacterial peritonitis (SBP), by definition an infection developing 
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in the absence of an intra-abdominal source such as appendicitis or visceral perforation.
(14) The most common theory implicates that bacterial colonization of ascites is caused 
due to gut bacteria migration through the intestinal wall into the lymph system/systemic 
circulation or secondary translocation from a concomitant infection from extra-intestinal 
sites (e.g. urogenital or respiratory tract). In addition, in cirrhosis several abnormalities 
in the systemic immune system have been described, decreasing the opsonisation and 
killing of translocated bacteria.(14) The prognosis of SBP is poor with a mortality as high 
as 29% during the first month after hospital admission.(15)
 Bacterascites is a different clinical entity than SBP, characterized by the presence of 
bacteria without a neutrophil reaction.(16) Its clinical significance seems to vary according 
to the mode of acquirement and the presence of clinical symptoms.(17, 18) Ascites is 
also associated with other complications, in particular hepatic hydrothorax and inguinal, 
umbilical and cicatricial hernias.(19, 20)
Development of varices and variceal bleeding
Collateral/variceal formation starts due to increased portal pressure at sites with pre-
existing communicative vessels between the portal and systemic circulation.(10) These 
small calibre vessels are functionally of no or minor importance in healthy conditions, but 
open up in portal hypertension. Varices are superficially located porto-systemic collaterals 
that develop mainly in the distal oesophagus, at the gastro-esophageal junction and in 
the distal rectum. Varices may rupture and cause life-threatening bleeding. Approximately 
5% of bleedings originate from varices outside the gastro-oesophageal junction area and 
these varices are referred to as ectopic.(21) Ectopic varices may develop anywhere along 
the gastrointestinal tract and around enterocutaneous stomas, but can also be present in 
the biliary system, pelvic organs, peritoneum and skin. Abdominal and pelvic surgery is a 
main risk factor for the development of ectopic varices in patients with portal hypertension 
because postoperative adhesions and the creation of entero- and ureterostomies 
facilitates the formation of portosystemic collaterals.(21) The risk for rupture of varices is 
dependent on the size of varices, the severity of liver disease and local abnormalities of 
the variceal wall known as ‘’red spots’’.(22) The bleeding risk has been reported to range 
from 5 – 76% per year.(23) Variceal bleeding is associated with an increased mortality up 
to 20% within 6 weeks.(24)
Hepatic encephalopathy
Hepatic encephalopathy refers to a complex of neuropsychiatric changes in personality, 
intellectual capacity, cognitive function, and consciousness, due to advanced liver disease.
(25) The clinical spectrum varies from non-manifest or very subtle psychological changes 
that may only become apparent during specific testing, to marked changes in behaviour, 
lethargy and coma. Patients become more susceptible for hepatic encephalopathy 
with increasing age. The most accepted theory of pathogenesis implies that impaired 
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hepatocellular metabolism and porto-systemic shunting cause an increased systemic 
level of gut-derived toxins effecting brain function.(26) Ammonia has been identified as 
the most important toxin causing cerebral edema. Hepatic encephalopathy is frequently 
provoked by causes such as infections, gastrointestinal bleeding, constipation and 
use of diuretics or psychoactive drugs, and correction of the underlying cause may be 
curative.(27) However, this complication may also occur spontaneously, i.e. without clear 
precipitating factors and constitute a chronic condition. Hepatic encephalopathy heralds 
a poor prognosis, in particular when symptoms occur spontaneously or have a chronic 
character.(1) 
 The medical management of hepatic encephalopathy primarily involves the treatment 
of underlying conditions and correction of precipitating factors, such as gastrointestinal 
bleeding, dehydration, electrolyte disturbances, infections, obstipation, use of diuretics 
and sedative drugs. Since many decades lactulose and lactitol are the main drug treatment 
options. More recently rifaximin is also shown to have important therapeutic potential.(28) 
This drug is currently used as a second line treatment, in particular when symptoms recur 
or persist despite lactulose treatment. 
Malnutrition 
Malnutrition is common in advanced chronic liver disease, affecting more than 
60% of patients, and refers in this context to undernutrition.(29, 30) The condition is 
multifactorial and the main pathophysiologic mechanisms include: inadequate dietary 
intake (due to loss of appetite or early satiety), impaired digestion and absorption 
(related to portal hypertension or bacterial overgrowth), metabolic alterations (impaired 
glucose storage as glycogen, increased lipid turnover), and hypermetabolism due to 
chronic inflammation.(31)
 Malnutrition is diagnosed based on the presence of sarcopenia, characterized by a loss 
of muscle mass, decreased muscle strength, and reduced physical performance. Although 
various methodologies exist to assess sarcopenia, detection of muscle mass depletion on 
CT is currently considered to be the gold standard.(1, 30, 32)
 Although malnutrition is a consequence of liver disease and the severity of malnutrition 
is correlated to the stage of liver disease, malnutrition itself can affect the natural course 
of liver disease and independently worsen prognosis.(33) Studies have shown that 
malnutrition is associated with increased waiting list mortality and reduced post-transplant 
survival and overall survival.(32) Malnutrition is also associated with a higher risk for 
developing complications such as hepatic encephalopathy and bacterial infections.(29)
Medical treatment 
Treatment in advanced liver disease aims to prevent further decompensation and 
death and is primarily based on treatment of the underlying liver disease. Examples 
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include alcohol abstention in alcoholic liver cirrhosis, antiviral therapy in viral hepatitis, 
ursodeoxycholic acid in primary biliary cholangitis, immunosuppression in autoimmune 
hepatitis, weight loss in non alcoholic steatohepatitis, and ceasing chemical or medication 
exposure in toxic liver disease. Avoidance of (further) decompensation is often based on 
treatment of the pathophysiological mechanism: increased portal sinusoidal pressure 
(transjugular intrahepatic port-systemic shunt placement (TIPS); liver transplantation), 
collateral formation/bleeding (non-selective beta-blockers; endoscopic variceal band 
ligation; variceal obliteration with tissue adhesives; balloon-occluded retrograde 
transvenous obliteration), hyperkinetic circulation (sodium restricted diet; diuretics; 
terlipressin; somatostatin; albumin), hyperammonemia (lactulose; rifaximin), and bacterial 
translocation/infection (antibiotic therapy).(1)
 However, the abovementioned medical interventions are also accompanied by 
complications, for example in patients using long-term antibiotic treatment for the 
secondary prevention of spontaneous bacterial peritonitis an antibiotic-resistant 
bacterial flora may emerge, and diuretic therapy and TIPS are significant risk factors for 
hepatic encephalopathy. In this population with patients being in precarious equilibrium, 
the ‘primum non nocere’-principle (translated from Latin to ‘First, do no harm’) should be 
conscientiously kept in mind. Thus, the indication of medical interventions should be 
carefully weighed against the potential complications of treatment.
Liver transplantation
Liver transplantation is a life-saving, highly invasive procedure for patients with progressive 
irreversible liver injury.(1, 34, 35) However, liver transplantation is limited by the scarcity 
of suitable donor organs resulting in a waiting list mortality of approximately 20%.(36)
 Patients undergo an extensive liver transplantation screening including evaluation of 
the liver disease, surgical suitability, anaesthetic suitability, presence of infectious diseases, 
presence of malignant diseases, mental health condition, and nutritional condition. To 
this end, the indication and suitability for liver transplantation can be determined, contra-
indications for transplantation can be excluded (e.g. uncorrectable cardiopulmonary 
disease, ongoing extra-hepatic infection, metastatic malignancy, and severe brain 
damage) and management of the liver disease and complications can be optimized.(34)
 Overall 1 and 5 year survival rates after liver transplantation are approximately 90% 
and 70%, respectively, and are mainly influenced by graft dysfunction, rejection, infection, 
and co-morbidities.(4)
AIM OF THE STUDIES IN THIS THESIS
In patients with severely advanced liver disease, we studied clinical, diagnostic and 
therapeutic aspects of frequent complications, including spontaneous bacterial peritonitis, 
bacterascites, other infections, (ectopic) variceal bleeding, hepatic encephalopathy and 
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malnutrition, with the general aim to evaluate current and new diagnostic and therapeutic 
strategies and with the ultimate aim to optimize patient management. 
More specifically the highly prevalent problem of infections in advanced liver disease 
was addressed by studying diagnostic methods, microbiological characteristics and 
therapeutic aspects of spontaneous bacterial peritonitis and bacterascites, and the 
impact of infections in patients with most severely advanced disease, i.e. patients listed 
for liver transplantation.
 In addition to studying infectious problems in candidate patients for transplantation, 
we performed an in depth study of the value of screening colonoscopy, a standard but 
invasive procedure potentially associated with an increased risk for complications, such 
as infections, in this vulnerable population. In this population we also studied diagnostic 
and prognostic aspects of malnutrition, a frequent and important feature of advanced 
liver disease, and evaluated the validity of a recent international guideline in a well-
characterized Rotterdam cohort.
 While the efficacy of TIPS has been widely studied in gastro-esophageal variceal 
bleeding, relatively few and only small studies have been performed in patients with 
bleeding form ectopic varices. We studied the efficacy and safety of TIPS in ectopic variceal 
bleeding in a multicentre cohort, in particular to assess potential differences between 
subtypes of ectopic varices. 
 Finally, aspects related to the recent introduction of rifaximin to prevent recurrent 
overt hepatic encephalopathy were studied in a population in our hospital.
In Part II, clinical, diagnostic, microbiological and therapeutic aspects of ascites, ascitic 
infections, and other common infections complicating end-stage liver disease are 
considered. Chapter 2 discusses the current recommended diagnostic approach in 
patients presenting with ascites and summarizes potential future diagnostic targets. 
Chapter 3 reports a prospective study of the diagnostic accuracy of leucocyte esterase 
reagent strips for detection of spontaneous bacterial peritonitis. In Chapter 4, the 
causative microorganisms of spontaneous bacterial peritonitis over a decade were studied 
in order to detect potential changes in the causative pathogens and antibiotic sensitivity. 
Chapter 5 contains a study on bacterascites, a not infrequent but relatively little studied 
clinical entity, in particular to assess clinical and microbiological characteristics and put 
our findings in perspective with current general guidelines. In Chapter 6, the results are 
described of a study examining the frequency and clinical impact of infections in patients 
listed for liver transplantation.
In Part III of this thesis, findings and implications of diagnostic assessments during 
liver transplantation screening are discussed. In Chapters 7 and 8 the yield and safety 
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of screening colonoscopy in patients evaluated for liver transplantation are reported. 
The studies report the prevalence of advanced colorectal neoplasms and compare the 
incidence of clinical events after colonoscopy with the standard risk in patients with 
advanced chronic liver disease in an effort to make a recommendation to optimize 
colorectal cancer screening in this population. Chapter 9 include a study describing the 
frequency of malnutrition in patients screened for liver transplantation, evaluated by 
different tools, and show the impact on clinical outcome.
Part IV includes studies evaluating treatment of ectopic variceal bleeding and hepatic 
encephalopathy. In Chapter 10 we report the results of a study evaluating the long-term 
control of bleeding and clinical course in subgroups of patients with ectopic variceal 
bleeding treated with TIPS. In Chapter 11, the addition of rifaximin to lactulose treatment 
in the secondary prevention of hepatic encephalopathy was evaluated by studying the 
effect on hospital resource use and safety.
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ASCITES AND INFECTIONS
Part II

CHAPTER 2
The diagnostic work-up in patients with 
ascites: current guidelines and future 
prospects
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ABSTRACT
Accumulation of fluid in the peritoneal cavity - ascites - is commonly encountered 
in clinical practice. Ascites can originate from hepatic, malignant, cardiac, renal, and 
infectious diseases. This review discusses the current recommended diagnostic approach 
towards the patient with ascites and summarizes future diagnostic targets.
The diagnostic work-up in patients with ascites: current guidelines and future prospects
27
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INTRODUCTION
Ascites is a pathologic accumulation of fluid in the peritoneal cavity. It is a symptom of 
numerous medical conditions and has a broad differential diagnosis.(Table 1) Ascites 
can be classified by the underlying pathophysiologic mechanism: portal hypertension, 
peritoneal disease, hypoalbuminaemia and miscellaneous disorders. Liver cirrhosis (75%) 
is the most common cause in adults in the Western world, followed by malignancy (10%), 
heart failure (3%), tuberculosis (2%), and pancreatitis (1%).(1) An adequate diagnosis is 
necessary for successful treatment.
 Ascites can be classified as: mild ascites only detectable by ultrasound (grade 1), 
moderate ascites evident by moderate symmetrical distension of the abdomen (grade 2), 
and large or gross ascites with marked abdominal distension (grade 3). 
 Ascites is a common problem and patients present to a broad range of medical 
specialties. This review aims to provide a comprehensive overview of the current diagnostic 
approach of ascites and also discusses recent developments in ascites research.
Table 1. Differential diagnosis of ascites.
Portal hypertension
    Cirrhosis
    Alcoholic hepatitis
    Hepatic congestion
        Congestive cardiac failure
        Constrictive pericarditis
        Hepatic venous outflow obstruction (hepatic vein thrombosis, sinusoidal obstruction    
        syndrome)
    Portal vein thrombosis 
    Non-cirrhotic portal hypertension
Malignancy
    Peritoneal carcinomatosis
    Hepatocellular carcinoma
    Mesothelioma
    Metastatic liver disease
    Other intra-abdominal malignancies
Infectious
    Spontaneous bacterial peritonitis
    Secondary bacterial peritonitis 
    Tuberculous peritonitis
    Chlamydia
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Table 1. Differential diagnosis of ascites. (continued)
Miscellaneous
    Pancreatitis
    Hypoalbuminaemia
    Nephrotic syndrome
    Lymphatic leakage
    Myxedema 
    Urinary leakage
Diagnosis
History
Patients with ascites should be questioned about a pattern of body weight gain, change 
in abdominal girth, and ankle oedema. Information about the medical history, medication 
use, lifestyle, risk factors for liver disease, and infectious disease risk (e.g. migration) are 
relevant to discover the underlying aetiology.
Physical examination
A screening physical exam should be carried out in every patient, with awareness on signs 
of liver disease (erythema palmare, spider naevi, splenomegaly), heart failure (peripheral 
oedema, jugular venous distension, third heart sound, pulmonary rales) and malignancy 
(lymphadenopathy).(2)
 The abdomen should be inspected for the presence of bulging flanks and percussion 
can reveal flank dullness. Flank dullness is present when approximately 1500 mL of ascites 
is present. These combined findings have a sensitivity of 75% and a specificity of 
57%.(3) Shifting dullness, determined by a 3 cm flank dullness shift when the patient 
changes between a supine to a lateral decubitus position, has a sensitivity of 69% 
and a specificity of 69%. Detection of a fluid wave or puddle sign is less reliable.(3,4) 
Complications accompanying ascites such as umbilical, inguinal and other hernias and 
pleural fluid (hepatic hydrothorax) are particularly common in cirrhotic patients. 
Blood tests 
It is recommended to assess serum levels of creatinine, urea, electrolytes, prothrombin 
time and liver function tests and to order a complete blood cell count.(5)
Abdominal ultrasound
Abdominal ultrasound is the first-line imaging method to confirm the presence and 
quantity of ascites.(5-7) Additionally ultrasound can provide crucial information about the 
cause of ascites, detect signs of portal hypertension (splenomegaly and portosystemic 
collaterals), and offer guidance during paracentesis.
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Abdominal paracentesis
Abdominal paracentesis is the most important step in the diagnostic work-up. It is 
indicated in every patient with new-onset ascites, patients with known ascites and clinical 
deterioration or a new presentation at an emergency department. Paracentesis is usually 
performed in the left lower quadrant, 3 cm cranial and 3 cm medial from the anterior 
superior iliac spine. Other sites include the right lower quadrant and the midline linea 
alba between the umbilicus and the pubic bone.(7) Paracentesis should be performed 
under sterile conditions. Complications occur infrequently and include abdominal wall 
hematoma (1%), hemoperitoneum (<0.1%), bowel perforation (<0.1%), and infection 
(<0.1%).(7, 8)
Ascitic fluid analysis
Visual inspection 
Visual inspection of the ascitic fluid can show a milky, cloudy, bloody, straw coloured 
or clear appearance.(Figure 1) Milky ascites suggests the presence of chylomicrons, 
containing predominantly triglycerides, and is therefore called chylous ascites. Chylous 
ascites can be caused by malignancy, (iatrogenic) trauma, liver cirrhosis, infection, 
pancreatitis, congenital disease and more uncommon causes.(9) Cloudy ascites, also 
known as pseudochylous ascites, may indicate peritonitis, pancreatitis or a perforated 
bowel. Bloody ascites is often associated with malignancies or result from traumatic 
paracentesis, whereas straw coloured or clear ascites is common in liver cirrhosis.(10) 
The first impression of the appearance of ascites is non-specific, but can steer the 
direction of diagnosis.
Figure 1. Appearance of ascitic fluid.
 
A: straw coloured ascites in a patient with micronodular liver cirrhosis. B: chylous ascites in 
a patient with lymph vessel obstruction caused by a small bowel neuroendocrine tumour.
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Biochemical testing
Serum-ascites albumin gradient
The serum-ascites albumin gradient (SAAG) is the most sensitive marker to distinguish 
between ascites due to portal hypertension/hepatic congestion and other causes, with an 
accuracy of 97%.(11) The SAAG is obtained by subtracting the ascitic fluid albumin level 
from the serum albumin level, both measured at the same time. A value equal or greater 
than 1.1 g/dL (or 11 g/L) indicates underlying portal hypertension or hepatic congestion; 
a value smaller than 1.1 g/dL indicates aetiologies not due to portal hypertension, such as 
malignancy, pancreatitis or infection.(6, 11) 
Total protein
Current international guidelines still recommend measuring the total protein 
concentration in ascites.(5-7) Traditionally, this was thought to indicate the aetiology of 
ascites according to the transudate-exudate concept, but this approach is now generally 
considered inferior. The total protein concentration does have prognostic value as 
concentrations smaller than 15 g/L are associated with an increased risk for spontaneous 
bacterial peritonitis (SBP) in cirrhotic patients.
Amylase
The amylase concentration in ascitic fluid should be measured in particular when 
pancreatic disease is considered. Pancreatic ascites can be caused by leakage from 
pancreatic pseudocysts or due to pancreatic duct rupture. An amylase ascitic fluid/blood 
serum concentration ratio of 6.0 is indicative for pancreatic disease, considering that a 
ratio of 0.4 is normal in non-pancreatic ascites.(12) However, high-levels of amylase have 
also been detected in patients with malignancy and other conditions making it a rather 
non-specific finding. Still it can be of significant value in patients with comorbidities such 
as alcoholic cirrhosis and pancreatitis.(13) 
Triglycerides
A concentration of triglycerides in the ascitic fluid that exceeds the blood serum level (2.2 
mmol/L) indicates chylous ascites. Previous abdominal surgery, pancreatitis, trauma and 
(retro-peritoneal) lymphoma are among the main causes.(9) Malignancy is diagnosed in 
80% of patients with chylous ascites, however, it must be noted that ascites in up to 6% of 
cirrhotic patients has a chylous character.(14) 
Adenosine deaminase activity
Adenosine deaminase activity (ADA), an enzyme of purine metabolism, is a reliable 
marker to differentiate tuberculous ascites from other aetiologies. An ADA cut-off value 
between 36 to 40 IU/L has a high sensitivity (100%) and specificity (97%) for diagnosing 
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abdominal tuberculosis.(15) In the Netherlands, the ADA assay is available in a limited 
number of centers.
Glucose and lactate dehydrogenase
Traditionally, determining glucose and lactate dehydrogenase concentrations in ascites 
constituted part of the diagnostic work-up. A lower glucose concentration in ascites than 
in blood serum can indicate the presence of bacteria, white blood cells or cancer cells.
(16, 17) A low level of lactate dehydrogenase is associated with non-malignant ascites, 
high levels suggest a malignant aetiology.(18) Unfortunately both measurements are 
influenced by the SAAG, are non-specific and are no longer recommended.(19)
Urea and creatinine
A very uncommon cause of ascites is urinary leakage into the peritoneal cavity. Urinary 
ascites is associated with pathological bladder changes and outlet obstruction.(20, 21) 
Normally the ascites/plasma creatinine ratio is approximately one, whereas a ratio of five 
is reported in case of urinary ascites. Importantly, urinary ascites can be accompanied by 
pseudo-renal failure due to peritoneal absorption of urea.(20)
Non-biochemical testing
Polymorphonuclear leukocytes counts
An ascites polymorphonuclear neutrophil (PMN) count should be performed in the ascitic 
fluid of all patients with ascites being admitted to the hospital or showing clinical signs 
suggestive of SBP. A PMN count equal or greater than 250 cells/mm3 (0.25 x 109 cells/L) 
confirms the diagnosis of SBP in the absence of an evident intra-abdominal source 
of infection.(22) A PMN count repeated after 48 hours of antibiotic administration can 
distinguish between SBP and secondary bacterial peritonitis, a decrease suggests SBP and 
a sustained increase secondary bacterial peritonitis. A repeated PMN count after 48 hours 
after starting antibiotic therapy is recommended to document the efficacy of antibiotic 
therapy for SBP.(7, 16) Although SBP is mainly a complication of ascites due to portal 
hypertension, it may also develop in patients with ascites of other aetiologies. 
Bacterial cultures
Ascitic fluid should be cultured if SBP is clinically suspected. Bedside inoculation of 10 mL 
under sterile conditions using blood culture bottles, containing aerobic and anaerobic 
media, leads to identification of an organism in ~80% of patients with SBP.(7, 23, 24) 
Ascitic fluid cultures should be carried out before antibiotic treatment is initiated. 
PCR bacterial DNA Mycobacterium tuberculosis
Bacterial DNA of Mycobacterium tuberculosis in ascitic fluid can be detected using 
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polymerase chain reaction (PCR) and can be performed when tuberculous ascites is 
suspected. This method has a high sensitivity (94%) compared to microscopic acid-
fast bacilli smears (~0%) and mycobacterial culture (~50%).(25, 26) Alongside a higher 
diagnostic accuracy, PCR offers a timesaving method in contrast to current Mycobacterium 
culture techniques. PCR is a widely available biomolecular technique, however, PCR 
specific for the genus of Mycobacterium may not be available in all centers. Furthermore, 
culturing Mycobacterium from ascitic fluid or peritoneal biopsy remains the gold standard 
test according to international guidelines, also allowing antibiotic susceptibility testing.(7)
Cytology
Ascitic fluid cytology should be performed in case of suspicion of malignant ascites 
or in doubt of the underlying aetiology (e.g. no decrease in PMN count after 48 hours 
of antibiotic treatment). Clearly, positive cytology is highly indicative for peritoneal 
carcinomatosis. The sensitivity of cytology is 83%, but can be as high as 97% if three 
samples from separate paracenteses are analysed.(27) Crucial factors are avoiding any time 
delay between obtaining the ascitic fluid and cytology processing as well as obtaining at 
least 50 mL ascitic fluid, or even 1000 mL if the first test was negative.(27) The sensitivity of 
cytology in patients with hepatocellular carcinoma and ascites is low (~27%).(28) 
Diagnostic laparoscopy
If the conventional work-up fails to disclose the cause of ascites laparoscopy should be 
considered. Laparoscopy offers the advantages of visual inspection of the peritoneal 
cavity in combination with the ability to obtain targeted biopsies for histological and 
microbiological studies. The procedure may be particularly helpful to diagnose peritoneal 
carcinomatosis, tuberculous peritonitis and other peritoneal or omental diseases such 
as mesothelioma and sclerosing peritonitis.(29, 30) Figure 2 shows schematically the 
diagnostic approach to the patient with ascites.
Diagnostic developments
Novel markers in ascitic fluid analysis have been proposed for the initial differential 
diagnosis as well as for predicting prognosis in specific diseases. Most discoveries either 
target on simplifying, accelerating or reducing the costs of the diagnostic process or they 
result from advancing biochemical laboratory techniques.
Leucocyte esterase reagent strips 
Leukocyte esterase reagent strips are widely used for urinary analysis with the advantages 
of a simple, inexpensive and rapid bedside method. Several studies have examined the 
usefulness of this method for diagnosing SBP and found a sensitivity and specificity of 
this test ranging from 80 – 93% and 93 – 98%, respectively.(31) The negative predictive 
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value is remarkable high ranging from 97 – 99%, which makes it an ideal tool to rule 
out SBP.(31) Together with the other advantages, the reagent strip could gain a place in 
routine practice. Recently, an ascitic-specific reagent strip with a cut-off value of 250 cells/
mm3 was introduced, which could further improve the diagnostic accuracy.(32)
Viscosity
A few studies have reported the potential usefulness of viscosity measurement of ascitic fluid. 
Measuring viscosity was found to be able to discriminate between portal hypertension 
and non-portal hypertension related aetiology and showed a high correlation with the 
SAAG.(33) These preliminary results await confirmation by additional studies.
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is a protein, fundamental in the process of 
vasculogenesis and angiogenesis. High concentrations of vascular endothelial growth 
have been associated with malignant ascites.(34) Additional research is necessary to 
define the diagnostic value of this test.
Bacterial DNA, cytokines and other proteins
Bacterial DNA was studied in two series of 30 patients with ascites due to liver cirrhosis. The 
presence of bacterial DNA in ascites was regularly found documenting bacterial translocation, 
which could indicate a worse clinical prognosis in this patient group, without implicating a 
diagnosis of SBP. Markers, such as endotoxin and peptidoglycan/β-glucan, could predict a 
poor clinical outcome.(35, 36) Another study, including 52 patients with SBP and 27 control 
patients with cirrhotic ascites, found that blood serum concentrations of procalcitonin and 
an ascitic fluid concentration of calprotectin were significantly higher in SBP patients. Both 
serum and ascitic levels of TNF-α and IL-6 were significantly higher in SBP patients than in 
non-SBP patients.(37) These findings need to be confirmed in larger series of patients.
Platelet indices
Increased platelet indices, e.g. mean platelet volume and platelet distribution width, have 
been reported in blood of cirrhotic patients with SBP. The diagnostic accuracy was not 
sufficient, however, to consider these indices as a potential diagnostic tool.(38)
Tumour markers
Several studies have addressed the diagnostic value of tumour markers in ascitic fluid 
including α-fetoprotein (AFP), des-gamma-carboxy prothrombin, carcinoembryonic 
antigen (CEA), cancer antigen 19-9 (CA19-9) and cancer antigen 125 (CA-125). Increased 
concentrations have been associated with underlying malignancies but are also found in 
medical conditions such as gastritis, diverticulitis, cirrhosis and pancreatitis.(33)
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Figure 2. Diagnostic approach to the patient with ascites.
Standard diagnostic steps Suspected disease Additional ascitic fluid analysis
History
Physical examination
Blood tests
Abdominal ultrasound
Abdominal paracentesis with 
ascitic fluid analysis:
  - Visual inspection
  - Albumin (SAAG)
Liver cirrhosis
Infection
Peritoneal 
carcinomatosis
Pancreatic disease
Tuberculosis
Lymphatic leakage
Urinary leakage Urea
Creatinine
PMN count
PMN count
Bacterial cultures
Cytology
Amylase
ADA
Mycobacterium 
culture
PCR Mycobacterium
Triglycerides
When the cause of ascites remains unknown after performing the tests stated above, diagnostic laparoscopy 
should be considered.
ADA, adenosine deaminase activity; PMN, polymorphonuclear neutrophil; SAAG, serum-ascites albumin 
gradient.
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SYNOPSIS
The differential diagnosis of ascites is broad and includes a large number of benign and 
malignant causes. A structured diagnostic approach will likely reveal the aetiology in 
the large majority of cases and is based on the following elements: history, physical 
examination, blood tests, abdominal ultrasound and diagnostic paracentesis. Standard 
ascitic fluid analysis includes visual inspection and determination of the serum-ascites 
albumin gradient. In patients with suspected infection or underlying liver disease a 
PMN count and bacterial cultures are standard. According to clinical circumstances 
other established diagnostic studies are ascites cytology and determination of levels of 
amylase and triglycerides. In exceptional cases measuring urea and creatinine levels may 
be crucial. Adenosine deaminase activity measurements, Mycobacterium cultures and 
PCR for Mycobacterial DNA are indicated when tuberculosis is considered. Leucocyte 
esterase reagent strips are useful, in particular to rule out SBP in patients with a low a 
priori risk. New diagnostic markers such as viscosity, VEGF, bacterial DNA, cytokines and 
platelet indices have been proposed, but further research is needed to validate the value 
of these markers.
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CHAPTER 3
Reagent strips are efficient to rule out 
spontaneous bacterial peritonitis in 
cirrhotics
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ABSTRACT
Background: The gold standard to diagnose spontaneous bacterial peritonitis (SBP) is a 
polymorphonuclear neutrophil count ≥ 250 cells/μL in ascitic fluid. This test is laborious 
and expensive. Urine reagent strips measuring leukocyte esterase activity have been 
proposed as a rapid and inexpensive alternative. The aim of this study was to assess the 
diagnostic accuracy of the Combur reagent strip for diagnosing SBP. Furthermore the 
possible advantage of photospectrometer reading over visual reading of the strip was 
investigated. 
 
Methods: This prospective study includes all ascitic fluid samples of cirrhotic patients 
undergoing diagnostic or therapeutic paracentesis over a 12-month period. The samples 
were collected for standard diagnostic work-up and in addition tested with a bedside 
Combur reagent strip. The strip was read visually and with an automated spectrometer.
 
Results: A total of 157 samples were obtained from 53 patients, and spontaneous bacterial 
peritonitis was diagnosed in 12 patients based on ascitic PMN count. The sensitivity, 
specificity, positive predictive value and negative predictive value of the reagent strip 
according to the photospectrometer were 100%, 93%, 55% and 100% respectively, and 
75%, 99%, 82% and 98%, respectively, for visual interpretation. The diagnostic accuracy 
of the photospectrometer was found to be higher than visual interpretation (p = 0.007).
 
Conclusion: The diagnostic accuracy of leucocyte esterase reagent strips read out by 
a photospectrometer was comparable to the gold standard test and was excellent to 
exclude SBP. Our results support implementation of reagent strips in the diagnostic work-
up of ascitic fluid.
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INTRODUCTION
Spontaneous bacterial peritonitis (SBP) is a life-threatening complication in cirrhotic 
patients with ascites.(1) Late or misdiagnosed SBP can lead to increased mortality 
due to consequences such as gastrointestinal bleeding, development of hepatorenal 
syndrome and progressive liver failure. Therefore, the threshold for performing diagnostic 
paracentesis and ascitic analysis should be low.(2) 
 The reported prevalence of SBP in cirrhotic patients differs from 0-2,8% in outpatients 
to 10-30% in hospitalised patients.(3-9)  The gold standard test to diagnose SBP is a 
polymorphonuclear neutrophil (PMN) count of equal or greater than 250/µL in ascites 
using a manual counting chamber, regardless of the outcome of the culture of ascitic fluid.
(2) This analysis is laborious, time-consuming and expensive. Automated cell counting has 
been proposed to be a reasonable alternative with a high diagnostic accuracy.(10) 
 In the past two decades several studies have examined the use of leukocyte esterase 
reagent strips for the bedside diagnosis of SBP.(8, 11-25) These strips are widely used for 
rapid urinary analysis and the principle is based on the detection of leukocyte esterase 
activity of granulocytes.
 Varying levels of diagnostic accuracy to diagnose SBP with reagent strips have been 
reported, with a sensitivity ranging from 45-100%, a specificity from 90-100%, a positive 
predictive value from 42-100% and a negative predictive value from 93-100%.(8, 9, 11-
31) These inconsistent results could be related to variability in reagent strips, patient 
populations, different cut-off values and the subjective interpretation of the reagent strip 
result. However, the consistent high negative predictive value could make the reagent 
strips a very useful rule-out tool.
 This study was performed to (1) assess the diagnostic accuracy of reagent strips in 
comparison with the current gold standard test for diagnosing SBP in a mixed population 
of low-risk and high-risk patients, and to (2) investigate the possible advantage of 
automated analysis of the reagent strips over visual non-automated reading. 
MATERIALS AND METHODS
Study design
This prospective cohort study was carried out at the department of Gastroenterology 
and Hepatology in a referral centre for liver disease in the Netherlands. The study was 
designed and carried out in accordance with the principles of the Helsinki Declaration and 
approval was given by the local medical ethical committee of the hospital.
Patients
Consecutive patients with cirrhosis undergoing diagnostic or therapeutic paracentesis 
were prospectively enrolled from July 2006 up to and including July 2007. The total study 
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population was subdivided into a low- and high-risk population for the development 
of SBP. The low-risk population was defined as patients undergoing therapeutic, large 
volume paracentesis or outpatients undergoing diagnostic paracentesis.(4, 5, 9) The high-
risk population was defined as hospitalized patients undergoing a standard diagnostic 
paracentesis at admission or because of clinical deterioration.(2) Patients with ascites 
secondary to causes other than liver disease were excluded. 
Methods
Paracentesis was performed under strict sterile conditions. Ascitic fluid was routinely 
analyzed in the central clinical laboratory with automated determination of the white 
blood cell count with differential. Ten millilitres of fluid was inoculated at bedside in 
aerobic and anaerobic blood culture bottles (Bactec®). Fluid was collected in a sterile 
tube and assessed by two leukocyte esterase reagent strips (Combur10 strips, Roche 
Diagnostics). Both strips were read out after 60 seconds, one strip visually and one with a 
photospectrometer (Urisys 1100®, Roche Diagnostics). The observer was unaware of the 
results of the spectrometer. The observer could differentiate between 4 different colour 
shades corresponding to 0, 25, 100 or 500 leukocytes/µL.
Statistical analysis
Data analysis was performed using IBM SPSS Statistics for Windows, Version 21.0 (Armonk, 
NY: IBM Corp.). A mean and standard deviation was computed for continuous variables 
and compared with the Student’s t-tests if normally distributed. A two-sided p-value 
<0.05 was considered significant. Sensitivity, specificity, positive and negative predictive 
values with confidence intervals of 95% were calculated. ROC-curves were computed and 
the optimal categorical cut-off point was analysed. Diagnostic performance between 
photospectometer reading and visual interpretation was statistically compared using a 
McNemar test.(32)
 
RESULTS
A total of 157 ascitic fluid samples were collected from 52 patients (range 1–14 samples 
per patient); 87 samples (55%) were obtained in the low-risk population and 70 (45%) in 
the high-risk population.(Table 1) The prevalence of SBP according to polymorphonuclear 
count was 4 (4,5%) in the low-risk group and 8 (11,6%) in the high-risk group.(Figure 1) In the 
low-risk population, one culture (25%) was positive, identifying an Enterococcus faecium, 
whereas three cultures (37,5%) were positive in the high risk population, identifying 
Enterococcus coli, Haemophilus parainfluenzae and Pseudomonas aeruginosa in one case 
each. 
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Table 1. Baseline characteristics in 52 patients in the low- and high-risk group.
All patients
(n=52)
Low-risk group 
(n=20)
High-risk group 
(n=32)
p-value
Male, n (%) 35 (67%) 17 (85%) 18 (56%) 0.038
Age*, years 51 ± 10 51 ± 8 51 ± 11 0.581
Child-Pugh score* 10 ± 1.5 9 ± 1.4 10 ±1.6 0.962
Etiology of liver cirrhosis, n (%) 0.325
        Alcohol 18 (35%) 11 (55%) 7 (22%)
        Cryptogenic 10 (19%) 3 (15%) 7 (22%)
        Viral 7 (13%) 2 (10%) 5 (16%)
        Viral + alcohol 3 (6%) 0 (0%) 3 (9%)
        Other 14 (27%) 4 (20%) 10 (31%)
*Mean ±standard deviation. 
Figure 1. Flowchart study participants and sample collection.
 
 
Photospectrometer versus visual reading
Of the total of 12 (25%) cases of SBP, three were not detected by optical reading of the strip 
but correctly diagnosed with the photospectrometer. With visual reading, the sensitivity for 
diagnosing SBP was 75% (95% CI 43-93), the specificity 99% (95% CI 95-100), the positive 
predictive value 82% (95% CI 48-97) and the negative predictive value 98% (95% CI 94-100). 
The diagnostic accuracy for automated reading was slightly superior (p = 0.007 McNemar test): 
sensitivity 100% (95% CI 70-100), specificity 93% (95% CI 87-97), positive predictive value 55% 
(95% CI 33-75) and negative predictive value 100% (95% CI 97-100).(Table 2) ROC curve analysis 
indicated that the diagnostic accuracy of the strips was optimal at a cut-off of 100 leukocytes/μl.
157 ascites samples from 52 patients
SBP
4 (5%)
SBP
8 (12%)
Samples from the  
high-risk group 
70 (45%)
Samples from the  
low-risk group 
87 (55%)
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Table 2. Diagnostic accuracy of visual and automated reading of the leukocyte esterase reagent 
strip compared to gold standard.
Visual reading Photospectrometer reading
Sensitivity 75% (95% CI 43 - 93%) 100% (95% CI 70 - 100%)
Specificity 99% (95% CI 95 - 100%) 93% (95% CI 87 - 96%)
Positive predictive value 82% (95% CI 48 - 97%) 55% (95% CI 33 - 75%)
Negative predictive value 98% (95% CI 94 - 99%) 100% (95% CI 97 - 100%)
Low- and high-risk group analysis
The diagnostic performance of the strip with automated reading in the low- and high-risk 
populations was similar: the negative predictive value was 100% (95% CI 92 -100%) and 
the specificity was 93% (95% CI 83 -98%). 
Table 3. Overview of studies assessing the diagnostic value of Combur leukocyte esterase reagent 
strips for diagnosing SBP.
Author, year
[corresponding number 
in reference list]
Samples
Prevalence 
SBP (%)
Sensitivity Specificity
Positive 
Predictive 
Value
Negative 
Predictive 
Value
Thevenot, 2004 [13] 100 9 (9%) 89 100 100 99
Sarwar, 2005 [26] 214 38 (18%) 83 83 42 97
Braga, 2006 [27] 100 9 (9%) 100 98.9 92.3 100
Campillo, 2006 [18] 443 33 (7%) 63 99.2 91 92.9
Rerknimitr, 2006 [28] 200 42 (21%) 88 81 55 96
Rerknimitr, 2010 [30] 250 30 (12%) 90 93.2 64.3 98.6
Present study, 2015 157 12 (8%) 100 93 55 100
DISCUSSION
The results of the present study support the diagnosing value of leukocyte esterase 
reagent strips in ascitic fluid analysis in patients with cirrhosis. In particular, this simple, 
quick and inexpensive method could reliably rule out SBP, with a 100% negative predictive 
value in populations low- and high-risk for SBP. Automated reading of the reagent strip 
was superior to visual interpreting and prevented false-negative results. 
 The diagnostic accuracy of the Combur10 strip in ascitic fluid analysis has been 
studied previously by several groups.(13, 18, 26-28, 30) The results of these studies were 
Reagent strips are efficient to rule out spontaneous bacterial peritonitis in cirrhotics
47
3
comparable with our results in terms of a high negative predictive value of reagent strip 
testing.(Table 3) The cumulative data suggest that the sensitivity of strips for diagnosing 
SBP is variable and may not be optimal. A negative test result, however, strongly predicts 
absence of SBP. Thus, in patients undergoing diagnostic paracentesis, a negative reagent 
strip result may imply that further diagnostic studies - polymorphonuclear neutrophil 
count and bacterial cultures - are not useful and can be omitted. Obviously, preventing 
unnecessary diagnostic studies in a substantial proportion of patients presenting with 
ascites may lead to a marked reduction in costs.
 Although an automated reader has been used in previous studies, this study is, to our 
knowledge, the first to compare visual and automated reading of reagent strips in ascitic 
fluid analysis.(7,15) Our results suggest that automated reading is superior and may be 
the preferred method in clinical practice. Additional studies would be useful to confirm 
this finding. 
 One of the limitations of our study may be that the reagent strips we used are not 
specifically designed for ascitic fluid analysis. The cut-off levels are not based on the PMN-
count of 250 leukocytes/µL, the gold standard for SBP. It has been suggested that protein 
could interfere with the test and has a negative effect on the accuracy. One study found 
significantly higher mean ascitic protein content in patients with false-negative results 
than in patients with true-positive results.(29) Furthermore little is known regarding the 
effects of the different composition of ascites as compared to urine, for example with 
respect to bilirubin or pH level, on reagent strip diagnostic accuracy. Remarkable results  - 
a 100% sensitivity and negative predictive value - have been reported with the Periscreen 
strip, a strip with specific characteristics for ascitic fluid analysis.(31) These results await 
confirmation in a large cohort, which is currently investigated in the Per-DRISLA study.(33)
 In conclusion, this study adds to already available data suggesting that Combur 
reagent strips are useful for ascitic fluid analysis in cirrhotic patients. Cumulative evidence 
clearly indicates that a negative test result reliably rules out SBP. We found reagent strips 
an inexpensive, time- and money-saving tool, which is available both during and after 
regular working hours. Reading the strips with a photospectometer may be superior to 
visual reading. 
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ABSTRACT
Background: Recent investigations suggest an increasing prevalence of Gram-positive 
and antibiotic-resistant bacteria causing spontaneous bacterial peritonitis (SBP), probably 
related to changes in antibiotic prescription patterns, in particular more widespread and 
long-term use of antibiotic prophylaxis with quinolones.
 
Objective: The primary objective of this study was to assess potential changes in the 
microbiology of SBP in two patient cohorts studied at a 10-year interval. Further aims were 
to study prognostic factors and outcome of SBP.
 
Methods: A retrospective double-cohort study, including all ascitic cultures from patients 
with cirrhosis obtained 2003–2005 and 2013–2014, was conducted.
 
Results: In total 312 patients were included, 125 patients in the first and 187 patients in 
the second cohort. SBP was diagnosed in 132 of 840 analyzed ascitic fluid samples; 62 
samples were culture positive. An increase of Gram-positive bacterial isolates was noted 
from 26% to 46% between cohorts (p=0.122). The prevalence of multidrug-antibiotic–
resistant pathogens increased from 25% to 32% (p=0.350). Survival after SBP among the 
two cohorts was comparable.
 
Conclusion: This single-center study in the Netherlands found a modest but non-
significant increase in the proportion of patients with SBP caused by Gram-positive 
bacteria and multidrug-antibiotic–resistant bacteria over a 10-year period. Our findings 
differ from reported data in other countries and suggest empiric antibiotic prophylaxis 
and treatment of SBP should be based on national and regional microbiological findings 
and resistance patterns.
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INTRODUCTION
Spontaneous bacterial peritonitis (SBP) is a common infection in patients with cirrhosis 
and ascites. Reportedly, this infection can be diagnosed in up to 30% of cirrhotic patients 
with ascites who are admitted to the hospital. SBP is associated with significant morbidity 
and mortality.(1-4) Intestinal bacterial translocation, altered immunity and the presence 
of ascites are key in the development of SBP.(5-7)
 SBP is diagnosed by a polymorphonuclear neutrophil (PMN) count in ascitic fluid equal 
to or greater than 250/μl. Approximately 40% of SBP episodes are culture positive.(3, 8, 
9) Numerous, in particular older, studies reported that Gram-negative enteric bacteria 
were involved in the majority of SBP episodes. International guidelines recommend third-
generation cephalosporin as empirical treatment for SBP and quinolones for secondary 
prophylaxis.(10, 11) However, in the last decade Gram-positive bacteria and antibiotic-
resistant bacteria have been increasingly found to cause SBP.(3, 8, 9, 12-14) This change 
in microbiology has been attributed to long-term and widespread quinolone use and 
increased prevalence of hospital and intensive care unit admissions. These findings have 
raised doubts about the currently recommended antibiotic strategy in SBP.
 The prevalence of antibiotic-resistant pathogens substantially differs geographically.
(15) Antibiotic consumption has been identified as the main cause for increasing 
rates of antibiotic resistance. The Netherlands is known for a restrictive antibiotic 
policy and has had the lowest antibiotic use in Europe for years.(15-17) Consequently, 
microbiological study results in SBP in our country could differ from those observed 
in other countries - i.e. Spain, Greece, Germany and the United States - over time. This 
would mean that international guidelines for prophylaxis and treatment of SBP would 
need to differentiate between countries based on antibiotic resistance rates. Therefore, 
we investigated causative microorganisms in two patient cohorts who were hospitalized 
with a 10-year interval in a tertiary referral hospital in the Netherlands. In addition, we 
aimed to identify the patients most at risk for SBP and to evaluate the associated short- 
and long-term survival.
MATERIALS AND METHODS
All consecutive ascitic cultures performed in patients with cirrhosis between January 2003 
and December 2005 (first cohort) and between January 2013 and December 2014 (second 
cohort) at Erasmus MC, University Medical Center, Rotterdam, were included. Demographic, 
clinical, biochemical and survival data from patient hospital records were retrospectively 
studied to evaluate the prevalence, risk factors, microbiology, and mortality of SBP. The 
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as 
reflected in an approval by the ethical review board of the Erasmus MC in February 2017.
 The diagnosis of cirrhosis was based on liver histology or a combination of clinical, 
biochemical, and radiologic findings.(18) SBP was defined as a PMN count equal to or 
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greater than 250/µL in ascites without evidence of an intra-abdominal source of infection.
(10, 11) All ascites samples obtained during the two study periods were studied, implying 
that, if applicable, multiple samples per patient were taken into account. However, only 
the first positive culture per SBP episode, and thus one culture per SBP episode, was 
included in the analysis. Multidrug-antibiotic–resistant organisms (MDR) were defined, 
according to international guidelines, as an acquired resistance to at least three antibiotic 
classes.(19) Nosocomial acquisition was defined as SBP diagnosed at least 48 hours after 
hospital admission. During the study periods, the standard antibiotic prophylaxis for 
SBP was norfloxacin 400mg daily.(10, 11, 20) The primary choice for empirical antibiotic 
treatment for SBP was ceftriaxone 2000mg daily for five to seven days and the secondary 
choice was amoxicillin/clavulanic acid 1000/200mg every eight hours for five to seven 
days, according to international guidelines.(10, 11, 20)
 All ascitic fluid samples were routinely analyzed in the central clinical laboratory with 
automated determination of the white blood cell count with differential. In addition, at 
least 10 ml of ascitic fluid was inoculated at bedside under sterile conditions in aerobic and 
anaerobic blood culture bottles (Bactec®) for culture in the central medical microbiology 
laboratory. For identification of positive cultures, the ascitic fluid was plated on agar 
and current identification methods were used. Susceptibility was determined with the 
VITEK® 2 system (VITEK AMS; bioMerieux Vitek Systems Inc, Hazelwood, MO, USA). Cultures 
collected until 2013 were called resistant using Clinical and Laboratory Standards Institute 
criteria; later cultures were called resistant using European Committee on Antimicrobial 
Susceptibility Testing criteria 2013.
Statistical analysis
A mean and standard deviation (SD) was computed for approximately normally 
distributed variables and compared using the Student’s T-test. Non-normally distributed 
continuous variables were summarized by their median and interquartile range (IQR), and 
compared using the Mann-Whitney ranks sum test. Categorical variables were expressed 
with percentages and compared using the Chi-square test. A two-sided p value < 0.05 
was considered significant. Patients were followed up to a maximum of one year. This 
time frame was chosen based on the severity of decompensated advanced chronic liver 
disease. Survival was analyzed using the Kaplan-Meier method. The actual 30-day mortality 
and one-year mortality was calculated after the first ascitic fluid analysis; both liver 
transplantation and death were considered as events. The survival rates were compared 
using log-rank test. Univariable and multivariable Cox’s proportional hazard analyses 
were carried out to identify independent predictors for 30-day mortality and one-year 
mortality after SBP. The variables selected for univariable analysis were based on previous 
studies: gender, age, etiology of liver disease, community- or nosocomial-acquired SBP, 
positive microbial ascites culture, causative microorganism, antibiotic susceptibility, use of 
Microbiology and antibiotic susceptibility patterns in spontaneous bacterial peritonitis
57
4
antibiotic prophylaxis, use of immunosuppressant drug, hepatocellular carcinoma (HCC), 
model for end-stage liver disease (MELD) score, albumin in serum, platelets in serum, and 
protein in ascites at time of ascites analyses. Variables with a p value of < 0.10 in univariate 
analysis were included in the multivariate Cox’s proportional hazards model.
RESULTS
In the first (2003–2005) cohort of 125 patients, 343 ascitic fluid samples were obtained for 
analysis. In the second (2013–2014) cohort of 187 patients, 497 samples were obtained. 
The diagnosis of SBP was established in 132 of the total 840 (16%) ascitic fluid samples in 
95 patients.(Figure 1)
 The total study population included 197 men and 115 women with a mean age of 56 
years (±12) and a mean MELD score of 19 (±8). Norfloxacin was used by 12% and 10% of 
patients at the time of paracentesis in the first and second cohort, respectively (p=0.638).
 The clinical characteristics of patients with and without SBP are shown in Table 1. 
Patients with SBP had more frequent liver disease of autoimmune origin, more frequently 
used immunosuppressive drugs (p=0.012) and had higher baseline MELD scores (p=0.020).
Figure 1. Flow chart of study population.
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Table 1. Clinical characteristics of the study population with and without SBP.
SBP negative
(n=217)
SBP positive
(n=95)
p-value
Male, n (%) 138 (64%) 59 (62%) 0.802
Age in years 57 (±12) 54 (±13) 0.036
Etiology of cirrhosis, n (%)
    Alcohol
    Viral
    Auto-immune 
    Other
92 (42%)
51 (24%)
28 (13%)
46 (21%)
31 (33%)
23 (24%)
24 (25%)
17 (18%)
0.045
Child-Pugh class, n (%)
    A
    B
    C 
25 (12%)
74 (34%)
118 (54%)
5 (5%)
33 (35%)
57 (60%)
0.215
MELD score 19 (±8) 21 (±8) 0.020
Creatinine (mmol/L) 96.8 (±1.7) 110.1 (±1.8) 0.052
Albumin (g/L) 29 (±6) 29 (±6) 0.912
INR 1.5 (±1.0) 2.0 (±1.5) 0.006
Bilirubin (mmol/L) 62 (±3) 76 (±4) 0.260
Thrombocytes (109/L) 107 (±2) 97 (±2) 0.304
Ascites protein (g/L) 10.6 (±2.0) 16.3 (±2.6) 0.009
Hepatocellular 
carcinoma, n (%)
30 (14%) 11 (12%) 0.589
Diabetes mellitus, n (%) 37 (17%) 11 (12%) 0.218
Use of 
immunosuppressant 
drug, n (%)
21 (10%) 19 (20%) 0.012
Use of norfloxacin, n (%) 26 (12%) 8 (8%) 0.353
 
Microbiology
In the two cohorts a culture-positive SBP was found in 23/56 (41%) and 33/76 (43%) 
episodes with SBP, respectively.(Figure 1) The microbiological culture results are shown in 
Table 2. In the first cohort, 61% of culture-positive SBP was due to Gram-negative bacteria 
vs. 51% in the second cohort. Candida albicans was isolated in four cultures. Although the 
percentage SBP with Gram-positive organisms increased over time, the differences were 
not statistically significant (p=0.122).(Table 2)
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Table 2. Microbiological findings in two cohorts of patients; 62 organisms were identified in 56 
episodes of culture-positive SBP.
cohort
2003 – 2005 
(n=23)
cohort
2013 – 2014 
(n=39)*
Gram-negative bacteria 14 (61%) 20 (51%)
Escherichia coli 9 13
Enterobacter aerogenes - 2 
Enterobacter cloacae - 2 
Pseudomonas aeruginosa 2 -
Klebsiella pneumoniae 1 3
Morganella morganii 1 - 
Aeromonas spp. 1 -
Gram-positive bacteria 6 (26%) 18 (46%)
Staphylococcus aureus 1 3
Staphylococcus haemolyticus - 1
Staphylococcus (coagulase negative) 3 3
Enterococcus faecium - 5 
Streptococcus oralis 1 3
Streptococcus anginosus - 1
Streptococcus salivarius - 1
Streptococcus viridans - 1
Streptococcus pneumoniae 1 -
Yeast 3 (13%) 1 (3%)
Candida albicans 3 (13%) 1 (3%)
* Including 6 cultures showing two microorganisms.
Antibiotic susceptibility patterns
In the first cohort 5/20 (25%) of the isolated bacteria were MDR versus 12/38 (32%) in the 
second cohort.(Table 3) There was no significant change in prevalence of MDR organisms 
over time (p=0.350). In the MDR organisms, the most frequently detected resistance 
mechanism was due to extended-spectrum beta-lactamase (ESBL) production (Escherichia 
coli n=9, Klebsiella n=1). Furthermore, methicillin-resistant Staphylococcus aureus (MRSA) 
(n=4), intrinsically cephalosporin-resistant Enterobacter (n=2), and vancomycin-resistant 
Enterococci (VRE) (n=1) were found. There was no evidence that the risk of SBP caused by 
MDR organisms was related to a Gram-negative or Gram-positive microbiologic isolate 
(p=0.192), a nosocomial acquisition of the infection (p=0.677), a previous history of SBP 
(p=0.245), or the use of antibiotic prophylaxis (p=0.316).
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 Three of the 20 (15%) and six of the 38 (16%) isolated organisms were norfloxacin 
resistant, in the first and second cohort, respectively (p=0.274).
 Analysis with respect to ceftriaxone showed that in the first cohort 3/20 (15%) of 
bacterial isolates were resistant to this agent as compared to 5/38 (13%) in the second 
cohort. Amoxicillin/clavulanic acid-resistance was slightly more prevalent. In the first 
cohort 6/20 (30%) organisms were found to be resistant versus 8/38 (21%) in the 
second cohort. The frequency of ceftriaxone and amoxicillin/clavulanic acid-resistant 
organisms did not differ significantly between the cohorts (p=0.952 and p=0.254, 
respectively).(Table 3)
Table 3. Antimicrobial susceptibility patterns of bacteria from culture-positive SBP.
Bacterial isolates in SBP 
(n=58)
p-value
cohort 
2003 – 2005 
(n=20)
cohort 
2013 – 2014 
(n=38)
Multidrug resistant 5 (25%) 12 (32%) 0.350
Norfloxacin resistant* 3 (15%) 9 (24%) 0.274
Ceftriaxon resistant* 3 (15%) 5 (13%) 0.952
Amoxicillin/clavulanic acid resistant* 8 (40%) 8 (21%) 0.254
* Intrinsically and/or acquired antimicrobial resistance. 
Survival
At one year, 153 patients had died (49%) and 48 patients had received a liver transplant 
(15%). Furthermore, 83 patients (27%) were alive after one year, while 28 patients (9%) were 
lost to follow-up. The median follow-up time of the patients not reaching the endpoint of 
death or liver transplantation was 365 days (IQR 12 days). The survival of patients with SBP 
did not differ significantly between the cohorts (log-rank p=0.442), nor did survival differ 
significantly between the cohorts for patients without SBP (log-rank p=0.216).
 The median survival after the first ascites analyses was 168 days for SBP-negative 
patients and 77 days for SBP-positive patients (log-rank p=0.001).(Figure 2) The 30-day 
mortality rate was 33% (32/95) for patients with SBP compared to 25% (55/217) for patients 
without SBP.(Figure 2) Univariable and multivariable Cox-regression analyses were carried 
out to identify risk factors for 30-day mortality and one-year mortality after SBP. MELD 
score was the only independent predictive factor for 30-day mortality (hazard ratio (HR) 
1.106 per point, 95% CI 1.061–1.154, p<0.001) and one-year mortality (HR 1.060 per point, 
95% CI 1.030–1.091, p<0.001).(Table 4)
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Figure 2. One-year mortality after first ascites analysis. SBP-negative patients (black solid line) 
have a median survival of 168 days and SBP-positive patients (grey dotted line) of 77 days (log-rank 
p=0.001).
*Liver transplantation and death are considered as event.
 
 
Chapter 4
62
Table 4. Demographic and clinical factors after SBP in 95 patients predicting 1-year mortality using 
Cox-regression analysis.
  Univariate Multivariate
  HR 95% CI p-value HR 95% CI p-value
Gender 
    Female (ref.)
    Male
1
0.424 0.263-0.682
<0.001
Age (per year) 0.999 0.981-1.017 0.911
Etiology 
    Alcohol (ref.)
    Viral 
    Auto-immune
    Other
1
0.841
1.545
0.837
0.444-1.596
0.836-2.858
0.431-1.625
0.206
Acquisition SBP
    Community
    Nosocomial
1
1.761 0.938-3.303
0.078
Positive microbial ascites culture 1.406 0.886-2.231 0.148
Causative microorganism type
    Gram-negative 
    bacteria (ref.)
    Gram- positive
    bacteria 
    Yeast
1
0.764
1.511
0.359-1.625
0.444-5.146
0.561
Multi-drug resistant microorganism 1.989 0.972-4.073 0.060
Antibiotic prophylaxis 0.662 0.286-1.531 0.335
Immunosuppressant use 0.508 0.260-0.992 0.047
HCC 0.971 0.465-2.026 0.937
MELD score (per point) 1.060 1.030-1.091 <0.001 1.060 1.030-1.091 <0.001
Albumin in serum (per point) 0.967 0.927-1.008 0.109
Platelets in serum 
(< 150 x 109/L)
2.179 1.226-3.870 0.008
Low protein in ascites 
(<15 g/L)
1.287 0.530-3.124 0.578
DISCUSSION
In this single-center study in the Netherlands, the microbiological characteristics and 
antibiotic susceptibility patterns of organisms causing SBP in liver cirrhosis patients were 
compared between the periods 2003–2005 and 2013–2014. No significant increase in 
Gram-positive bacteria was observed and Gram-negative bacteria remained the primary 
cause. Bacteria resistant to empirical treatment with third-generation cephalosporin 
accounted for 13%–15% of all causative pathogens.
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 There was no evidence that mortality was influenced by causative microorganisms, 
antibiotic susceptibility, use of prophylactic antibiotics, intensive care admission or a 
nosocomial acquisition of SBP. The main predictors for mortality were age, MELD score, 
and platelet count.
 Our most important finding is that in the era of quinolone prophylaxis for SBP, we 
cannot confirm observations made elsewhere regarding a significant increase in Gram-
positive and MDR organisms causing SBP.(3, 8, 9, 12, 13) Although in the Netherlands 
antibiotics are used prudently, a rise in quinolone use in the last decades has been 
described.(21, 22)
 Third-generation cephalosporin may poorly cover the causative pathogens in SBP, 
with reported antibiotic resistance rates ranging from 57% to 69%.(9, 23, 24) However, our 
results show a susceptibility rate of 85–87%. We hypothesize this difference can be most 
likely attributed to different national antibiotic policies. High consumption of antibiotics 
has been related to higher rates of antibiotic resistance.(15) The Netherlands has always 
had a restrictive national policy regarding antibiotic prescription and a conservative 
approach toward the prescription of new broadspectrum antibiotic agents.(15, 16, 25)
 The microbiology and susceptibility patterns’ differences can be hospital and 
region dependent, implying difficulties with recommending antibiotic treatment and 
prophylaxis in international guidelines. The results of this study in the Netherlands do not 
support the need to revise guidelines as previously proposed.(3, 23) Empirical antibiotic 
treatment should be based on known regional and national differences of antibiotic 
resistance patterns.
 A previous study from our institution on the microbiology of SBP in the period 1987–
1991, before the implementation of long-term quinolone prophylaxis in the relevant 
patient population, reported that causative pathogens were isolated in 25 of 31 SBP 
episodes.(26) Gram-negative bacteria were detected in 60% of the episodes and Gram-
positive bacteria in 40% of the episodes. Despite the small sample size, the proportions of 
causative pathogens seem comparable to those identified in the cohorts reported here.
 Although optimizations in bacterial culture techniques have been implemented, an 
organism was isolated in a minority of all SBP episodes (40%). This is a stable percentage 
over the last decade and similar proportions have been documented in other studies.(3, 
8, 9) It may be expected that, with technologies arising from bacterial DNA detection and 
microbiome studies, more causative pathogens can be identified rapidly in the future for 
targeted antibiotic therapy.
 There are a few limitations of the study regarding methodology. This study was 
designed as a retrospective, double-cohort study, which implied some laboratory 
and clinical data were missing. For instance, we have no information about short-term 
antibiotic use prescribed by general practitioners and clinicians outside the hospital, 
but it is not to be expected that this would differ significantly between the cohorts. 
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Furthermore, multiple tests have been performed that may lead to an increased risk of 
finding spurious significant results and results should be interpreted while keeping this in 
mind. Prospective cohort studies comparing multiple regions during a large time frame 
could provide more insight as to the microbiology of SBP in diverse regions over time.
 In this study we show that the microbiology of pathogens causing SBP did not change 
significantly in our center over the last decade. These findings suggest that guidelines 
with respect to antibiotic prophylaxis and treatment of SBP should carefully take into 
account potential national and regional differences in the microorganisms causing SBP 
and antibiotic resistance patterns.
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ABSTRACT
Background: Knowledge about bacterascites is limited and management guidelines 
are based on small patient series. The purpose of this study was to add further insight 
into the clinical characteristics, microbiological findings and prognosis of patients 
diagnosed with bacterascites.
 
Methods: Retrospective analysis of patients with advanced chronic liver disease 
diagnosed with bacterascites and SBP between January 2003 and August 2016.
 
Results: In this study, 123 patients were included with 142 episodes of bacterascites. 
The median MELD score was 20 and clinical symptoms of infection were present in 78%. 
Empiric antibiotic treatment was initiated in 68%. In 26 untreated patients undergoing 
repeated paracentesis, 42% were diagnosed with either ongoing bacterascites or SBP. 
The presence of signs or symptoms of infection was not an independent predictor for 
mortality or spontaneous resolution of infection. The 1-month and 1-year mortality rates 
of the 123 patients studied, were 32% and 60%, respectively; these results were in line 
with data pertaining to the prognosis of SBP.
 
Conclusions: Patients with bacterascites and SBP are highly comparable with respect to 
severity of liver disease and overall prognosis. If left untreated, bacterascites is likely to 
persist or to evolve to SBP in a significant proportion of patients. The results of this study 
support current guidelines regarding the treatment of ascitic fluid infection, but could 
not confirm the prognostic relevance of symptomatic disease at the time of diagnosis. 
We suggest that the threshold to initiate antibiotic treatment, in particular in cases with 
severely advanced liver disease, should be low.
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INTRODUCTION
Bacterascites is defined by an ascitic fluid polymorphonuclear neutrophil (PMN) count 
below 250/μL and a positive ascitic fluid culture result in the absence of an evident intra-
abdominal, surgically treatable source of infection.(1) It is a different clinical entity than 
spontaneous bacterial peritonitis (SBP), which is characterized by a neutrophil reaction in 
ascites regardless of the bacterial culture result. Bacterascites is prevalent in 8-11% of all 
patients with cirrhosis and ascites, and the clinical significance seems to vary according to 
how the infection was acquired.(2-7)
 Several hypotheses have been proposed to explain the potential underlying 
pathophysiological mechanisms. The most common theory implicates that the bacterial 
colonization of ascites is caused by bacterial translocation from the intestinal lumen 
or by secondary translocation from a concomitant infection from extra-intestinal sites 
(e.g. urogenital or respiratory tract). The absence of an inflammatory response could be 
interpreted as an early phase of SBP, in which the neutrophil response has not commenced 
yet, or a spontaneously resolving infection, determined by good host defenses or 
less virulent pathogens.(1, 4) In this context, the term ‘symptomatic bacterascites’ has 
been introduced for patients with bacterascites and clinical symptoms of infection, in 
order to identify those patients who may require treatment. Furthermore, bacterascites 
caused by commensal skin bacteria has been attributed to exogenous contamination 
of the ascitic fluid sample and bacterascites with multiple pathogens may be caused by 
traumatic paracentesis.(2, 3) The indication for antibiotic treatment of bacterascites is 
generally regarded to be dependent on the supposed pathophysiologic mechanism and 
the clinical situation. 
 The AASLD practice guideline regarding the management of ascites states that 
patients with ascites and convincing signs or symptoms of infection should receive 
empiric antibiotic treatment.(8) This recommendation is based on one study with 36 
cases of bacterascites receiving a follow-up paracentesis, in which 62% of the cases 
spontaneously resolved and 38% progressed to SBP.(4) The EASL clinical practice guideline 
endorses this recommendation and further states asymptomatic patients should undergo 
a second paracentesis when culture results come back positive. Patients in whom the 
repeated ascitic PMN count is greater as or equal to 250/μL should be treated for SBP, 
and the remaining patients (i.e., PMN count below 250/μL) should be followed up.(9) This 
guideline is based on a consensus document of the International Ascites Club in 2000.(1)
 Although bacterascites is not an uncommon condition, relatively few studies on 
prognostic factors and outcome of this ascitic fluid infection have been reported. 
(2-7) Therefore, the purpose of this study was to assess the clinical characteristics, 
microbiological findings and clinical course in consecutive patients diagnosed with 
bacterascites. We further attempted to study the prognostic impact of bacterascites in 
comparison to SBP, and to define the most logical therapeutic approach.
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PATIENTS AND METHODS
Study design and data collection
All consecutive ascites cultures performed in patients with advanced chronic liver disease 
between January 2003 and August 2016 at Erasmus MC, University Medical Center, 
were retrospectively reviewed to identify patients fulfilling the diagnostic criteria for 
bacterascites. The Medical Ethics Committee Erasmus MC, approved the study protocol on 
February 27th, 2017 and stated that written informed patient consent was not necessary 
considering the design of the study.
 All ascites samples obtained during the study period were reviewed, implying that, 
if applicable, multiple bacterascites episodes per patient were taken into account. The 
lower-case letter n was used to indicate the number of patients and the capital letter N for 
the number of bacterascites episodes.
 Paracentesis was performed in patients with new-onset ascites, clinical deterioration, 
and large-volume removal in refractory ascites.(9) White blood cell (WBC) and PMN count 
in ascites were automatically determined and aerobic and anaerobic blood culture bottles 
(Bactec®) were used for bacterial cultures. Blood cultures taken within two hours before or 
after ascites cultures were considered to be concomitant.
 Demographic, clinical, biochemical and survival data from patient hospital records 
were collected.
 To determine the prognostic impact of bacterascites in comparison with reported 
outcomes of SBP, a control cohort was established with patients from our center with SBP, 
performed as described in a previous publication.(10) In order to create homogenous 
groups for survival analyses, patients with both episodes of bacterascites and SBP were 
categorized as SBP when the first ascites infection was SBP or bacterascites developed 
within 48 hours to SBP. Patients with bacterascites developing SBP after 48 hours, but 
within 30 days were excluded from survival analysis. In addition, the MELD score-
dependent relation of the prognosis of bacterascites patients was studied and compared 
with SBP patients.(11, 12)
 Furthermore, a PubMed search was performed on December 1st, 2017 with the 
following search terms: spontaneous bacterial peritonitis (ALL) AND (outcome (ALL) OR 
mortality (ALL)) AND prognos* (ALL). The studies were reviewed and included when the 
following criteria were met: (1) observational studies, (2) study population consisted of 
patients with SBP defined as a PMN count of 250/μL or greater in ascites, (3) minimum 
study population of 50 adult patients, (4) reporting survival analysis and 1-month or in-
hospital mortality rate, and (5) written in English. Interventional studies (e.g. randomized 
controlled trials), studies with a selected population (e.g. HIV patients), and abstracts were 
excluded. Study and clinical characteristics were collected from the included studies.
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Definitions
Bacterascites was defined as an ascitic fluid sample with a PMN count below 250/µL and 
a positive bacterial culture, in the absence of evidence for an intra-abdominal source of 
infection.(1) Infection acquisition was categorized as nosocomial (infection was detected 
after 48 hours after hospital admission), health-care associated (<48 hours after hospital 
admission in patients with any 90-day prior health-care contact), or community acquired 
(within 48 hours after hospital admission in patients without any 90-day prior health-
care contact).(13) Ascites was graded as diuretic-responsive or diuretic-refractory, and 
hepatic encephalopathy (HE) as none, or West Haven grade 1-4. Patients were categorized 
as symptomatic, when one or more of the following symptoms, shown to be frequently 
present in patients with SBP, were recorded: abdominal discomfort (feeling of fullness), 
abdominal pain/tenderness, fever, and a change in mental status (recorded as HE grade).
(14) Recent gastrointestinal (GI) bleeding was defined as a diagnosed upper GI bleeding 
in the 72 hours prior to index paracentesis. During the study period, the standard primary 
antibiotic treatment in patients with variceal bleeding was oral norfloxacin 400 mg twice 
daily or intravenous ceftriaxone 1 g daily during five days. The secondary prophylaxis for 
SBP was norfloxacin 400 mg once daily.(8, 9)
Statistical analysis
Continuous variables were reported as mean with standard deviation (SD), after visual 
confirmation of approximate normality, and compared using the Student’s T-test. 
Categorical variables were reported as count with proportion and compared using the 
Chi-square test. A two-sided p-value <0.05 was considered significant.
 Transplantation-free survival was analyzed using Kaplan-Meier survival analysis. 
Follow-up started at the time of the first ascitic fluid analysis. A multivariable logistic 
regression analysis was carried out to identify predictors for treatment of bacterascites, 
a multivariable logistic regression analysis in the untreated patient group to identify risk 
factors for worse outcome (i.e. liver-related death before culture results were known, SBP 
development, and persisting bacterascites), and a multivariable Cox’s proportional hazard 
analysis to identify independent predictors for 3-month mortality. These analyses were 
performed using the candidate predictor variables: age, gender, etiology of liver disease, 
MELD score, hepatocellular carcinoma, gastrointestinal bleeding, HE, grade of ascites, 
symptoms of infections, immunosuppressive medication use, antibiotic prophylaxis 
use, Staphylococci cultured, and PMN count in ascites, with the addition of initiation of 
antibiotic treatment for bacterascites in the Cox’s regression. The regression models were 
employed using the backward stepwise selection method with removal testing based on 
the probability of the likelihood-ratio statistic. Statistical analyses were performed using 
IBM® SPSS® Statistics for Windows, version 21.0.
Chapter 5
74
RESULTS
Patients
Between January 2003 and August 2016, 142 episodes of bacterascites were diagnosed 
in 123 patients. The demographic, clinical and laboratory data are summarized in Table 
1. Patients with bacterascites were mainly male with a mean age of 63 years (±14) and a 
median MELD score of 20 (IQR 14–25).
Table 1. Baseline demographic and clinical patient characteristics.
Patients with bacterascites
(n=123)
Male, n (%) 76 (62%)
Age in years, mean (SD) 63 (± 14)
Etiology of cirrhosis, n (%)
    Alcohol
    Viral
    Auto-immune related
    Alcohol + viral
    NASH 
    Other
35 (29%)
26 (21%)
19 (15%)
10 (8%)
9 (7%)
24 (20%)
MELD score, median (IQR) 20 (14 – 25)
Child-Pugh score, median (IQR) 8 (7 – 10)
Child-Pugh class, n (%)
    class A 
    class B 
    class C 
30 (24%) 
61 (50%)
32 (26%)
HCC, n (%) 21 (17%)
Sodium (mmol/L), mean (SD) 136 (± 8)
Creatinin (μmol/L), median (IQR) 109 (73 – 168)
Albumin (g/L), mean (SD) 29 (± 6)
Total bilirubin (μmol/L), median (IQR) 51 (26 – 135)
INR, mean (SD) 1.7 (± 0.7)
Ascites, n (%)
    Diuretic-responsive
    Diuretic-refractory
33 (27%)
90 (73%)
Hepatic encephalopathy, n (%)
    None
    West Haven grade 1 - 2
    West Haven grade 3 - 4
73 (59%)
32 (26%)
18 (15%)
PMN count in ascites (cells/μL), mean (SD) 48 (± 61)
Protein level in ascites (g/L), mean (SD) 16 (± 10)
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Table 1. Baseline demographic and clinical patient characteristics. (continued)
Recent GI bleed, n (%) 35 (28%)
Use of norfloxacin, n (%)
    Primary prophylaxis
    Secondary prophylaxis
27 (22%)
-
Admission status during paracentesis, n (%)
    Inpatient
    Outpatient
103 (84%)
20 (16%)
Abbreviations: GI, gastrointestinal; HCC, hepatocellular carcinoma; INR, international normalized ratio; IQR, 
interquartile range; MELD, model for end-stage liver disease; NASH, non-alcoholic steatohepatitis; PMN, 
polymorphonuclear neutrophil
Bacterascites
The infection was in 11% of the bacterascites episodes community acquired, in 55% 
health-care related, and in 34% nosocomial acquired.
 One or more clinical symptoms of infection were present in the majority (78%) of 
patients with bacterascites. Sole abdominal discomfort was reported by 18%, HE by 16%, 
abdominal pain by 9%, and fevers or chills by 3%. A combination of these symptoms were 
present in 32%: 13% had HE and abdominal pain, 11% HE, fever and abdominal pain, 5% 
fever and abdominal pain, and 3% HE and fever.
 Symptomatic patients had a similar age (mean 64 vs 63 years; p=0.907), MELD score 
(median 20 vs 19 points; p=0.313), serum creatinine (median 106 vs 104 mmol/L; p=0.606) 
and PMN count in ascites (median 23 vs 19 cells/µL; p=0.576) compared to asymptomatic 
patients. Table 2 shows additional characteristics in relation to the presence of symptoms. 
Monomicrobial bacterascites was just as likely to be symptomatic as polymicrobial 
bacterascites (p=0.660). Seventeen percent of patients with bacterascites were diagnosed 
with concomitant infections of the respiratory tract (6%), urinary tract (5%) or skin 
(6%). Concomitant blood cultures were obtained in 42% and 17% of symptomatic and 
asymptomatic cases, respectively. The proportion of positive blood cultures did not 
statistically differ between the groups.
 Fourteen patients were diagnosed with more than one episode of bacterascites. In 
5 patients, the second episode was diagnosed within 5 days, and in 9 patients after a 
median time of 31 days. Of these 14 patients, 9 patients died, 4 patients received a liver 
transplant, and 1 patient was lost to-follow-up. The median time till one of the endpoints 
was reached was 74 days. When patients with a single episode were compared with 
patients with multiple episodes, there were no statistical differences in age, gender, 
MELD score, PMN count in ascites, presence of symptoms, antibiotic prophylaxis use, or 
presence of a GI bleed.
 In 36 of 142 bacterascites episodes (25.4%), an admission to the intensive care unit 
(ICU) was necessary; 14 cases (9.9%) of bacterascites were diagnosed on the ICU and in 22 
cases (15.5%) patients were admitted to the ICU after organ failure development following 
bacterascites diagnosis. ICU admission was less than 7 days in 21 cases, between 7 and 14 
days in 6 cases, between 14 and 30 days in 4 cases, longer than 30 days in 5 cases.
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Microbiology
Monomicrobial bacterascites was found in 81% of all episodes, consequently multiple 
pathogens were cultured in 19% of all episodes. In polymicrobial bacterascites two or 
three different organisms were cultured. Gram-positive bacteria were predominantly 
cultured in monomicrobial bacterascites. The 177 species cultured in monomicrobial and 
polymicrobial bacterascites are listed in Figure 1. Staphylococci were most often isolated 
(43%), followed by Streptococci (17%), Enterococci (14%) and Escherichia (11%). The 
cultured species of these four most common found genera are subtyped in Supplementary 
Figure 1.
 
Figure 1. Type of pathogens cultured in 142 bacterascites episodes classified by genus in absolute 
numbers. 
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Multidrug-antibiotic resistant (MDR) organisms were isolated in 25% of all episodes. 
Methicillin-resistant Staphylococci were the most frequently found MDR organism 
(N=26), followed by extended-spectrum beta-lactamase (ESBL) producing bacteria (N=8). 
A similar proportion of patients using primary antibiotic prophylaxis were infected with a 
MDR organism (29.0%) compared to patients without prophylaxis (23.1%) (p=0.506).
Antibiotic therapy
In 96 (68%) of the total 142 episodes of bacterascites antibiotic treatment was initiated: in 
49 episodes after paracentesis and before culture results became available, in 47 episodes 
after culture results were known. In 16 cases the antibiotic treatment was modified based 
on culture results. Amoxicillin-clavulanic acid combination was most often prescribed 
(30%), followed by cephalosporin (14%) and vancomycin (10%). Symptomatic patients 
more often received treatment compared to asymptomatic patients (72% vs 52%; p=0.031). 
Patients with higher MELD score (HR 1.156 per point, 95%CI 1.060–1.260, p=0.001), higher 
PMN count in ascites (HR 1.017 per point, 95%CI 1.005–1.030, p=0.007), an infection with 
another bacterial genus than Staphylococci (HR 3.512, 95%CI 1.333–9.253, p=0.011), 
and a female gender (HR 2.837, 95%CI 1.066–7.547, p=0.037) were more likely to receive 
antibiotic treatment for bacterascites.
 In 46 episodes of bacterascites, antibiotic treatment was not initiated. In 31/46 
episodes (67%), patients had signs or symptoms of infection. A total of 111 episodes of 
bacterascites was symptomatic. The ascitic PMN count in 80 patients who were treated 
with antibiotics was significantly higher (median 31, range 0–235) than the count 
(median 13, range 0-71) in those patients (n=31) who did not receive antibiotic treatment 
(p=0.002). Figure 2 shows a flow chart of the clinical course of the untreated episodes of 
bacterascites. Of these 46 bacterascites episodes, the patient died before culture results 
were known in 8 cases, in all cases the patients died of decompensating liver disease. 
These 8 patients had a median MELD score of 29 (IQR 18–30), median serum creatinine 
of 147 μmol/L (IQR 100–250), and 5/8 patients were admitted at the ICU; either before 
paracentesis (2 patients), or after paracentesis (3 patients). SBP developed in 6 cases, 
and bacterascites persisted in 5 cases. The latter group and those diagnosed with SBP 
were immediately treated with antibiotics. A logistic regression analysis was performed 
in the untreated patients to identify risk factors for liver-related death before culture 
results were known, SBP development, and persisting bacterascites (19/46) compared 
to clinical remission (27/46). We found that MELD score (HR 1.286 per point, 95%CI 
1.071–1.546, p=0.007) and age (HR 1.113 per year, 95%CI 1.027–1.205, p=0.009) were 
independent risk factors.
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Clinical course and outcome
The survival analyses included 114 patients with bacterascites and 88 patients with SBP, 
after the exclusion of patients with both SBP and bacterascites. The median follow-up 
time in 114 patients was 38 days (IQR 15–272 days). In this study cohort, 27 patients were 
alive or lost to follow-up, 16 patients received a liver transplant, and 71 patients died. The 
causes of death were in 36 patients (50.7%) liver disease-related, in 29 patients (40.9%) 
unknown, and in 6 patients (8.4%) a combination of liver disease-related and non-liver 
disease-related.
 The cumulative mortality rates in bacterascites patients (1-month: 36%; 3-month: 
56%; 6-month: 62%; 1-year: 66%) are statistically comparable to that reported for SBP 
patients (1-month: 34%; 3-month: 54%; 6-month: 67%; 1-year: 77%) (log-rank test 
p=0.397).(Figure 3)
Figure 2. The clinical course of patients with bacterascites without antibiotic treatment.
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 The most important predictive factors for 3-month mortality after bacterascites 
diagnosis were: MELD score and the presence of hepatic encephalopathy.(Table 3) Figure 
4 shows the MELD score-dependent relation of survival in 114 patients with bacterascites 
and 88 patients with SBP.
Table 3. Independent predictive factors of 114 bacterascites patients predicting 3-month mortality 
(58 events) identified by multivariable Cox-regression analysis.
HR 95% CI p-value
MELD score (per point) 1.099 1.082 – 1.156 <0.001
Hepatic encephalopathy
    None (reference)
    West Haven grade 1 – 2
    West Haven grade 3 – 4 
1
1.411
3.209
0.697 – 2.856
1.614 – 6.381
0.002
Abbreviations: MELD, model for end-stage liver disease.
Figure 3. Comparable cumulative survival curves shown for 114 patients with bacterascites 
(grey solid line) and 88 patients with SBP (black solid line) (log-rank test p=0.3973). 
The dashed lines with corresponding colors display the 95% confidence interval.
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Bacterascites in comparison with SBP in the literature
Our literature search for relevant studies of SBP identified 17 publications.(Table 4)(10, 
15-30) The reported baseline clinical characteristics including age, gender distribution, 
and liver disease severity scores of SBP were comparable to those identified in our 
patient population with bacterascites. In addition, the cumulative mortality rate in our 
bacterascites cohort (1-month: 36%; 6-month: 62%; 1-year: 66%) also appears comparable 
to that reported for SBP (1-month: 13-49%; 6-month: 52-59%: 1-year: 49-70%).
Figure 4. The figure shows a MELD score-dependent relation for the three-month survival 
after bacterascites diagnosis of 114 patients (dark grey solid line with squares). The 
survival of 88 patients with SBP (black broken line with diamonds) and advanced chronic 
liver disease (light grey solid line with triangles) are plotted for comparison.
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DISCUSSION
Bacterascites is an infectious complication occurring in patients with advanced or end-
stage liver disease, and is associated with a high short-term mortality risk. Bacterascites 
tends to persist, or to evolve to SBP, in a significant proportion of cases. Further, our 
findings indicate that bacterascites diagnosed in in-hospital patients has great similarities 
to SBP. In particular, patients with bacterascites and SBP present with a similar degree of 
liver insufficiency and have a comparable poor prognosis.
 In our cohort, 78% of patients showed clinical symptoms of infection, which is 
reasonably similar to the rates of 66-71% in previously published studies.(4, 6) Although 
it is generally accepted that SBP is frequently accompanied by clinical symptoms, a 
proportion of 13-32% patients with SBP has been reported to be asymptomatic.(6)
 With the results of this study, it is difficult to clearly elucidate the underlying pathogenesis 
of bacterascites. Gram-positive bacteria were frequently isolated in bacterascites, which 
is in line with findings from other bacterascites series.(2, 5-7) However, only a minority of 
episodes of bacterascites was considered to be due to exogenous contamination. In many 
cases, patients showed evident symptoms of infection, had a concomitant positive blood 
culture, or there were evidence of a porte d’entrée from the skin through an inserted line 
or catheter. It could be hypothesized that Gram-positive bacteria are less virulent or less 
likely to induce an inflammatory host reaction, which has been previously postulated in 
studies analyzing patients with bacteremia.(31, 32) Furthermore, traumatic paracentesis 
were highly unlikely to explain any cases of bacterascites in our cohort. In all polymicrobial 
bacteracites a maximum of three different organisms were cultured and not the variety of 
bowel flora expected after perforation.(33) Thus, it is more likely bacterascites is an actual 
colonization of ascites, either behaving as a different form of peritonitis or with a large 
probability of evolving into a classic infection.
 Earlier reports have suggested bacterascites patients might have higher levels of 
bactericidal and opsonic activity, reflected by higher protein concentrations in ascites, 
preventing a full-blown inflammatory response.(4, 34) Despite the fact that protein 
concentrations in ascites were measured on an irregular basis in our cohort, the mean 
protein level of 16 g/L does not indicate patients are deviant from SBP patients.(35, 36)
Unexpectedly, female gender was one of the factors increasing the odds to receive 
antibiotic treatment for bacterascites. We found a correlation between female gender 
with auto-immune-related liver disease etiology and immunosuppressant use. Female 
patients were more likely to have auto-immune hepatitis, primary biliary cirrhosis, or non-
alcoholic steatohepatitis and more often used immunosuppressive medication. Possibly, 
the threshold to prescribe antibiotic treatment for bacterascites is lower in patients using 
immunosuppressive medication.
 One of the goals of this study was to determine the clinical course of bacterascites. 
In two-thirds of the cases, the treating physician decided to initiate antibiotic treatment. 
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However, in the 46 episodes not treated with antibiotics, 17% died before culture results 
were known. In the 26 untreated patients undergoing repeated paracentesis, 42% were 
diagnosed with either ongoing bacterascites or SBP.
 The results of this study do not support the importance to distinguish clinically between 
symptomatic and asymptomatic bacterascites. The proportion of untreated bacterascites, 
which spontaneously resolved, was equal in symptomatic and asymptomatic patients. 
Furthermore, the presence of signs or symptoms of infection was not an independent 
predictor for mortality.
 The rate of 25% MDR bacteria found in all bacterascites episodes was relatively high 
for the Netherlands, but it is in line with current international microbiologic SBP studies 
reporting MDR bacteria rates of 27–67%.(37-39) The involvement of MDR bacteria in 
bacterascites was not associated independently with mortality in our study. Whether 
there is an independent association between MDR bacteria and a worse prognosis is still 
unclear with contrasting findings in studies regarding SBP.(10, 20, 22, 40, 41)
 As shown in Figure 4, the prognosis after bacterascites is worse than the reported 
prognosis based on the MELD score, as developed in a large cohort of patients with 
advanced chronic liver disease.(11, 12) The relatively high rate of short-term mortality 
suggests bacterascites is either directly endangering the patient or a symptom of a critical 
condition. Therefore, this data suggests that these patients should be medically supported 
by all available means including antibiotic treatment. Timely and appropriate antibiotic 
treatment, as has been proven effective in SBP, seems appropriate in bacterascites.(9) 
Taking in consideration that 27 of the 46 untreated cases of bacterascites in our cohort 
spontaneously resolved bacterascites, this clinical measure might induce a significant over-
treatment. This study evidently does not proof that treating bacterascites in patients with 
spontaneously resolving infection will improve prognosis. Although we found age and MELD 
score important predictors for patients with a worse clinical course, it is clinically difficult to 
accurately distinguish these patients from patients resolving the infection spontaneously.
 To the best of our knowledge, this is one of the first studies concentrating solely on 
bacterascites by analyzing a large cohort of consecutive patients. Our cohort with 123 
patients is substantially larger than previously reported cohorts including 18-48 patients.
(2-7) One of the limitations of this study is that, due to the retrospective design, the 
natural course of bacterascites could not be optimally studied. For instance, it may well be 
that patients received antibiotic treatment while the bacterascites would have resolved 
spontaneously. It should also be pointed out that 14 patients had multiple bacterascites 
episodes, which could have led to a possible statistical bias, since a correlation between 
episodes of the same patient was ignored. Prospective studies would be necessary 
to further define the natural history of bacterascites and the optimal diagnostic and 
therapeutic strategy. Such studies could also confirm our finding that bacterascites carries 
a mortality risk comparable to that of SBP.
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 In conclusion, bacterascites is a complication of cirrhosis comparable to SBP with 
respect to clinical background and prognosis. Also considering that bacterascites seems to 
persist or to evolve into SBP in a substantial proportion of cases, with no clear differences 
in the course of symptomatic versus asymptomatic patients, our results may suggest that 
the (antibiotic) treatment strategy in bacterascites and SBP should be the same.
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Supplementary Figure 1. Four most common found bacteria genera cultured in bacterascites 
subtyped by species in absolute numbers.
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The impact of infections on delisting patients 
from the liver transplantation waiting list
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ABSTRACT
Background: Approximately 20% of the patients listed for liver transplantation die 
before transplantation can be accomplished. Understanding risk factors for waiting 
list mortality may help to improve survival and organ allocation. Infections are very 
common in patients with cirrhosis and are associated with significant morbidity 
and mortality. This study analysed the frequency and characteristics of infections 
in patients awaiting liver transplantation, identified risk factors for withdrawal from 
the waiting list and evaluated the impact of infections on the clinical outcome. 
Methods: Retrospective analysis of consecutive patients listed for liver transplantation in 
Erasmus MC, University Medical Center, Rotterdam, the Netherlands from 2007 to 2014. 
Results: Infections occurred in 144 of 327 studied patients (44%). In this cohort, 
23.4% of the patients on the liver transplantation waiting list were delisted or died 
before transplantation. Patients with an infection were 5.2 times more likely to 
become delisted than non-infected patients. In the 30 days after the first infection 
patients were 33.8 times more likely to become delisted compared to non-
infected patients. High age, high MELD score, refractory ascites and inappropriate 
antibiotic therapy were independent predictors for delisting due to infection. 
Conclusions: Infections occur frequently in patients on the liver transplantation waiting 
list and rapidly worsen patient’s prognosis.
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INTRODUCTION
Liver transplantation (LT) is a life-saving procedure for patients with sustained irreversible 
liver injury.(1, 2) However, LT from deceased donors is limited by the scarcity of suitable 
donor organs. The accumulating incidence of liver disease worldwide increases donor 
organ shortage and leads to a prolonged time for patients on the liver transplantation 
waiting list.(3) The median pretransplant waiting time among active wait-listed adults was 
9 months in 2015 in the United States and approximately 10 months in the Eurotransplant 
region.(4, 5) In the United States 19.8% of the listed patients died in 2015 before 
transplantation could be accomplished, which was comparable to the 18.4% mortality of 
listed patients in the Eurotransplant region.(4, 5)
 During the time awaiting transplantation, patients are at risk for progressive liver 
failure.(6) Infections are an important precipitating factor for acute decompensation and 
acute-on-chronic liver failure.(7, 8)
 Infections are present at admission or develop during hospitalization in 20 – 60 % 
of patients with liver cirrhosis and are associated with 4-fold increased mortality; up to 
30% of patients has been reported to die within 1 month and another 30% within 1 year.
(9-11) Intestinal bacterial overgrowth, increased bacterial translocation, and an altered 
inflammatory response are considered major etiological factors.(12, 13)
 Knowledge about risk factors for waiting list mortality may help improve organ 
allocation and reduce waiting list mortality. A recent study found that hospitalized 
cirrhotic patients with infections complicated by extrahepatic organ failure are at higher 
risk for delisting and death before LT.(14) However, the frequency of infections in wait-
listed patients and the subsequent risk of delisting and death after infection have not 
been clearly established.
 This study aimed to (1) analyse the frequency and epidemiology of infections in 
patients awaiting LT, (2) identify risk factors for infection-related removal from the 
waiting list, and (3) evaluate the impact of having an infection on the clinical outcome 
of listed patients.
PATIENTS AND METHODS
Patients
All consecutive patients on the liver transplantation waiting list from 2007 – 2014 at 
Erasmus MC, University Medical Center, Rotterdam, were studied retrospectively. Patients 
with acute liver failure or listed for a non-primary liver graft were excluded. Patients 
delisted because of clinical improvement, intercurrent psychiatric disorders (mostly 
substance-related disorders), non-liver-related mortality, or patients declining an offered 
organ were excluded.
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Data collection
Demographic and clinical data, and information on the clinical course, including details 
of infectious complications, were retrieved from hospital medical records. Diagnosis of 
infection and the type of infection were made according to definitions formulated by 
the Centers for Disease Control (CDC).(15-18) Episodes, clinically interpreted and treated 
as infection, without satisfying CDC-criteria were reviewed by two clinicians (infectious 
disease specialist and research physician). Statistical sensitivity analyses were performed 
to assess whether this subgroup was comparable to the group meeting CDC criteria for 
infection. All infections of patients were evaluated; hospitalized and non-hospitalized 
infections in both our center and in other centers. Infections taking place in other centres 
were communicated to physicians of our transplant center. Additional information was 
requested if information regarding the infection in other centres was not sufficient. 
Multidrug-resistant (MDR) bacteria were defined as bacteria with non-susceptibility to at 
least one agent in three or more antimicrobial categories, extended-spectrum β-lactamase 
(ESBL), or carbapenemase-producing Enterobacteriaceae.(19) Inappropriate antibiotic 
therapy was defined as: use of antimicrobial agents to which a pathogen was resistant in 
vitro or administration of antibiotic therapy with a delay of at least 24 hours after diagnosis 
of infection. Multidrug resistance and inappropriate antibiotic therapy were determined 
in a subgroup of patients with available antimicrobial susceptibility patterns and sufficient 
information about the timing of antibiotic therapy. Renal failure was defined as increase in 
serum creatinine of >50% from baseline, or a rise in serum creatinine of ≥ 26.4 µmol/L (≥ 0.3 
mg/dL) within 48 hours.(20) Refractory ascites was defined as ascites that did not recede 
or that reoccurred shortly after therapeutic paracentesis, despite sodium restriction and 
diuretic treatment.(21) Data were collected from the time of waiting list placement until 
the follow-up was completed. The follow-up was complete when a clinical endpoint was 
reached: 1) liver transplantation, 2) delisting or death due to infection, 3) delisting or death 
for other reasons (e.g. unmet Milan criteria), or 4) still registered on the waiting list on 1st 
May 2016. Delisting or death due to infection was defined as definite withdrawal from 
the list within 30 days after an infection was diagnosed due to clinical deterioration with 
suspicion of infection outside the liver. The endpoint ‘becoming delisted from the liver 
transplantation waiting list due to infection’ will be systematically used and will include: 
an inactive waiting list status without reactivation, delisting with infaust prognosis and 
death due to infection. 
Statistical methods
A mean and standard deviation (SD) was computed for numerical variables, if normally 
distributed, and compared using the Student’s T-test. Non-normal distributed continuous 
variables were summarized with a median and interquartile range (IQR), and compared 
using the Mann–Whitney Ranks Sum test. Categorical variables were expressed with 
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percentages and compared using the χ2 test. A two-sided p-value < 0.05 was considered 
significant. The probability for the occurrence of infection for the length of time after waiting 
list placement was presented using Kaplan-Meier. Patients were censored when a clinical 
endpoint was reached. Logistic regression modelling was employed to determine possible 
predictors for withdrawal from the waiting list due to infection and each determinant 
was reported with an odds ratio (OR). The analysed variables were age, gender, aetiology, 
MELD score, medication use, type of infection, microorganism of infection, MDR bacteria, 
inappropriate antibiotic therapy, events of acute decompensation, intensive care unit 
(ICU) admission, or an invasive procedure 30 days prior to infection. A time-dependent 
Cox proportional hazard model was used to study the non-proportional hazards effect 
of the first infection on the competing endpoints: liver transplantation, delisting or death 
due to infection, delisting or death with other reasons, and waiting on the list. The hazard 
for delisting is presumably highest during and right after the infection, while the hazard 
for liver transplantation commences to increase after the recovery of the infection. Thus, 
infection could have a non-proportional hazard on the competing endpoints compared 
to non-infected patients. The landmark analysis method was used to study time intervals 
after infection and the landmarks 30 days and 180 days after infection were chosen. The 
model was adjusted for covariates age, gender, aetiology, and MELD score at listing. The 
effect of the first infection on the various endpoints was assessed for the interval of 30 
days following infection, the interval between 30 to 180 days following infection and after 
180 days. Furthermore, the likelihood on becoming delisted in relation to the number 
of infections was analyzed using a multivariate Cox regression adjusted for age, gender, 
aetiology, and MELD score at listing. The odds on clinical endpoints are reported as hazard 
ratio (HR) on liver transplantation and delisting. In the logistic regression model, as well 
as the Cox proportional hazard models, variables with a p-value of < 0.20 in univariate 
analysis were included in a multivariate analysis, and maintained in the multivariate 
model with a p-value < 0.10. Statistical analyses were conducted using IBM SPSS Statistics 
for Windows, version 21.0 (Armonk, NY: IBM Corp.).
RESULTS
Patients
Four hundred forty-five patients were registered on the national liver transplant waiting 
list between January 2007 and January 2014. Three hundred twenty-seven patients were 
eligible for the present analysis.(Figure 1) The mean follow-up time was 208 days (IQR 
56 – 406). The study cohort included 217 men and 110 women. At time of waiting list 
placement, patients were aged 54 (IQR 46 - 60) years and had a median MELD score of 
16 (IQR 11 – 19). The baseline demographics and clinical characteristics of infected and 
non-infected listed patients at waiting list placement are shown in Table 1. Patients with 
infections had more frequent viral hepatitis or primary sclerosing cholangitis (PSC) as 
Chapter 6
96
aetiology, and less frequent hepatocellular carcinoma (HCC) (p<0.001). Furthermore, 
patients with infections had higher baseline MELD scores (p=0.003), and more often used 
antibiotic prophylaxis (p=0.005), diuretics (p=0.005), and laxatives (p=0.026).
Table 1. Demographic and clinical characteristics of patients at the time of listing for liver 
transplantation with respect to development of infections.
Characteristics
All patients
n = 327
Patients
without infection
n = 183
Patients
with infection(s)
n = 144
p-value
Age (years)* 54 (46 - 60) 54 (48 - 61) 52 (43 – 59) 0.239**
Male gender, n (%) 217 (66%) 129 (70%) 88 (61%) 0.075
Blood group, n (%)
     0
     A
     B
     AB
146 (45%)
117 (36%)
44 (13%)
20 (6%)
79 (43%)
69 (38%)
20 (11%)
15 (8%)
67 (47%)
48 (33%)
24 (17%)
5 (3%)
0.136
Aetiology of liver disease, n (%)
     Alcohol
     Viral
     PSC
     HCC
     Auto-immune & PBC
     Other
49 (15%)
32 (10%)
72 (22%)
90 (27%)
23 (7%)
61 (19%)
28 (15%)
7 (4%)
28 (15%)
76 (42%)
7 (4%)
37 (20%)
21 (15%)
25 (17%)
44 (31%)
14 (10%)
16 (11%)
24 (17%)
<0.001
MELD score* 16 (11 - 19) 15 (10 - 18) 17 (14 – 20) 0.003**
Child-Pugh score 8 (6 - 10) 8 (5-10) 9 (8-10) <0.001**
Medication use, n (%)
     Antibiotic prophylaxis
     Diuretics
     PPI
     Corticosteroids
     Non-corticosteroid                
     immunosuppressives
     NSBB
     Laxatives
86 (26%)
196 (60%)
160 (49%)
31 (10%)
19 (6%)
112 (34%)
110 (34%)
37 (20%)
97 (53%)
82 (45%)
11 (6%)
5 (3%)
66 (36%)
52 (29%)
49 (34%)
99 (69%)
78 (54%)
20 (14%)
14 (10%)
46 (32%)
58 (40%)
0.005
0.005
0.102
0.016
0.008
0.436
0.026
* Data are displayed as median with interquartile range. ** Mann-Whitney Rank Sum test.
(HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; NSBB, non-selective beta-blocker; PBC, 
primary biliary cirrhosis; PPI, proton-pump inhibitor, PSC, primary sclerosing cholangitis) 
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Figure 1. Flow diagram of study population.
  
Infections
In 144/327 (44%) of the listed patients at least one infection occurred; the number 
of infections in these patients ranged from one to eleven. The actuarial percentage of 
patients with an infection was 23% at 3 months, 29% at 6 months, 33% at 9 months 
and 37% after 12 months.(Figure 2) The median duration on the waiting list for patients 
with an infection was 381 days (IQR 137 - 753) compared to 163 days (IQR 43 - 320) for 
patients without infection (p<0.001). In total 318 infections occurred. Sixty-five patients 
experienced a single infection, 39 patients two infections, 40 patients three or more 
infections. Cholangitis (24%) was the most common infection, followed by spontaneous 
bacterial peritonitis (SBP) (18%), urinary tract infection (12%), respiratory infection (9%), 
bloodstream infection (7%), and gastro-intestinal infection (6%). The majority (83%) of 
infections were met by CDC criteria.
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Figure 2. The actuarial percentage of patients without an infection in the first year after waiting list 
placement.
In 78/318 (25%) of all infections microbiological studies were negative. Gram-negative 
bacteria were cultured in 73 infections (22%) and Gram-positive bacteria in 58 infections 
(18%).(Table 2) The antimicrobial susceptibility patterns and sufficient information about 
the timing of antibiotic therapy were available in 190 infections. Of these infections, 
25% were caused by multidrug-resistant organisms. The majority of multidrug-resistant 
organisms were Enterococci spp. (48%), followed by Enterobacteria spp. (32%), and 
Staphylococci spp. (13%). The initial antibiotic therapy was considered inappropriate 
in 34% of the infections. The reasons for inappropriate therapy were: microorganism 
not expected (Enterococcus n=20, Candida n=11, virus n=3, Pseudomonas n=1, 
Staphylococcus n=1, Streptococcus n=1), organism with acquired antibiotic resistance 
(n=14), negative cultures and clinical improvement after antibiotic switch (n=6), and 
administration of antibiotic therapy, according to guidelines, with a delay of at least 24 
hours after diagnosis of infection (n=7).
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Table 2. Results of microbiological studies for the most common types of infection.
Type of infection
Gram- 
negative 
bacteria
Gram- 
positive 
bacteria
Fungus
Multiple 
organisms
Negative or 
no culture 
performed 
SBP (n=58) 21 (36%) 16 (28%) 0 2 (3%) 19 (33%)
Cholangitis (n=75) 11 (15%) 10 (13%) 0 3 (4%) 51 (68%)
Urinary tract (n=39) 19 (49%) 11 (28%) 0 2 (5%) 7 (18%)
Respiratory (n=29) 2 (7%) 1 (3%) 0 5 (17%) 21 (73%)
Bloodstream (n=22) 9 (41%) 8 (36%) 1 (5%) 4 (18%) 0
Gastro-intestinal (n=19) 4 (21%) 2 (11%) 2 (11%) 0 11 (57%)
(SBP, spontaneous bacterial peritonitis)
Risk factors for delisting
In our study cohort, 245 (74.9%) patients underwent liver transplantation, 42 (12.8%) 
were delisted due to infection, 34 (10.4%) were delisted for other reasons, and 6 (1.8%) 
were still on the waiting list at the end of follow-up in the context of this study. The 
proportion of patients receiving a liver graft was higher in patients without infections 
(80.9%) as compared to patients with infections (67.4%) (p=0.012). 
 In 13.2% (42/318) of all infections, patients were delisted in the 30 days following 
infection. In this time interval no patients were delisted due to other reasons than 
infection. Risk factors associated with delisting due to infection were identified and 
univariate analysis indicated 15 possible predictors.(Supplement 1) Bloodstream 
infection, respiratory infection and SBP more often led to delisting compared to 
cholangitis, urinary tract infection and gastro-intestinal infection.(Figure 3a) In addition, 
delisting occurred more often after infections caused by multiple organisms or fungus 
in comparison with infection caused by single bacteria or when no microorganisms 
could be identified.(Figure 3b) Furthermore, an initial inappropriate antibiotic therapy 
and the presence of refractory ascites were significant predictors for delisting or death.
(Figure 4)
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Figure 3. Clinical endpoint 30 days after infection shown in boxplots for group variables A) type of 
infection (p=0.003), and B) isolated microorganism (p=0.001).
Multivariate logistic regression analysis revealed four independent predictors for delisting 
after adjusting for gender: age (OR 1.1 per year; 95% CI 1.0 – 1.2; p=0.001), MELD score (OR 
1.3 per point; 95% CI 1.2 – 1.4; p<0.001), inappropriate antibiotic therapy (OR 3.7; 95% CI 
1.1 – 12.4; p=0.035), and refractory ascites present within 30 days prior to infection (OR 3.3, 
95% CI 0.9 – 12.0).(Table 3)
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Figure 4. The survival of patients in the first year after the first infection. (A) Patients with an 
appropriate and inappropriate antibiotic treatment are shown in different curves. The solid line 
shows values for patients with an appropriate antibiotic treatment and the dotted line for patients 
with an inappropriate antibiotic treatment. (B) Patients with and without refractory ascites are 
shown in different curves. The solid line shows values for patients without refractory ascites and the 
dotted line for patients with refractory ascites.
 
Sensitivity analyses were performed on the subgroups of CDC-validated infections and 
non-CDC-validated infections. The multivariate logistic regression model identified the 
same predictors for delisting within the 30 days following infection in both groups. There 
were no statistical significant differences between the subgroups and the complete 
study cohort.
B
A
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Table 3. Multivariate regression analysis of risk factors for infection-related withdrawal from the 
waiting list.
Risk factors Odds ratio 95% CI p-value
Multivariate model (adjusted for gender)
Age at time of infection (per year) 1.133 1.049 – 1.223 0.001
MELD score (per point) at time of infection 1.295 1.169 – 1.435 <0.001
Refractory ascites 30 days prior to infection (n=83) 3.348 0.932 – 12.024 0.064
Inappropriate antibiotic therapy (n=58) 3.683 1.096 – 12.376 0.035
(MELD, model for end-stage liver disease)
The risk for delisting in the first month, half year, and afterwards
The Cox proportional hazard model showed that patients with one or more infections 
were more at risk of becoming delisted than patients without infections (HR 5.2; 95% CI 
3.0 – 8.8; p<0.001). There is a time-dependent hazard for becoming delisted or receiving 
a liver transplant following the first infection compared to wait-listed patients without 
infection. The hazard for delisting is highly increased in the first 30 days after infection (HR 
33.8; 95% CI 7.2 – 157.9; p<0.001), declines between 30 to 180 days (HR 5.7; 95% CI 2.6 – 
12.3; p<0.001) and further after 180 days (HR 2.2; 95% CI 1.1 – 4.5; p=0.036).
Impact of the number of infections
The likelihood of delisting or death for patients with 1 infection (n=65), 2 infections 
(n=39), or ≥ 3 infections (n=40) was compared with patients without infection (n=183).
(Supplement 2) The cumulative number of infections showed an increased risk for 
delisting after one and two infections (HR 12.1; 95% CI 6.8 – 21.7; p<0.001 and HR 25.0; 
95% CI 13.1 – 47.8; p<0.001, respectively). This effect was attenuated in patients with 3 or 
more infections (HR 3.3; 95% CI 0.8 – 14.7; p=0.114). 
DISCUSSION
This is the first study, to our knowledge, describing the impact of infection on liver 
transplantation waiting list dynamics. In this cohort, 23.4% of the patients became too 
sick or died before transplantation. Infection occurred in almost half of the patients (44%) 
and was the primary cause for delisting. Patients with an infection are 5.2 times more 
likely to become delisted than non-infected patients. In the 30 days after the first infection 
patients are likely to migrate from the waiting list with a hazard of 33.8 for becoming 
delisted. High age, high MELD score, initial inappropriate antibiotic therapy and the 
presence of refractory ascites were significant predictors for delisting or death.
 The results from our study indicate infection is the leading cause for delisting. This 
endorses the hypothesis that infection is the most important precipitating event for 
acute decompensation and acute on chronic liver failure resulting in (multi)organ 
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failure.(22) Interestingly, the risk for death or delisting attenuates after 3 infections. 
Most of these patients were listed for PSC or auto-immune hepatitis and experienced 
recurrent cholangitis, which does not lead to delisting. The high incidence of PSC could 
explain the relative high frequency of cholangitis compared to other studies.(23, 24) 
Cholangitis leads to delisting infrequently (as shown in Figure 3). We therefore postulate, 
that PSC-related cholangitis leads to an increased burden of disease but does not affect 
the rate of delisting.
 The observed epidemiological change that bacterial infections are more often caused 
by Gram-positive and MDR bacteria was confirmed in this study.(11, 25-28) The rate of 
25% MDR bacteria found in the study population was not expected from earlier studies 
in the Netherlands.(29, 30) This can be explained mainly by the difference of international 
guidelines and the Dutch national guideline to define MDR organisms.(19, 31) In particular, 
the definition for multidrug-resistant Enterococci spp. is much broader in international 
guidelines, which explains the majority of MDR organisms.
 In contrast to earlier studies, the use of antibiotic prophylaxis did not significantly 
protect patients for delisting within 30 days following infection. In patients with advanced 
liver disease, long-term administration of norfloxacin reduces the incidence of SBP, 
prevents further decompensation and improves survival.(32, 33) Several studies have 
already demonstrated that the current recommended antibiotic prophylaxis occasionally 
fails due to norfloxacin-resistant organisms.(25, 34, 35)
 In this cohort, 23.4% of the patients became too sick or died before transplantation, 
which is the unfortunate reality previously reported with data from transplant allocation 
programs.(4, 5, 36, 37) A recent prospective study by Reddy et al. discusses the impact of 
infection in hospitalized patients listed for LT on clinical outcome. This study only included 
infected patients and did not contain a control cohort of patients without infections.(14) 
Our study population consisted of all patients registered for LT, including patients with 
cirrhosis as well as patients with HCC. Naturally, HCC patients follow a different course in 
progress of liver disease, featured by lower MELD score, less liver-related comorbidities 
and less infections.
 Although the study was carefully prepared, this study entailed limitations arising from 
the study design and daily clinical practice. First, the retrospective design encompassed data 
from hospitalization episodes in other centres, which was occasionally unavailable. It was 
not feasible to differentiate between nosocomial, health care-acquired and community-
acquired infections, because patients were not prospectively and systematically screened 
for infection on hospital admission. Secondly, 83% of infections were classified by the 
standardized CDC criteria while an expert committee categorized the other proportion. 
This is inevitable in clinical practice when bacterial and fungal cultures are not standard 
performed or sometimes fail. Thirdly, the absence of predefined criteria for delisting 
patients is leading to subjective decision-making based on an expert opinion of the 
transplant hepatologist, which is representative of what occurs in daily clinical practice. 
Chapter 6
104
Fourthly, information about temporary delisting was unfortunately not at hand. This could 
have biased the results, since patients with a systemic infection acquire a temporarily 
inactive status on the waiting list and are not eligible for liver transplantation at that very 
moment. Lastly, we analysed patients and waiting list practices in the Netherlands. The 
Dutch population is presumably listed more often with PSC and with lower MELD scores 
compared to patients on the waiting list in the United States.(4) The results should be 
translated with care to other centers and geographical regions.
 The results of this study underline the importance of appropriate and timely antimicrobial 
therapy once more. The clinical importance has been discussed in multiple cohort studies 
including cirrhotic patients with SBP or septic shock.(38-41) However, the significance of 
this issue has not yet been demonstrated for various infections in patients waiting for LT. 
 Emphasis should be directed on the prevention and treatment for infection by adequate 
antibiotic prophylaxis and immediate effective antibiotics, respectively. Knowledge about 
multidrug-resistant bacteria and geographical susceptibility patterns is crucial in order 
to address these issues. We hypothesize the implementation of periodically microbial 
colonization swabs in listed patients could support clinicians to prescribe effective 
antimicrobial prophylaxis and initiate immediate successful treatment. Improving clinical 
care regarding infection prevention and treatment would hypothetically lower waiting 
list mortality and could positively influence the patient’s pre-transplantation and post-
transplantation condition.
 Future studies could focus on this window of opportunity for LT after the infection. It is 
necessary to gather more understanding when infection is likely to resolve or worsen, and 
which patients can benefit from early LT. Identifying biological and clinical parameters 
during the infection and the recovery could assist physicians in waiting list decision-making 
of re-activating patients’ waiting list status or delisting. Additionally, prospective studies 
could benefit the knowledge about the pathophysiology of the clinical deterioration 
following the infection. Following this argument, research needs to be conducted whether 
infection might be considered as an exception in the transplantation priority algorithm, 
similar to patients with HCC and PSC. At last, outlining defined criteria for delisting could 
make the decision as objective and well-considerate as the prioritization for LT.
 In conclusion, this study demonstrates a large proportion of patients on the liver 
transplantation waiting list have infections. Infections have a negative effect on the 
outcome for patients and therefore antimicrobial schedules should be properly individual 
adapted for effective prophylaxis and treatment of infections.
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Supplement 1. Univariate regression analysis of risk factors for infection-related withdrawal from 
the waiting list.
Risk factors odds ratio 95% CI p-value
Univariate model
Age at time of infection (per year) 1.079 1.037 – 1.122 <0.001
Male gender 0.500 0.260 – 0.962 0.038
Aetiology of liver disease
    ∙    Alcohol (n=33)
    ∙    Viral (n=52)
    ∙    Auto-immune (n=147)
    ∙    HCC (n=26)
    ∙    Other (n=60)
1 (ref.)
1.114
0.422
0.310
0.413
0.388 – 3.200
0.157 – 1.137
0.058 – 1.639
0.126 -1.352
  
0.085
MELD score (per point) at listing 1.102 1.049 – 1.157 <0.001
Medication use at listing
    ∙    Diuretics (n=205)
    ∙    Laxatives (n=110)
4.757
1.679
1.813 – 12.482
0.870 – 3.241
0.002
0.122
Decompensation 30 days prior to infection
    ∙    Kidney failure (n=55)
    ∙    Refractory ascites (n=83)
    ∙    Hepatic encephalopathy (n=83)
    ∙    GI bleeding (n=35)
6.476
3.590
4.825
2.218
3.191 – 13.143
1.829 – 7.049
2.422 – 9.613
0.930 – 5.286
<0.001
<0.001
<0.001
0.072
ICU admission 30 days prior to infection (n=29) 4.295 1.833 – 10.067 0.001
Invasive procedure 30 days prior to infection
    ∙    Endoscopy (n=50)
    ∙    Drip feeding (n=29)
    ∙    CVVH/MARS (n=10)
    ∙    Mechanical ventilation (n=12)
1.933
6.207
18.461
10.994
0.877 – 4.262
2.699 – 14.275
4.558 – 74.769
3.305 – 36.569
0.102
<0.001
<0.001
<0.001
Type of infection
    ∙    SBP (n=58)
    ∙    Cholangitis (n=75)
    ∙    Urinary tract infection (n=39)
    ∙    Respiratory infection (n=29)
    ∙    Sepsis (n=22)
    ∙    Gastro-intestinal infection (n=19)
    ∙    Other (n=76)
1 (ref.)
0.074
0.622
2.450
3.111
0.302
0.825
0.009 – 0.599
0.177 – 2.183
0.849 – 7.073
1.013 – 9.558
0.036 – 2.559
0.312 – 2.184
0.003
Microorganism
Gram-negative bacterium (n=73)
Gram-positive bacterium (n=58)
Fungus (n=15)
Multiple organisms (n=22)
Negative culture (n=78)
1 (ref.)
2.326
4.061
9.306
1.101
0.792 – 6.836
0.985 – 16.745
2.848 – 30.405
0.352 – 3.444
0.001
MELD score (per point) during infection 1.218 1.150 – 1.291 <0.001
Antibiotic therapy inappropriate (n=58) 3.463 1.483 – 8.087 0.004
(CI, confidence interval; CVVH, continuous veno-venous hemofiltration; GI, gastro-intestinal; HCC, hepatocellular 
carcinoma; ICU, intensive care unit; MDR, multidrug-resistant; MARS, molecular adsorbent recirculating system; 
MELD, model for end-stage liver disease; SBP, spontaneous bacterial peritonitis) 
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Supplement 2. Hazard ratios for liver transplantation or delisting from the liver transplantation 
list in patients with 1 infection, 2 infections, and ≥ 3 infections compared with patients without 
infection. The hazard ratios are obtained using a time-dependent Cox proportional hazard model 
and the model was adjusted for age, gender, and MELD score at listing.
 
 
Results are presented as hazard ratio (HR) and 95% confidence interval (CI).
* p-value < 0.05.
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ABSTRACT
Background: Colorectal cancer screening with colonoscopy is commonly used in 
candidate patients for liver transplantation. We initiated this study to define the risk-
benefit ratio of performing screening colonoscopy in this population.
 
Methods: A retrospective observational study of all consecutive patients undergoing 
colonoscopy during pre-liver transplantation screening between 2004-2017 was 
conducted. Endoscopic and pathological findings and clinical events potentially related 
to the colonoscopy in the 30 days after the procedure were registered and compared with 
a 30 days in-patient control time frame.
 
Results: A total of 858 colonoscopies were performed in 808 patients (65% male; median 
age 55 years (IQR 47-62); median MELD score 15 (IQR 11-18)). Colorectal cancer was found 
in 2 patients (0.2%) and advanced adenomas in 44 patients (5.4%). The only independent 
risk factor for an advanced neoplasm was age (OR 1.072 per year; 95%CI 1.031-1.115; 
p<0.001).
 During the 30 days post-procedure period 178 clinical events occurred in 128 patients 
compared to 101 clinical events in 72 patients in the control time frames (p<0.001). 
After colonoscopy, there was a significant increased risk for renal failure (p=0.001) and 
gastro-intestinal bleeding (p=0.023). Presence of ascites and MELD score were identified 
as independent risk factors for acute renal failure and gastro-intestinal bleeding. During 
the study observation period 53.5% of the screened population actually underwent liver 
transplantation.
 
Conclusion: Colorectal cancer screening in pre-liver transplantation patients is associated 
with a relatively low prevalence of colorectal cancer, and an increased risk of post-
colonoscopy complications such as acute renal failure and gastrointestinal bleeding, 
especially in patients with advanced liver disease. Since the risk-benefit ratio of standard 
performance of a screening colonoscopy in this population appears questionable, 
alternative screening strategies should be considered.
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INTRODUCTION
Colonoscopy is commonly performed as part of the standard screening for neoplastic lesions 
in candidate patients for liver transplantation, although international guidelines do not 
clearly state in which patients it should be mandatorily performed or might be omitted.(1-3)
 The prevalence of colorectal cancer (CRC) in liver transplantation candidates has not been 
well defined. Several studies have reported that the prevalence of premalignant colon lesions, 
i.e. advanced adenomas, in this patient population varies from 5.8 – 13.9%.(4-8) Removal of 
these precursor lesions is recommended, also considering the potentially accelerated rate of 
progression to CRC during long-term immunosuppressive therapy after transplantation.(9)
 In addition, little quantitative data are available pertaining to the safety of colonoscopy 
in this population. Several case series have suggested that patients with end-stage liver 
disease undergoing colonoscopy are at increased risk for haemorrhage and perforation after 
polypectomy.(10, 11) Other reported complications include bacteraemia, peritonitis, and 
renal failure.(12-19)
 The aim of the present study was to assess the yield and safety of screening colonoscopy 
in a large consecutive cohort of patients who underwent evaluation for liver transplantation, 
by investigating the prevalence and predictive factors for CRC and advanced adenomas and 
the incidence and predisposing factors for post-procedural complications.
METHODS
Study design and patients
All consecutive patients undergoing colonoscopy during pre-liver transplantation 
screening from 1st January 2004 - 1st May 2017 in the Erasmus MC, Rotterdam, the 
Netherlands, were retrospectively included. The study protocol conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki as reflected in approval by the institution’s 
human research committee on January 23rd 2017. Written informed consent was not 
necessary considering the nature of the study.
Colonoscopy procedure
Bowel preparation was achieved using polyethylene electrolyte glycol (PEG) solutions. 
Sedation, using midazolam and/or fentanyl, was given at the discretion of the patients’ 
preference and physicians’ judgement. Endoscopic reports were retrieved from the 
automated EndoALPHA reporting system (Endobase; Olympus Winter & Ibe, Hamburg, 
Germany). Specimens of resected colon tissue were processed and reviewed by specialized 
gastrointestinal pathologists using standard histologic methods.
Data collection
Clinical patient characteristics at the time of colonoscopy including gender, age, etiology 
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and severity of liver disease, presence of hepatocellular carcinoma (HCC), ascites (graded as 
none, diuretic-responsive and refractory), hepatic encephalopathy (HE) (graded according 
to the West Haven criteria) and laboratory values (creatinine, albumin, bilirubin and INR) 
were collected from electronic patients records. Data of the colonoscopy procedure, 
including use of premedication, adequacy of bowel preparation, cecal intubation rate, size, 
morphology, and histopathology of tumors, polyps and other endoscopic findings (e.g. 
inflammatory bowel disease (IBD), rectal varices and portal enteropathy) were recorded. 
In the context of this study, patients were followed till 1 year after liver transplantation, 
the date of death when not transplanted, or till the end of the study observation period 
(August 1st, 2018) when they were still on the waiting list.
Complications
All clinical events potentially related to the colonoscopy were registered in the 30 days 
period after the procedure. To assess colonoscopy associated risk in comparison with 
the general risk in this particular population, relevant clinical events were also registered 
in the 30 days period preceding the procedure, when this was performed in even years 
(e.g. 2004, 2006, etc.), and between day 31 to 60 after the procedure when this was 
performed in uneven years.(Figure 1) Patients who received a liver transplantation 
or died during the control time frame were not taken into account with respect to the 
assessment of complications. The following events were considered to be potentially 
related to colonoscopy: post-polypectomy haemorrhage, colon perforation, acute renal 
failure, gastrointestinal (GI) bleeding, new-onset or worsening of ascites and hepatic 
encephalopathy, bacterial infections (including bacteraemia, fever of unknown origin, 
spontaneous bacterial peritonitis (SBP), and respiratory, urogenital and other infections), 
cardiopulmonary events (including new-onset arrhythmias, myocardial infarction, 
congestive heart failure, aspiration pneumonia, and respiratory insufficiency), and 
significant rise in serum bilirubin.
Figure 1. Schematic view of the chosen control time frames in this study.
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Definitions
Liver disease severity scores were calculated and patients were classified according to 
Child-Pugh (CP).(20) The model for end-stage liver disease (MELD) score was calculated 
with the formula: 0.957 × log(creatinine in mg/dL) + 0.378 × log(bilirubin in mg/dL) + 
1.120 × log(INR) + 0.643.(21, 22) The adequacy of bowel preparation was classified as 
inadequate, poor, fair, good, or excellent using the Aronchick bowel preparation scale.
(23, 24) Cecal intubation was defined as complete visualisation and intubation of the 
caecum, confirmed by the visual landmarks of the ileocecal valve and triradiate cecal fold.
(25) Patients with an inadequate or poor bowel preparation were excluded from cecal 
intubation rate calculations. Colon tissue specimens were classified as normal colon 
tissue, hyperplastic polyps, inflammatory polyps, non-advanced adenomas, advanced 
adenomas, or CRC.(26) Non-advanced adenoma was defined as all tubular adenoma 
and serrated non-advanced adenoma.(26) Sessile serrated adenoma/polyp (SSA/P) was 
defined as predominantly architectural distortion with irregular dilated crypts that often 
have an L or T shape.(27) Traditional serrated adenoma (TSA) was defined as proburant 
or pedunculated grown pattern with distorted villiform configurations with columnar 
cells having abundant eosinophilic cytoplasm or centrally located elongated nuclei.
(27) Advanced adenomas were defined as adenomas ≥ 10 mm, adenomas with high-
grade dysplasia or with a villous component of at least 25%.(26, 28) Cancers were staged 
according to the 7th edition of the American Joint Committee on Cancer.(29) Advanced 
neoplasia was defined as advanced adenoma and/or colorectal cancer.
 Acute renal failure was defined as a serum creatinine increase by 50% or more within 
7 days or an increase of 0.3 mg/dL (26.5 μmol/L) within 2 days.(30, 31) GI bleeding was 
defined as all forms of variceal bleeding in the upper or lower gastrointestinal tract 
(thus excluding bleeding form a polypectomy site).(32) New-onset or worsening HE was 
defined as newly diagnosed or an increase of neurocognitive changes according to the 
West-Haven clinical criteria.(33, 34) New-onset ascites or worsening ascites was defined 
as a sudden increase of ascites and confirmation by ultrasound or fluid drainage by 
paracentesis. Bacterial infections were classified using Centers for Disease Control and 
prevention (CDC) criteria.(35, 36) Fever of unknown origin was defined as a prolonged 
febrile illness that persists without diagnosis after careful initial assessment.(37) SBP was 
defined as a polymorphonuclear (PMN) cell count in ascites ≥ 250/μL without a surgically 
treatable abdominal source of infection.(38) A bilirubin increase was defined as an increase 
of at least 5 mg/dL (85 μmol/L) within 2 days.
Statistical analysis
Continuous variables were reported as mean with standard deviation (SD), after visual 
confirmation of approximate normality, and compared using the Student’s T-test. 
Continuous variables with a non-normal distribution were reported as median with an 
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interquartile range (IQR) expressed as the 25th to the 75th percentile. Categorical variables 
were reported as count with proportion and compared using the Chi-square test. A two-
sided p-value <0.05 was considered significant.
 Multivariable logistic regression, carried out to identify risk factors for cecal intubation 
failure, included the candidate predictor variables: gender, age, MELD score, ascites, HE, and 
sedation medication during colonoscopy. Multivariable logistic regression, carried out to 
identify risk factors for an advanced neoplasm, included the candidate predictor variables: 
gender, age, liver disease aetiology, HCC, MELD score, and colorectal cancer screening (i.e. 
colonoscopy, FOBT/FIT test, CT-colonography or barium enema examination) in the prior 
5 years. Multivariable analyses for the logistic regression models were employed using the 
backward stepwise selection method with removal testing based on the significance of 
the likelihood-ratio statistic.
 Kaplan-Meier analysis was used to estimate 1- and 2-year survival rates after 
liver transplantation.
 All statistical analyses were performed using IBM® SPSS® Statistics for Windows, version 
24.0.0.1 (IBM Corp., Armonk, NY, USA).
RESULTS
Patient characteristics
From 1st January 2004 – 1st May 2017, 1145 patients underwent pre-liver transplantation 
screening in the Erasmus MC, Rotterdam, the Netherlands. A total of 337 patients were 
not included in the study, mainly because colonoscopy was performed in a referring 
hospital (n = 90), patients were listed with high urgent priority (n=74), or the screening 
was prematurely terminated because of clinical deterioration of the patient condition (n = 
41). The remaining 808 patients were included for the present analysis.(Figure 2) The study 
cohort included 524 men and 284 women with a median age 55 years (IQR 47 – 62) at 
the time of colonoscopy.(Table 1) The most frequent reason for pre-liver transplantation 
screening was alcoholic liver disease (22.9%), followed by viral hepatitis (21.4%), and 
primary sclerosing cholangitis (PSC) (17.6%).(Table 1) The prevalence of IBD in patients 
diagnosed with PSC was 59.9% (85/142 patients). HCC was present in 223 patients (27.6%). 
Median MELD score was 15 (IQR 11 – 18; range 6 – 40), 24.5% of patients had diuretic 
responsive ascites, 16.6% had refractory ascites and 97 (12%) patients had HE at the time 
of colonoscopy. Approximately 20% patients used at least one antibiotic agent during 
colonoscopy. One-fifth of patients received colorectal screening in the prior 5 years by 
colonoscopy; no cases were identified of patients undergoing colonoscopy after a positive 
screening with FOBT/FIT test, CT-colonography or barium enema examination.(Table 1)
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Figure 2. Flow chart of study inclusion.
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Table 1. Patient baseline characteristics at the time of screening colonoscopy.
Patients 
(n= 808)
Male gender, n (%) 524 (64.9%)
Age in years, median (IQR) 55 (IQR 47 - 62)
Etiology of liver disease, n (%)
    Alcoholic liver disease
    Viral hepatitis
    PSC
    PBC/auto-immune hepatitis
    Cryptogenic liver cirrhosis
    NASH
    Other
185 (22.9%)
173 (21.4%)
142 (17.6%)
65 (8.0%)
58 (7.2%)
41 (5.1%)
144 (17.8%)
HCC, n (%) 223 (27.6%)
Blood serum parameters
    Creatinin (μmol/L), median (IQR)
    Albumin (g/L), mean (SD)
    Bilirubin (μmol/L), mean (SD)
    INR, mean (SD)
71 (IQR 59 - 90)
33 (± 7)
87 (± 126)
1.4 (± 0.4)
Liver disease severity scores
    MELD score, median (IQR)
    Child-Pugh class, n (%)
        A
        B
        C
15 (IQR 11 - 18)
473 (58.5%)
294 (36.4%)
41 (5.1%)
Ascites, n (%)
    None
    Diuretic responsive
    Refractory
476 (58.9%)
198 (24.5%)
134 (16.6%)
Hepatic encephalopathy, n (%)
    None
    West-Haven grade 1 - 2
    West-Haven grade 3 - 4
711 (88.0%)
71 (8.8%)
26 (3.2%)
Antibiotic use*, n (%)
    Norfloxacin
    Rifaximin
    Rifamipicin
    Ciprofloxacin
    Amoxicilin and clavulanic acid
    Other
162 (20.0%)
82 (10.1%)
48 (5.9%)
9 (1.1%)
17 (2.1%)
5 (0.6%)
12 (1.5%)
Colorectal screening in the prior 5 years, n (%) 193 (23.9%)
* 11 patients used multiple antibiotic agents.
Abbreviations: HCC: hepatocellular carcinoma; INR: International Normalized Ratio; IQR: interquartile range; 
MELD: Model For End-Stage Liver Disease; NASH: non-alcoholic steatohepatitis; PBC: primary biliary cirrhosis; 
PSC: primary sclerosing cholangitis; SD: standard deviation. 
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Colonoscopy procedure
A total of 864 colonoscopies were performed in 808 patients. Bowel preparation adequacy 
was available in 663 patients and was scored excellent in 7.1%, good in 54.6%, fair in 16.1%, 
poor in 3.3%, and inadequate in 1%. Cecal intubation rate of the index colonoscopy was 
96.7%. Cecal intubation failed due to loop formation in 15 patients and abortion due 
to patient discomfort/abdominal pain in 12 patients. Multivariable logistic regression, 
carried out for risk factors for cecal intubation failure, identified MELD score (OR 1.090 per 
point; 95% CI 1.015 – 1.170; p=0.018), as an independent risk factor.
 In total, 56 re-colonoscopies were performed because of several reasons: poor 
bowel preparation (n=13), initial cecal intubation failure (n=25), anticoagulation status 
contra-indicated polypectomy (n=9), patients needed a re-colonoscopy after a period 
of 3 years on the liver transplantation waiting list or for re-liver transplantation (n=6), or 
for additional polypectomy or surveillance after polypectomy (n=3). In 6 patients with 
initial cecal intubation failure and in 5 patients with poor bowel preparation subsequent 
colonoscopy was postponed till after the transplantation.
 In this cohort, 799/864 (92.4%) colonoscopies were performed under conscious 
sedation using intravenous midazolam and fentanyl. Sixty-five procedures were performed 
using fentanyl (n=25), remifentanil (n=7), or without any premedication (n=33). Patients 
did not receive standard peri-procedural antibiotic prophylaxis.
Diagnostic yield
In total, 625 polypectomies were performed during colonoscopy with an average of 2.3 
polypectomies (± 1.3) per patient. At colonoscopy advanced neoplasia was found in 46 
(5.6%) patients: advanced adenoma in 44 (5.4%) and CRC in 2 (0.2%). Non-advanced 
adenoma in 151 (18.7%) including SSA/P or TSA in 13 (1.6%), hyperplastic polyps in 130 
patients (16.1%), inflammatory polyps in 3 (0.4%).(Table 2)
 In 58 of the remaining 465 patients, a lesion was macroscopically present, but 
polypectomy was not attempted due to impaired coagulation and/or a macroscopically 
benign character (n=41), or histopathologic evaluation was not possible due to loss or 
insufficient yield of tissue (n=17). At a subsequent colonoscopy, advanced adenoma was 
diagnosed in 3/58 cases and CRC in none.
 The only independent risk factor for advanced neoplasia was age (HR 1.072 per 
year; 95% CI 1.031 - 1.115; p<0.001). Advanced neoplasm was diagnosed in 5.6% of the 
patients aged 60 years or older, in 5.4% of the patients aged 50 – 59 years, in 1.8% of the 
patients aged 40 – 49 years, and no advanced neoplasm was diagnosed below the age of 
40 years.(Figure 3) The two patients with CRC were a 62-year old female with a T2N0M0 
rectal adenocarcinoma and a 64-year old female with a T2N0M0 adenocarcinoma of the 
sigmoid colon.
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Table 2. Findings at colonoscopy.
Patients (n= 808)
Diagnostic yieldⁱ, n (%)
    Colorectal cancer
    Advanced adenoma
            ≥ 10 mm
            ≥ 25% villous
            high-grade dysplasia
            ≥ 10 mm + high-grade dysplasia
            ≥ 10 mm + ≥ 25% villous 
            ≥ 25% villous + high-grade dysplasia
            ≥ 10 mm + ≥ 25% villous + high-grade dysplasia
    Non-advanced adenoma
            SSP/A or TSA
    Hyperplastic polyp
    Inflammatory polyp
    No lesions
2 (0.2%)
44 (5.4%)
17 
9 
4 
3
8
1
2
164 (20.3%)
13 
130 (16.1%)
3 (0.4%)
465 (57.6%)
Other pathologies*, n (%)
    Inflammatory bowel disease
    Rectal varices
    Angiodysplasia
    Portal  hypertensive colopathy
    Diverticulosis
    Hemorrhoids
92 (11.4%)
72 (8.9%)
61 (7.5%)
58 (7.2%)
57 (7.1%)
42 (5.2%)
ⁱAccording to the most advanced lesion.
*Patients could have multiple other pathologies.
Abbreviations: SSP/A: sessile serrated polyp/adenoma; TSA: traditional serrated adenoma. 
Figure 3. Most advanced lesion per participant found during colonoscopy.
The yield and safety of screening colonoscopy in patients evaluated for liver transplantation
123
7
Other colon abnormalities
In 294 patients (36.4%) other colon abnormalities were reported.(Table 2) There were no 
cases of newly diagnosed IBD.
Complications after colonoscopy
During the 30 days period after colonoscopy 178 clinical events occurred in 128 (14.9%) 
patients compared to 101 clinical events in 72 (8.6%) patients with an event in the control 
time frames (p<0.001).(Table 3)
Table 3. Frequency of complications in patients undergoing screening colonoscopy.
Complications during 30 
days 
post-colonoscopy 
(n=858)
Complications during 30 
days 
control time frame 
(n=835)
p-value
Acute renal failure, n (%) 33 (3.8%) 10 (1.2%) 0.001
Gastro-intestinal bleed, n (%) 25 (2.9%) 11 (1.3%) 0.023
Bacterial infection, n (%)
    SBP
    Fever of unknown origin
    Bloodstream infection
    Respiratory infection
    Gastro-intestinal infection 
    Urogenital infection
    Other
54 (6.3%)
18
15
12
4
4
3
0
37 (4.4%)
17
6
3
-
7
3
1
0.089
Hepatic encephalopathy, n (%) 47 (5.5%) 32 (3.8%) 0.109
Pulmonary complications, n (%)
    (Aspiration) pneumonia
    Respiratory insufficiency
10 (1.2%)
3
7
3 (0.4%)
-
3
0.058
Cardiac complications, n (%)
    New-onset arrhythmia
    Congestive heart failure
    Myocardial ischemia
7 (0.8%)
5
2
-
4 (0.5%)
1
2
1
0.391
Ascites (new-onset or 
worsening), n (%)
1 (0.1%) 4 (0.5%) 0.169
Bilirubin increase, n (%) 1 (0.1%) - 0.324
Abbreviation: SBP: spontaneous bacterial peritonitis.
After colonoscopy, there was a significant increased risk for acute renal failure (33 vs. 10; 
p=0.001). Patients with acute renal failure had an average creatinin rise of 66 μmol/L; 35 
were treated with volume expansion, albumin and/or vasopressors and 8 with dialysis. The 
presence of ascites (diuretic responsive ascites OR 1.199; 95% CI 0.356 – 4.038, refractory 
ascites OR 5.384; 95% CI 1.935 – 14.978, p=0.001) and high MELD score (OR 1.265 per 
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point; 95% CI 1.180 – 1.356; p<0.001) were independent risk factors for post-colonoscopy 
renal failure.
 The risk for GI bleeding not originating from polypectomy sites was also significantly 
elevated after colonoscopy (25 vs. 11; p=0.023). MELD score (OR 1.127 per point; 95% CI 
1.061 – 1.197; p<0.001) was found to be an independent risk factor for post-colonoscopy 
GI bleeding.
 Furthermore, there was a non-significant increase in bacterial infections (54 vs. 37 
cases; p=0.089), HE (47 vs. 32 cases; p=0.109), pulmonary complications (10 vs. 3 cases; 
p=0.058), and cardiac complications (7 vs. 4 cases; p=0.391), in the post-colonoscopy and 
control time frames, respectively.(Table 3)
 Post-polypectomy haemorrhage occurred in two patients, both could be 
endoscopically managed. In one patient colon perforation occurred after polypectomy, 
which was successfully treated conservatively.
 Since the study duration was 13.5 years, the impact of the time of screening was 
measured on the detection of advanced adenomas and complication occurrence. There 
were no statistical significant differences regarding the time of screening on these 
outcome measures.(Supplement 1)
Clinical course
The median follow-up time was 285 days (IQR 106 – 636). In this cohort, 260 patients 
(32.2%) died, 432 patients (53.3%) received a liver transplant, and 116 patients (14.4%) 
were waiting for a liver transplant at the end of the observation period. The 1-year survival 
rate after liver transplantation was 91%, and the 2-year survival rate 88%.
DISCUSSION
In this study, we assessed the diagnostic yield and safety of performing a screening 
colonoscopy in patients evaluated for liver transplantation. We found that CRC was 
diagnosed in 0.2% of the population and advanced adenoma in 5.4%. Age was the only 
significant predictive factor for advanced neoplasia. Furthermore, colonoscopy with 
standard PEG bowel preparation was associated with a significantly increased risk for 
renal failure and non-polypectomy GI bleeding, especially in patients with most severe 
liver disease.
 A key finding of the present study is the relatively low prevalence of CRC in this patient 
population. These results are consistent with those of comparable studies that did not 
find any case of CRC in patients undergoing pre-transplantation evaluation.(6, 8, 39) The 
5.4% prevalence of advanced adenomas in our study was comparable to that reported by 
Weismuller et al. (prevalence 5.8%; 243 patients with a mean age of 53 years), but differs 
markedly from the 13.9% prevalence (567 patients; median age of 54 years) reported 
by Jeschek et al.(6, 8) These diverging results may be related to differences in study 
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methodology since the latter study results were not based on the actual diagnosed rate 
of advanced adenomas, but rather to a statistical adjustment of this number assuming 
the same rate of advanced adenomas among resected and non-resected polyps.(8) The 
results of large cohort studies assessing the prevalence rate of advanced neoplasms in 
unselected healthy subjects, although of slightly older age, are in line with those in our 
study. Imperiale et al. reported a CRC rate of 0.6% and an advanced adenoma rate of 5.6% 
in 1994 patients with a mean age of 60 years and Stoop et al. found a rate of 0.5% and 
8.2%, respectively, in 1276 patients with a mean age of 61 years.(40, 41)
 Another important finding is that 53.5% of the population undergoing screening 
actually underwent liver transplantation. Although 14.4% are still waiting for a liver 
transplant, a substantial proportion of patients have died on the waiting list or were 
not placed on the waiting list due to contra-indications for liver transplantation.(42) 
Moreover, 9% of the 432 transplanted patients died within 1 year and an additional 
3% in the second year after transplantation. Thus, the number of patients that could 
theoretically benefit from screening colonoscopy is further decreased by the operative 
and post-operative mortality.
 Our results indicate that colonoscopy increases the risk for complications such as 
acute renal failure and GI bleeding. We hypothesize that this may be related to bowel 
preparation with an inherent substantial fluid load that may induce unwanted circulatory 
alterations and fluid shifts. Indeed, water retention in patients with a pre-existent 
hyperdynamic circulation, increasing the portal venous pressure, has been previously 
reported in patients undergoing bowel preparation with decompensated liver disease, 
congestive heart failure and chronic renal insufficiency.(13, 43) Our study result that MELD 
score is the most important predictive factor for these complications after colonoscopy 
supports this theory.
 The cecal intubation rate of 96.7% in our study is fairly similar to the rate of 83 – 96% 
found in other cohorts of patients evaluated for liver transplantation.(6, 39) Multiple 
explanations are proposed for the slightly lower cecal intubation rate in this population 
compared to that in healthy subjects. The presence of ascites may lead to more mobile 
bowel loops floating in ascitic fluid, and may lower the efficacy of external abdominal 
pressure in order to reduce loop formation.(39) Also, the cecal intubation rate may be 
adversely affected by other factors including overall poor general condition and reduced 
possibilities for effective use of premedication.(39) In the present study, MELD score was 
identified as an independent predictor for cecal intubation failure, which may support 
these hypotheses.
 Currently, the American Association for the Study of the Liver (AASLD) clinical practice 
guideline recommends that liver transplantation candidates should undergo an age 
and risk factor-appropriate cancer screening including colonoscopy without further 
specifications.(2) The European Association for the Study of the Liver (EASL) clinical 
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practice guideline states that CRC screening is mandatory for candidates older than 50 
years.(3) However, considering the currently available data, the indication for standard 
pre-liver transplantation screening colonoscopy may be questioned considering the 
balance between yield and associated risks and costs, also considering important other 
factors such as the substantial waiting list and perioperative mortality.
 We suggest that other screening strategies should be considered. A possible 
alternative approach could be the use of a fecal immunochemical test (FIT) as a general 
first line screening test in subjects aged 50 years or older, and to consider colonoscopy 
only in FIT-positive patients. Patients with inflammatory bowel disease, primary sclerosing 
cholangitis and other conditions associated with an increased risk for CRC should be 
managed according to generally accepted guidelines.
 This is the first study, to the best of our knowledge, that systemically assessed the 
complication risk of pre-liver transplantation screening colonoscopy, taking into account 
the underlying general risk for unwanted events associated with the liver disease. The 
considerable size of the study population and the completeness of data are other 
factors likely contributing to the reliability of our results. A limitation is that patients who 
underwent colonoscopy in another centre before referral were not taken into account. 
However, this was a relatively small group and our study design reflects the real world 
situation in a referral hospital for liver transplantation. Also, due to the retrospective 
design of the study, not all relevant factors, such as adequacy of bowel preparation, could 
be fully analysed.
 Future research projects regarding CRC screening in transplant candidates could focus 
on the assessment of factors relevant for more refined risk stratification in this population, 
such as age, gender, aetiology of liver disease, family history of CRC, body mass index, 
smoking and drinking habits, and comorbidities such as diabetes. It may be equally 
important to prospectively assess the results of alternative screening strategies.
 In conclusion, this study describes the yield and safety of colonoscopy in 
patients evaluated for liver transplantation screening and provides arguments why a 
reconsideration of guidelines regarding the necessity of colonoscopy in unselected 
patients seems appropriate. We propose that alternative colorectal screening strategies 
should be considered and further explored.
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Supplement 1. Sensitivity analyses of the time period of screening on the 
primary endpoints. 
 
A. Detection of advanced neoplasms during colorectal screening, 
separately shown for each time period of screening (p=0.135). 
 
B. Prevalence of complications after colonoscopy during colorectal 
screening, separately shown for each time period of screening (p=0.709). 
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Supplement 1. Sensitivity analyses of the time period of screening on the primary endpoints.
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We thank the colleagues for their interest in our study.(1) Although the risk for colorectal 
carcinoma after liver transplantation may be increased, our study shows that in this 
particular, vulnerable population the yield of advanced neoplasia detected by colonoscopy 
is low and is associated with an elevated risk of complications. In addition, we should like 
to stress the fact that only just over 50% of the screened patients actually underwent liver 
transplantation. Based on these data the timing of performing a screening colonoscopy 
may be reconsidered, e.g. performing screening colonoscopies post liver transplantation 
in a subset of patients.
 Although the sensitivity of FIT is low for adenoma and serrated lesions, sensitivity for 
CRC is around 80%. Therefore, FIT may be used as an alternative to screen patients pre-
liver transplantation. We agree that if FIT is chosen the cut-off used will be essential to 
assure an optimal benefit- risk balance.
 We continue to believe that the benefit-harm ratio of screening colonoscopy in 
all potential candidate patients for liver transplantation is questionable and that other 
strategies should be considered and further explored.
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ABSTRACT
Background: Sarcopenia is prevalent in patients with liver cirrhosis and is negatively 
associated with clinical outcomes. In a population screened for liver transplantation we 
aimed to assess the prevalence of abnormal nutritional status and to what extent a clinical 
screening tool is able to reliably select patients for extensive nutritional assessment 
including CT. We also evaluated which nutritional parameters are independently 
associated with clinical outcomes.
Methods: Analysis of consecutive patients undergoing detailed nutritional assessment 
during pre-liver transplantation screening from October 2015 to April 2017.
 
Results: In 102 included patients (66.7% male; median age of 56.3 years (IQR 43.9-64.0); 
median MELDNa score of 14.7 (IQR 9.4-19.0)), presarcopenia was diagnosed in 30/102 
patients (29.4%), sarcopenia in 20/102 (19.6%), and impaired muscle quality in 19/102 
(18.6%). Application of the EASL rapid screen tool as the primary instrument for nutritional 
assessment would have resulted in selection of 40/69 cases, thus 42.0% of patients with 
actual muscle mass depletion and/or impaired muscle function would not have been 
selected for further nutritional evaluation. In contrast to muscle mass depletion, impaired 
muscle function was a significant predictor for 6-month decompensation-free (p=0.006) 
and hospitalization-free (p=0.003) survival, when adjusted for age and MELDNa score.
 
Conclusion: In our population the efficacy of a clinical screening tool for malnutrition 
was unsatisfactory. A detailed nutritional assessment is therefore recommended in all 
patients undergoing liver transplantation screening. Impaired muscle function might be 
clinically more relevant than muscle mass depletion, and muscle function testing should 
be considered an integral part of nutritional assessment in chronic liver disease.
Identification and prognostic impact of malnutrition in a population screened for liver transplantation
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INTRODUCTION
Malnutrition – a nutrition-related disorder resulting from lack of intake or uptake 
of nutrition – is a frequent complication of advanced chronic liver disease and has 
been reported in 22-70% of patients awaiting liver transplantation.(1-4) Sarcopenia, 
characterized by a reduction in muscle mass and function, is a major component of 
malnutrition.(5) It is associated with a higher rate of complications (including infections, 
hepatic encephalopathy, and ascites), in addition to waiting list and transplantation-
related mortality.(2-6)
 The recent European association for the Study of the Liver (EASL) clinical practice 
guideline for nutrition recommends detailed multicomponent nutritional evaluation 
compromising assessment of 1) muscle mass by CT, 2) muscle function by handgrip 
strength or short physical performance battery, and 3) dietary intake including the 
quality and quantity of food and supplements.(Supplement 1)(4) Although the EASL 
and the European Society of Clinical nutrition and metabolism (ESPEN) emphasize 
that the definition sarcopenia includes both muscle mass and function, most recently 
published papers regarding sarcopenia in advanced chronic liver disease focus solely 
on muscle mass depletion by analysing skeletal muscle mass on the third lumbar level 
using CT.(1, 2, 4, 7-9)
 Performing a detailed nutritional assessment in all patients is resource and time 
consuming, and could be unnecessary. The EASL guideline proposes a rapid screen in 
all patients with severe advanced liver disease.(4) Patients with Child–Pugh class C liver 
disease, a body mass index (BMI) below 18.5 kg/m2, or with a medium or high risk for 
malnutrition according to a screening tool (e.g. the Royal Free Hospital-nutritional 
prioritizing tool) should undergo more detailed assessment.(4) Currently, there are 
no published studies evaluating the adequacy of this stepwise approach in a patient 
population screened for liver transplantation.
 The primary aim of the present study was to assess, in a population of patients with 
advanced liver disease, to what extent the EASL rapid screen reliably identifies patients 
screened for liver transplantation who could benefit from a more detailed nutritional 
assessment. Furthermore, we aimed to assess which nutritional findings are independently 
associated with the risk for complications and survival.
MATERIALS AND METHODS
Study design and data collection
All patients undergoing liver transplantation screening between 1st October 2015 to 1st April 
2017 in the Erasmus MC, Rotterdam, the Netherlands, were eligible for inclusion. Patients 
were excluded if liver transplantation screening terminated prematurely, screening was 
performed in a referring hospital, patients were listed with high urgency priority, or a 
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detailed nutritional assessment was not performed. The study protocol conforms to the 
ethical guidelines of the in 2013 revised Declaration of Helsinki as reflected in approval by 
the institution’s human research committee on 12th June 2017 (MEC-2017-290), with the 
determination that written informed consent was not necessary considering the design 
of the study.
 Data were collected from the electronic patient records at time of liver transplantation 
screening and during at least 6 months follow-up. Demographic, biochemical, nutritional 
and clinical characteristics as well as clinical outcome parameters were collected for 
each patient. Patients were followed till 1) liver transplantation, 2) death on the liver 
transplantation waiting list or permanent delisting from the liver transplantation waiting 
list, or 3) end of the observation period (1st March 2018).
Radiographical assessment of muscle mass
Each patient routinely underwent abdominal computed tomography (CT) during liver 
transplantation screening as part of the surgical screening. The cross-sectional skeletal 
muscle area was determined on a single abdominal cross-sectional image at the third 
lumbar vertebral level by the identification of the psoas muscle, paraspinal muscles 
(erector spinae, quadratus lumborum), and abdominal wall muscles (transversus 
abdominus, external and internal obliques, rectus abdominus) by two research physicians, 
and automatically all tissue with a radiodensity between -30 to +150 Hounsfield units 
was calculated. The skeletal muscle index in cm2/m2 was calculated using the cross-
sectional skeletal muscle area, as previously described,(10) and adjusted for body height. 
The calculation of cross-sectional skeletal muscle area and skeletal muscle index were 
performed using FatSeg®, an in-house software program, developed by Erasmus MC, 
University Medical Center, Rotterdam, the Netherlands.(11)
Detailed nutritional assessment
A dietician experienced in managing patients with liver disease assessed dietary 
intake (protein intake in g/kg/day, energy intake percentage of requirement) and the 
nutritional status by anthropometry (weight [kg], height [cm], handgrip strength [kg]), 
and bioelectrical impedance analysis (phase angle, fat-free mass [kg, %]). The handgrip 
strength was measured using the handgrip dynamometer (Jamar) and reported as 
percentile reference values adjusted for age and gender.(12) Fat free mass and phase 
angle were measured using bioelectrical impedance analysis (BIA, Bodystat). Phase angle 
measurements were done as previously reported.(13, 14) Fat-free mass was reported as 
percentile reference values adjusted for age and gender.(12) 
Definitions
The model for end-stage liver disease (MELD) score was calculated with the formula: 0.957 
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× log(creatinine in mg/dL) + 0.378 × log(bilirubin in mg/dL) + 1.120 × log(INR) + 0.643, and 
MELD sodium (MELDNa) score by the formula: MELD – Na (in mmol/L) − [0.025 × MELD × 
(140 − Na)] + 140 with Na.(15) Decompensation was defined as occurrence of one of the 
following clinical events: acute renal failure, new-onset or worsening of ascites and hepatic 
encephalopathy, and bacterial infections. Acute renal failure was defined as a serum 
creatinine increase by 50% or more within 7 days or an increase of 0.3 mg/dL (26.5 μmol/L) 
within 2 days.(16, 17) Ascites was classified as none, mild-moderate in case of diuretic 
responsive ascites, and refractory if additional large-volume paracentesis was necessary 
during an optimized treatment with diuretic agents. New-onset or worsening hepatic 
encephalopathy was defined as newly diagnosed or an increase of neurocognitive changes 
according to the West-Haven clinical criteria.(18, 19) Diagnosis of bacterial infection was 
made according to Centers of Disease Control and Prevention criteria.(20, 21)
 Body mass index (BMI) was calculated by dividing weight in kg by square height in 
m2, and adjusted for ascites by subtracting 5% of weight in mild/moderate ascites, and 
15% in refractory ascites.(4) Inadequate dietary intake was defined as a protein intake 
below 1.2 g/kg/day,(22) or an energy intake below 50% of requirement.(23, 24) The Royal 
Free Hospital-nutritional prioritizing tool classified patients as medium and high risk for 
malnutrition.(25) Muscle function loss was defined as a handgrip strength below the 
10th percentile.(12) A phase angle equal or below 5.4 was considered to be prognostic 
unfavourable.(13, 14) Patients were classified as having muscle mass depletion if skeletal 
muscle index was below 43 cm2/m2 in males with a body mass index (BMI) below 25 kg/
m2, and below 53 cm2/m2 in males with a BMI equal or above 25 kg/m2, and for females 
a skeletal muscle index below 41 cm2/m2 regardless of BMI.(8) Sarcopenia was defined 
as muscle mass depletion and muscle function loss.(1, 4) Presarcopenia was defined as 
muscle mass depletion with normal muscle function.(26) Impaired muscle quality was 
defined as muscle function loss with normal muscle mass.(27)
Statistical analysis
Continuous variables were reported as mean with standard deviation (SD), after visual 
confirmation of approximate normality, and compared using the Student’s T-test. A 
median and range from the first to the third quartile (IQR) was computed for continuous 
variables with a non-normal distribution. Categorical variables were reported as count 
with proportion and compared using the Chi-square test. A two-sided p-value <0.05 was 
considered significant.
 Multiple multivariable logistic regression analyses were carried out to identify 
predictive factors for inadequate dietary intake, muscle mass depletion, impaired muscle 
function, and muscle mass depletion or impaired muscle function, using the following 
candidate predictor variables: age, gender (female; male), liver cirrhosis (none; present), 
MELDNa score, alcohol use (none; <14 IU for women or <21 IU for men; ≥14 units IU for 
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women or ≥21 IU for men), and BMI adjusted for ascites. The multivariable analysis for 
the logistic regression models were employed using the backward stepwise selection 
method with removal testing based on the probability of the likelihood-ratio statistic of 
the maximum partial likelihood estimates.
 The actuarial probabilities of decompensation-free survival, hospitalization-free 
survival and transplant-free survival (death and liver transplantation as event) after 
detailed nutritional assessment were estimated using the Kaplan-Meier method and 
a comparison was made in patients with muscle mass depletion and impaired muscle 
function using log-rank tests.
 Multivariable Cox regression analyses were carried out to identify whether muscle 
mass depletion and impaired muscle function were, independent of age and MELDNa 
score, significant predictors for 6-month decompensation-free, 6-month hospitalization-
free and 6-month transplant-free survival after detailed nutritional assessment.
All statistical analyses were performed using IBM® SPSS® Statistics for Windows, version 
24.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Patients
Between 1st October 2015 to 1st April 2017 137 patients were evaluated for liver 
transplantation. We could include 102 patients in the present study.(Figure 1) The 
population comprised of 68 men and 34 women with a median age of 56.3 years (IQR 
43.9 - 64.0).(Table 1) Cirrhosis was diagnosed in 80.4% cases and hepatocellular carcinoma 
(HCC) in 37.3%. Nearly fifty percent of patients suffered from chronic cholestatic, 
autoimmune or viral liver disease. The median MELDNa score was 14.7 (IQR 9.4 - 19.0).
Figure 1. Flow chart of study population.
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Table 1. Demographic and clinical patient characteristics.
Included patients (n=102)
Male, n (%) 68 (66.7%)
Age (years), median (IQR) 56.3 (43.9 – 64.0)
Etiology of liver disease, n (%)
    Biliary and auto-immune disease
    Viral hepatitis
    Alcohol
    Non-alcoholic steatohepatitis 
    Metabolic disorder
    Polycystic liver disease
    Other
28 (27.5%)
18 (17.6%)
17 (16.7%)
10 (9.8%)
8 (7.8%)
7 (6.9%)
14 (13.8%)
Concomitant hepatocellular carcinoma, n (%) 38 (37.3%)
Liver cirrhosis, n (%) 82 (80.4%)
MELDNa score, median (IQR) 14.7 (9.4 – 19.0)
Child-Pugh score, median (IQR) 7 (5 – 9)
Child-Pugh class, n (%)
    A 
    B 
    C 
44 (43.1%)
35 (34.3%)
23 (22.5%)
Ascites, n (%)
    Diuretic-responsive
    Diuretic-refractory
19 (18.6%)
20 (19.6%)
BMI adjusted for ascites (kg/m2), mean (SD) 26.9 (5.1)
Hepatic encephalopathy, n (%)
    None
    West Haven grade 1 - 2
93 (91.2%)
9 (8.8%)
Blood serum parameters‡
    Creatinin (μmol/L), median (IQR)
    Sodium (mmol/L), median (IQR)
    Albumin (g/L), median (IQR)
    Bilirubin (μmol/L), median (IQR)
    INR, median (IQR)
    ASAT (U/L), median (IQR)
    ALAT (U/L), median (IQR)
    ɣ-glutamyltransferase (U/L), median (IQR)
    Alkaline phosphatase (U/L), median (IQR)
    Haemoglobin (mmol/L), median (IQR)
    Thrombocytes (109/L), median (IQR)
    Leucocytes (109/L), median (IQR)
74.5 (63.0 – 90.0)
140.0 (137.0 – 142.0)
34.5 (30.8 – 42.2)
33.0 (13.8 – 71.0)
1.3 (1.2 – 1.6)
57.5 (35.8 – 96.3)
46.5 (27.8 – 79.0)
128 (52.5 – 191.8)
151.5 (106.8 – 270.0)
7.5 (6.4 – 8.4)
118 (86 – 203)
5.7 (3.8 – 8.0)
Medical history with chronic disorder, n (%)
    Diabetes 
    Renal disease
    Cardiovascular disease
    Pulmonary disease
18 (17.6%)
17 (16.7%)
10 (9.8%)
10 (9.8%)
‡ Normal laboratory reference ranges: Creatinin 55 – 115 μmol/L, Sodium 136 – 145 mmol/L, Albumin 35 – 50 
g/L, Bilirubin 0 – 16 μmol/L, INR <1.7, ASAT 0 – 34 U/L, ALAT 0 – 44 U/L, ɣ-glutamyltransferase 0 – 54 U/L, Alkaline 
phosphatase 0 – 114 U/L, Haemoglobin 7.5 – 10.5 mmol/L, Thrombocytes 150 – 370 109/L, Leucocytes 3.5 – 10 109/L.
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Table 1. Demographic and clinical patient characteristics. (continued)
Abbreviations: ALAT: alanine transaminase, ASAT: aspartate transaminase, BMI: body mass index, INR, interna-
tional normalized ratio, IQR: interquartile range, MELDNa: model for end-stage liver disease model including 
sodium.
Prevalence of abnormal nutritional findings
Dietary intake assessment revealed that protein intake was below 1.2 kg/g/day in 64.7% 
patients and energy intake was below 50% requirement in 1.0%. The prevalence of 
inadequate dietary intake, defined as either inadequate protein or caloric intake, was 
64.7%, because inadequate energy intake always co-existed with inadequate protein 
intake. Presarcopenia (low muscle mass and normal muscle function) was diagnosed 
in 30/102 patients (29.4%), sarcopenia (low muscle mass and low muscle function) in 
20/102 (19.6%), and impaired muscle quality (normal muscle mass and low muscle 
function) in 19/102 (18.6%). Thus, sixty-nine patients (67.6%) were diagnosed with either 
presarcopenia, sarcopenia, or impaired muscle quality).(Figure 2) There was no association 
between inadequate dietary intake and presarcopenia (p=0.851), sarcopenia (p=0.311), or 
impaired muscle quality (p=0.364).
Figure 2. Prevalence of muscle mass depletion and impaired muscle function.Figur  2.  Prevalence of muscle mass depletion and 
impaired muscle function. 
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Evaluation of EASL nutritional screening protocol
Figure 3 summarizes the results of the work-up according to the recently proposed EASL 
rapid screen for identifying patients with liver disease at risk for malnutrition/sarcopenia. 
(Supplement 1) In our liver transplantation screening cohort, 49 patients (48.0%) fulfilled 
at least one of the criteria for an extensive nutritional assessment including CT: 23 patients 
had Child–Pugh class C liver disease, an additional 5 patients had a BMI <18.5 kg/m2, and 
another 21 patients were at medium or high risk according to evaluation using the Royal 
Free Hospital-nutritional prioritizing tool. Applying the EASL screen to our population 
resulted in identification of 11/30 (36.7%) cases with presarcopenia, 16/20 (80%) with 
sarcopenia, and 13/19 (68.4%) with impaired muscle quality. The EASL algorithm resulted 
in identification of 27/50 (54.0%) patients with muscle mass depletion, 29/39 (74.4%) 
patients with impaired muscle function, and 40/69 (58.0%) patients with at least one 
muscle abnormality (i.e. presarcopenia, sarcopenia, or impaired muscle quality).
Figure 3. Flow chart for rapid screen protocol in this population.
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Table 2. Results of bioelectrical impedance analysis according to muscle mass and function.
Muscle mass
(skeletal muscle index)
Normal
(n=52)
Presarcopenia, or sarcopenia
(n=50)
p-value
Phase angle (°), (%)
≤ 5.4 16 (30.8%) 29 (58.0%) 0.006
Fat–free mass, (%)
< 10th percentile 1 (2.0%) 6 (12.0%) 0.044
Muscle function
(handgrip strength)
Normal
(n=63)
Sarcopenia or impaired muscle 
quality
(n=39)
Phase angle (°), (%)
≤ 5.4 23 (36.5%) 22 (56.4%) 0.049
Fat–free mass, (%)
< 10th percentile 4 (6.3%) 3 (7.7%) 0.794
Muscle mass and function Normal
(n=33)
Presarcopenia, sarcopenia or 
impaired muscle quality
(n=69)
Phase angle (°), (%)
≤ 5.4 7 (21.1%) 38 (55.1%) 0.001
Fat–free mass, (%)
< 10th percentile 1 (3.0%) 6 (8.7%) 0.290
Bioelectrical impedance analysis 
A phase angle ≤ 5.4° was measured in 39.4% patients with inadequate dietary intake.
(Table 2) Patients with muscle mass depletion (p=0.006), impaired muscle function 
(p=0.049), and either muscle mass depletion or impaired muscle function (p=0.001) 
had significantly more often a phase angle ≤ 5.4°. However, not more than 60% of 
the population was correctly identified with a phase angle ≤ 5.4°. Fat-free mass below 
the 10th percentile was diagnosed in 12.0% of patients with muscle mass depletion, 
7.7% patients with impaired muscle function, and 8.7% patients with presarcopenia, 
sarcopenia or impaired muscle quality.
Predictive factors for inadequate dietary intake, muscle mass depletion, 
and impaired muscle quality
Inadequate dietary intake was found more often in patients with higher age (OR per 
year: 1.035, 95%CI 1.001 – 1.070, p=0.046) and high BMI (OR per kg/m2: 1.173, 95%CI 
1.044 – 1.319, p=0.007). Muscle mass depletion was independently associated with low 
BMI (OR per kg/m2: 0.898, 95%CI 0.819 – 0.986, p=0.024), impaired muscle function with 
female gender (OR: 2.868, 95%CI 1.119 – 7.349, p=0.028), higher MELDNa score (OR per 
point: 1.095, 95%CI 1.010 – 1.187, p=0.027), and low BMI (OR per kg/m2: 0.894, 95%CI 
0.806 – 0.992, p=0.034). Presarcopenia, sarcopenia or impaired muscle quality was 
likewise independently associated with female gender (OR: 3.199, 95%CI 1.031 – 9.929, 
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p=0.044), higher MELDNa score (OR per point: 1.101, 95%CI 1.004 – 1.207, p=0.041), and 
low BMI (OR per kg/m2: 0.850, 95%CI 0.759 – 0.953, p=0.005).(Table 3)
Table 3. Independent predictive factors for inadequate dietary intake, muscle mass depletion and/
or impaired muscle quality identified by multivariable logistic regression analysis.
OR 95% CI p-value
Inadequate dietary intake
Age (per year) 1.035 1.001 – 1.070 0.046
BMI adjusted for ascites (per kg/m2) 1.173 1.044 – 1.319 0.007
Muscle mass depletion
BMI adjusted for ascites (per kg/m2) 0.898 0.819 – 0.986 0.024
Impaired muscle function
BMI adjusted for ascites (per kg/m2) 0.894 0.806 – 0.992 0.034
MELDNa score (per point) 1.095 1.010 – 1.187 0.027
Gender
male (reference)
female
1
2.868
-
1.119 – 7.349
0.028
Presarcopenia, sarcopenia or impaired muscle quality
BMI adjusted for ascites (per kg/m2) 0.850 0.759 – 0.953 0.005
MELDNa score (per point) 1.101 1.004 – 1.207 0.041
Gender
male (reference)
female
1
3.199
-
1.031 – 9.929
0.044
Abbreviations: BMI: body-mass index; CI: confidence interval, MELDNa score: Model for End-Stage Liver Disease-
Sodium score; OR: odds ratio.
Clinical outcome
At the end of follow-up, 33 patients (32.4%) were still registered on the liver 
transplantation waiting list with a median follow-up time of 362.0 days (IQR 272.0 – 
436.0), 55 patients (53.9%) had received a liver transplant after a median waiting time 
of 167.0 days (IQR 116.0 – 315.0), and 14 patients (13.7%) were removed on the waiting 
list due to death, clinical deterioration or hepatocellular carcinoma progression after a 
median time of 199.0 days (IQR 114.5 – 316.5).
 Comparing patients with normal muscle mass and muscle mass depletion showed no 
significant differences with respect to 6-month decompensation-free survival (63% vs 75%, 
p=0.188), hospitalization-free survival (77% vs 87%, p=0.307), and transplant-free survival 
(62% vs 64%, p=0.928).(Figure 4A) However, when patients with or without impaired muscle 
function were compared, significant differences were found in 6-month decompensation-
free survival (54% vs 78%, p=0.006), and hospitalization-free survival (67% vs 91%, p=0.003), 
but not in transplantation-free survival (62% vs 70%, p=0.535).(Figure 4B)
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 Cox-regression analysis revealed that muscle mass depletion was not an independent 
predictor for 6-month decompensation-free, hospitalization-free, or transplant-free 
survival. Impaired muscle function was a predictor for worse decompensation-free 
survival (HR 2.171, 95%CI 1.010 – 4.666, p=0.047) and hospitalization-free survival (HR 
3.319, 95%CI 1.433 – 7.690, p=0.005), independent of age and MELDNa score, but not for 
transplant-free survival.
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Figure 4. Kaplan-Meier estimates of decompensation-free survival (upper row), hospitalization-free 
survival (middle row), and transplantation-free survival (lower row), according to abnormalities in 
muscle mass (A) and muscle function (B).
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DISCUSSION
In this cohort study a detailed nutritional assessment was performed in patients evaluated 
for liver transplantation. We noted muscle mass depletion and/or impaired muscle 
function in two thirds of patients, thereby confirming previous studies that this is highly 
prevalent in populations with advanced liver disease. If a detailed nutritional assessment 
would have been restricted to medium- or high-risk patients according to the rapid screen 
as proposed by the EASL, 42% of patients screened for liver transplantation with muscle 
mass depletion and/or impaired muscle function would have been missed. Furthermore, 
in contrast to muscle mass depletion, impaired muscle function was a significant predictor, 
independent of liver disease severity, of decompensation and mortality.
 In this study 49% of patients were diagnosed with muscle mass depletion based on 
the third lumbar level skeletal muscle index, which is in line with other studies reporting 
a prevalence of 38-45%.(3, 8, 28) Similarly, the prevalence of 38% of impaired muscle 
function as assessed by handgrip strength was comparable to the findings of another 
study (30%) in 292 liver transplant candidates.(28)
 Muscle function was a better predictor of 6-month decompensation-free and 
hospitalization-free survival than muscle mass in the present study. The key prognostic 
impact of muscle function has previously been reported by a prospective study 
including 373 patients. Physical performance, assessed by handgrip strength and gait 
speed (walking pace over a 5 meter distance), was found to predict cirrhosis-related 
complications requiring hospitalization independently from liver disease severity.(29) 
Similarly, two prospective studies including 213-292 patients both concluded that 
impaired muscle function, in contrast to muscle mass depletion, predicted waiting list 
mortality, independently from liver disease severity.(28, 30) 
 Altogether, these data indicate that decreased muscle function, possibly related 
to structural and functional changes such as fat accumulation, decreased muscle fiber 
volume or contractility and mitochondrial dysfunction, more than muscle mass or volume, 
is strongly correlated with outcome in advanced liver disease.(27, 31) Consequently, for 
prognostication measuring muscle function, such as with the simple handgrip strength 
test, seems more relevant than CT-based muscle volumetry.
 Interestingly, in our population a high BMI was associated with inadequate dietary 
intake, whereas a low BMI was a risk factor for muscle mass depletion and impaired muscle 
function. Possibly, for patients with a high BMI it is more challenging to reach a protein 
intake of 1.2 g/kg/day, which is important to keep in my mind in relation to lifestyle and 
nutritional treatment programs in sarcopenic obesity. Our patients with a low BMI and of 
female gender were more prone to have muscle mass and function abnormalities, which 
is in line with findings of other studies.(3, 7, 8)
 In addition, a phase angle ≤ 5.4°, assessed by bioelectrical impedance analysis, was 
significantly associated with a diagnosis muscle mass depletion and impaired muscle 
Identification and prognostic impact of malnutrition in a population screened for liver transplantation
151
9
function, but this finding had a low sensitivity with 56-58% for both muscle abnormalities. 
Measurements of fat-free mass were not associated with muscle abnormalities, which 
might be explained by the interference of ascites or oedema. Therefore, the data supports 
the conclusion that BIA does not have additional beneficial diagnostic value in this 
particular population.
 This study has several limitations related to the study design. The size of the study 
population could possibly have been too small to detect a significant relationship 
between muscle mass and the clinical outcome and our liver transplantation screening 
cohort might demographically differ in MELD score and liver disease aetiology compared 
to other countries. Furthermore, in this study an observer effect might have occurred. 
Results of impaired muscle function were known by clinicians, and could have influenced 
clinical decisions, whereas muscle mass tests were only retrospectively performed for 
research purposes and unknown to clinicians. However, this is an unlikely explanation, 
since the main reasons for delisting liver transplant candidates are clinical deterioration 
and hepatocellular carcinoma progression, and not nutritional status.(32, 33)
 Future prospective studies in this population are necessary to investigate whether 
reversibility of impaired muscle function and muscle mass depletion is possible, which 
nutritional and exercise programs are effective, and whether this subsequently positively 
influences clinical outcome. In addition, although oncologic and geriatric studies found 
sarcopenia is a measure of frailty (i.e. the physiological condition to have a reduced 
capacity to withstand environmental stresses), knowledge of the exact pathophysiologic 
mediators of this reduced capacity and worse clinical outcome is missing.(27, 34, 35)
 In conclusion, among patients with advanced liver disease the results of nutritional 
screening according to the recent EASL practice guideline were suboptimal since 
this instrument would not lead to identify a substantial proportion of individuals with 
muscle mass depletion and/or impaired muscle function (sarcopenia, pre-sarcopenia and 
diminished muscle strength). Our data suggest a detailed nutritional assessment should 
be performed in all patients with advanced liver disease. We confirm previous studies that 
muscle function, rather than muscle mass, has major prognostic significance. Therefore, 
testing muscle function may be more relevant than assessing muscle mass.
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Supplement 1. Identification of patients with rapid screen for detailed nutritional screening and 
sarcopenia assessment in patients with advanced chronic liver disease as proposed by the EASL 
Clinical Practice Guidelines on nutrition in chronic liver disease.
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ABSTRACT
Background: Evidence for the efficacy of transjugular intrahepatic portosystemic stent 
shunt (TIPSS) in ectopic variceal bleeding (EctVB) is largely based on relatively small series.
 
Aims: To define the efficacy of TIPSS in EctVB.
 
Methods: Retrospective analysis of consecutive patients with chronic liver disease who 
presented with EctVB and received TIPSS in three tertiary centers in 1992-2016.
 
Results: The study included 53 patients (70% male, median age 61 years, median model 
for end-stage liver disease (MELD) score 11). The ectopic varices were located around 
the insertion of stomas (40%), duodenum (23%), rectum (17%), and at other sites (20%). 
Three-quarter of the patients had received previously unsuccessful medical, endoscopic 
or surgical therapy.
 The median follow-up time was 14.0 months. Following TIPSS bleeding recurred in 12 
cases: 6/12 (50%) with duodenal varices, 2/9 (22%) with rectal varices, and one each case 
with stomal (1/21), intraperitoneal (1/3), hepaticojejunostomy (1/2), and ascending colon 
varices (1/2).
 The risk factors for rebleeding were MELD score at TIPSS placement (HR: 1.081 per 
point; 95% CI: 1.012 - 1.153;  p=0.034), varices located at another site than an enterostomy 
(HR: 9.770; 95% CI: 1.241 - 76.917;  p=0.030), and previous local therapy (HR: 5.710; 95% 
CI: 1.211 - 26.922;  p=0.028). The estimated cumulative rebleeding rate was 23% at 1 year, 
26% at 3 years and 32% at 5 years. Post-TIPSS hepatic encephalopathy manifested or 
worsened in 16/53 patients (30%).
 
Conclusion: TIPSS provides long-term control of bleeding in the majority of cirrhotic 
patients with EctVB. TIPSS is particularly effective in stomal EctVB, the most frequent cause 
of EctVB, but might not be as effective in duodenal EctVB.
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INTRODUCTION
Approximately 5% of variceal bleedings occur outside the cardio-esophageal junction 
and are denoted as ectopic.(1) Ectopic varices are predominantly located in the small 
and large intestine and around enterocutaneous stomas, but can also be present in the 
peritoneum, biliary tree, and pelvic organs.(2) Abdominal and pelvic surgery is a well-
known risk factor because post-operative adhesions and the creation of an enterostomy 
facilitate the formation of porto-systemic collaterals.(1, 2)
 The management of ectopic variceal bleeding (EctVB) is challenging and not 
based on the results of controlled trials. Local endoscopic treatment modalities (band 
ligation, injection sclerotherapy, clips, argon plasma coagulation) and selective variceal 
embolization frequently fail to prevent rebleeding with reported recurrence rates up to 
80% within 6 months.(3, 4) Surgical treatment, such as local sutures, devascularization 
procedures, or stoma revision with resiting, will only occasionally provide long-term 
control of bleeding in selected patients. The creation of surgical portosystemic shunts 
is associated with significant morbidity and mortality, particularly in patients with 
decompensated cirrhosis, and is rarely performed nowadays.(5-7)
 Transjugular intrahepatic portosystemic stent shunt (TIPSS) creation is used to 
treat patients suffering from EctVB.(8) Although evidence suggests that TIPSS is usually 
effective to prevent recurrent bleeding, research publications are restricted to patient 
series including only 8 – 28 patients.(9-13) Also, variable results have been published with 
respect to concomitant variceal embolization, and the additional therapeutic value of 
embolization combined with TIPSS placement remains unclear.(9, 11-14)
 We therefore aimed, in a multicenter cohort of patients with EctVB, to further 
determine the efficacy of TIPSS, and to evaluate outcomes in subgroups with different 
types of ectopic varices. We also intended to explore the benefit of concomitant vascular 
embolization of collateral vessels feeding the ectopic varices.
PATIENTS AND METHODS
Study design and data collection
We included all consecutive patients with advanced chronic liver disease, who underwent 
TIPSS placement for EctVB using bare metal stents or expanded polytetrafluoroethylene 
(e-PTFE)–covered nitinol stents (Viatorr, W.L. Gore & Associates Inc, Flagstaff, AZ, USA) in 
three tertiary referral centers: Erasmus MC, Rotterdam, the Netherlands, between January 
1992 – December 2016; Academic Medical Center (AMC), Amsterdam, the Netherlands, 
between January 1998 – December 2016; and UZ Leuven, Leuven, Belgium, between 
January 2000 – December 2013. Demographic, biochemical clinical, and survival data were 
collected from patient hospital records and entered into a database for statistical analysis. 
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki 
as reflected in approval by the Medical Ethics Committee Erasmus MC, Rotterdam, the 
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Netherlands, on April 18th, 2017 (MEC-2017-217), stating that written informed consent 
was not necessary considering the retrospective study design.
Definitions
The diagnosis of advanced chronic liver disease was based on liver histology, or a 
combination of clinical, biochemical, and radiologic findings.(15) The model for end-stage 
liver disease (MELD) score was calculated with the formula: 0.957 × log(creatinine in mg/
dL) + 0.378 × log(bilirubin in mg/dL) + 1.120 × log(INR) + 0.643.(16, 17) Comorbidity with 
a cardiovascular condition, pulmonary condition, or renal condition was defined as a 
condition requiring long-term medical treatment for which regular specialist follow-up 
care was necessary. Early TIPSS was defined as TIPSS insertion within 72 hours after an 
EctVB episode.(18) Bleeding was defined as a decrease in hemoglobin (Hb) by 2 g⁄dL (1.24 
mmol/L), or the requirement of more than 2 units of packed red cells within 24 hours to 
stabilize hemoglobin concentration or signs of volume depletion (systolic blood pressure 
below 100 mmHg and/or heart rate above 100⁄min).(13) Rebleeding was defined as a single 
episode of clinical significant recurrent melena or hematemesis from portal hypertensive 
sources after day 5 that resulted in any of the following: a) hospital admission, b) blood 
transfusion, c) drop in Hb of 3 g/dL (1.86 mmol/L), or d) death within 6 weeks.(19)
 The standard follow-up protocol for stent function differed per center: in the Erasmus 
MC a functional assessment of bare TIPSS stents with Doppler ultrasound (US) was 
performed 2, 7, and 30 days after placement, at 3-month intervals during the first year of 
follow-up, and every 6 months thereafter. Following TIPSS with covered stents standard 
follow-up imaging was not performed. In the AMC all stents were assessed at 3-7 days, 
3 months, 6 months, and 12 months after placement, and every year thereafter. In UZ 
Leuven stent function was assessed every 6 months. In all centers, patients received an 
angiography with venous portal pressure measurements when shunt dysfunction was 
suspected based on findings during Doppler ultrasound or clinical symptoms. Shunt 
dysfunction was defined as shunt stenosis greater than 50% of the shunt and/or hepatic 
venous portal gradient higher than 12 mmHg.(20)
Statistical analysis
Continuous variables were reported as mean with standard deviation (SD), after visual 
confirmation of approximate normality, and compared using a T-test. A median and range 
from the first to the third quartile (IQR) was computed for continuous variables with a 
non-normal distribution, and compared using a Mann-Whitney test. Categorical variables 
were reported as count with proportion and compared using the Chi-square test.
 The actuarial probabilities of being free of shunt dysfunction (shunt dysfunction as 
event, censoring at death or liver transplantation), being free of rebleeding (rebleeding 
as event, censoring at death or liver transplantation), and transplant-free survival (death 
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as event, censoring at liver transplantation) after TIPSS creation were estimated using the 
Kaplan-Meier method and compared using log-rank tests.
 A univariable Cox regression analysis was carried out to identify risk factors for 
rebleeding at TIPSS placement using candidate predictor variables, hereinafter mentioned, 
as described in the literature and based on the clinical and research experiences of 
co-investigators: MELD score, location of EctVB, local treatment of the EctVB, urgency 
placement of TIPSS, type of stent used during TIPSS, portal-pressure gradient after TIPSS 
placement above 12 mmHg, and concomitant embolization.(2, 11-13, 18, 21, 22) The 
univariable Cox regression models were adjusted with a propensity score to take into 
account differences in MELD score at TIPSS placement for each individual covariate. 
 Furthermore, the effect of concomitant embolization during the TIPSS procedure 
compared to TIPSS alone on rebleeding and mortality was analysed. For this analysis as 
well, a propensity score was calculated using a logistic regression model, estimating the 
probability to receive concomitant embolization given the following observed baseline 
characteristics: MELD score, location of EctVB, type of stent used during TIPSS and urgency 
placement of TIPSS as predictor variables.
 A two-sided p-value <0.05 was considered significant for descriptive statistics and a p-value 
<0.10 was considered significant for univariable regression models. All statistical analyses were 
performed using IBM® SPSS® Statistics for Windows, version 24.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Patient characteristics and TIPSS procedures
In the three centers, 53 patients received TIPSS for EctVB during the study period, 
representing 5.4% of the total population (n=979) undergoing a TIPSS procedure.
(Figure 1) The study population consisted predominantly of males with a median age of 
61 years (IQR 51 – 66), and a median MELD score of 11 (IQR 9 – 17).(Table 1) The ectopic 
varices were most often located near the mucocutaneous junction of stomas (40%), 
followed by the duodenum (23%), rectum (17%), and other sites (20%). TIPSS placement 
was the initial treatment for EctVB in 23% of the patients. 77% of the patients had been 
unsuccessfully treated for EctVB with one or multiple modalities; 24 patients (45%) had 
undergone previous endoscopic treatment (band ligation, injection therapy, coagulation), 
22 (42%) had received vasoactive medication (non-selective beta-blockers, somatostatin, 
terlipressin), 9 (17%) had undergone abdominal surgery (stoma revision or relocation, 
bowel resection), and 1 patient (2%) had received endovascular treatment (embolization). 
 TIPSS were created with a bare metal stent in 8 patients and with an e-PTFE–covered 
stent in 45 patients.(Table 2) Hemodynamic measurements showed that the median pre-
TIPSS portosystemic gradient (PSG) decreased from 14 mmHg (IQR 10 – 20) to 6 mmHg (IQR 
4 – 7) after TIPSS placement. The post-TIPSS PSG remained above 12 mmHg in 4 patients. 
Eighteen (34%) patients received early TIPSS and initial hemostasis was achieved in all cases.
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Figure 1. Flow diagram of inclusion.
Abbreviations: e-PTFE: expanded polytetrafluoroethylene; TIPSS: transjugular intrahepatic portosystemic 
stent shunt.
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Table 1. Clinical characteristics of the study population.
Patients with ectopic variceal 
bleeding
(n= 53)
Male gender, n (%) 37 (69.8%)
Age in years, median (IQR) 61 (51 - 66)
Etiology of portal hypertension, n (%)
    Alcoholic liver cirrhosis
    PSC/PBC/auto-immune hepatitis 
    Cryptogenic liver cirrhosis
    Viral hepatitis
    Other
25 (47.2%)
11 (20.8%)
7 (13.2%)
2 (3.8%)
8 (15.0%)
Child-Pugh class†, n (%)
    A
    B
    C
34 (65.4%)
15 (28.8%)
3 (5.8%)
MELD score†, median (IQR) 11 (9 - 18)
Portal vein thrombosis, n (%) 5 (9.4%)
Comorbidity‡, n (%)
    Previous medical history of malignancy§
        Colorectal cancer
        Urothelial carcinoma
        Pancreatic cancer
        Hepatocellular cancer
        Lung cancer
        Hodgkin’s disease
        Cardiovascular condition
        Inflammatory bowel disease
        Diabetes
        Pulmonary condition
        Renal condition
11 (20.8%)
5
3
2
1
1
1
9 (17.0%)
8 (15.1%)
6 (11.3%)
4 (7.6%)
4 (7.6%)
Medical history of gastro-esophageal variceal bleeding, n (%) 8 (15.1%)
Number of previous episodes of gastro-esophageal variceal 
bleeding, n (%)
    1 – 3
    4 – 6
    7 or more
6 (11.3%)
1 (1.9%)
1 (1.9%)
History of abdominal surgery, n (%) 36 (67.9%)
Location of bleeding ectopic varices, n (%)
    Enterostomal¶
        Colostomy
        Ileostomy
        Urostomy 
    Duodenum
    Rectum
    Intraperitoneal 
    Hepaticojejunostomy
    Ascending colon 
    Jejunum
    Caecum
21 (39.7%)
11
8 
3
12 (22.6%)
9 (17.0%)
3 (5.7%)
2 (3.8%)
2 (3.8%)
1 (1.9%)
1 (1.9%)
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Table 1. Clinical characteristics of the study population. (continued)
Number of previous episodes of ectopic variceal bleeding, n (%)
    1 – 3
    4 – 6
    7 or more
26 (49.1%)
7 (13.2%)
20 (37.7%)
Previous treatment of ectopic variceal bleeding, n (%)
    None
        Medication‡
        Non-selective β-blocker
        Somatostatin
        Terlipressin
    Endoscopic‡
        Band ligation
        Injection therapy
        Coagulation
    Endovascular embolization‡
    Surgery‡
12 (22.6%)
22 (41.5%)
14
12
1
24 (45.3%)
9
17
2
1 (1.9%)
9 (16.9%)
† Data regarding liver disease severity missing in 1 case.
‡ Patients could have multiple concomitant comorbidities or received multiple treatment modalities, either 
concomitant or successive.
§ Two patients had a history with two malignancies.
¶ One patient presented with concomitant colostomy and urostomy bleeding.
Abbreviations: IQR: interquartile range; MELD: model for end-stage liver disease.
Table 2. TIPSS procedural data.
All patients 
(n=53)
Patients with 
bare metal 
stents
(n= 8)
Patients with 
e-PFTE–covered stents
(n= 45)
pre-TIPSS placement PSG 
(mmHg), median (IQR)
14 (10 - 20) 22 (12 - 26) 14 (9 - 19)
post-TIPSS placement PSG 
(mmHg), median (IQR)
6 (4 - 7) 12 (7 - 16) 5 (4 - 7)
Decrease in PSG (mmHg), median 
(IQR)
8 (6 - 13) 8 (6 - 12) 8 (6 - 13)
Concomitant embolization, n (%) 13 (24.5%) 1 (12.5%) 12 (26.7%)
Early TIPSS placement, n (%) 18 (34%) 4 (50%) 14 (31%)
Diameter stent (mm), median 
(IQR)
9 (8 - 10) 9 (8 - 10) 9 (8 - 10)
Abbreviations: e-PTFE: expanded polytetrafluoroethylene; IQR: interquartile range; PSG: portosystemic gradient; 
TIPSS: transjugular intrahepatic portosystemic stent shunt.
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Clinical outcome
The median follow-up time was 14.0 months (IQR 3.8 – 45.9). Following TIPSS, EctVB from 
the same site occurred in 12/53 (23%) patients.(Figure 2) Bleeding recurred in 1/21 (5%) 
cases with stomal varices, 6/12 (50%) cases with duodenal varices, in 2/9 (22%) with rectal 
varices, in 1/3 cases with intraperitoneal varices, in 1/2 cases with varices in the ascending 
colon, and in 1/2 cases with varices located at the hepaticojejunostomy. The four patients 
with jejunal, cecal, sigmoid, or umbilical vein ectopic varices remained free of rebleeding.
 Most rebleeds were diagnosed shortly after TIPSS creation; in 8 patients (4 with 
duodenal varices, 1 with varices at the hepaticojejunostomy, 1 with intraperitoneal 
varices, 1 with rectal varices, and 1 with ascending colon varices) in the first month after 
the TIPSS procedure (15%), in 2 patients (1 with duodenal varices and 1 with rectal varices) 
after 1 – 6 months (4%), and in 2 patients (1 with duodenal varices and 1 with urostomal 
varices) after 6 months (4%). In 9 of these 12 patients, rebleeding was associated with 
shunt dysfunction. After TIPSS placement, the estimated cumulative ectopic variceal 
rebleeding rate was 23% at 1 year, 26% at 3 years, and 32% at 5 years.(Figure 3) Rebleeding 
from other sources occurred in 4 patients: 3 from gastro-oesophageal varices and 1 from 
haemorrhagic gastropathy. The univariable Cox regression to identify risk factors for 
rebleeding found three predicting variables: high MELD score (HR: 1.081 per point; 95% 
CI: 1.012 – 1.153; p=0.020), EctVB located at another site than an enterostomy (HR: 9.770; 
95%CI: 1.241 – 76.917; p=0.030), and local treatment preceding TIPSS (HR: 5.710; 95% CI: 
1.211 – 26.922; p=0.028).(Table 3)
 The rebleeding risk in the two main subcategories of EctVB – stomal and duodenal 
varices – differed markedly. A comparison of these groups with respect to aetiology of 
liver disease, MELD score, type of stent, concomitant embolization, post-TIPSS PSG > 12 
mmHg, and established stent dysfunction, did not reveal significant differences. However, 
age was significantly lower in patients with duodenal EctVB (54 vs. 65 years, p=0.016), 
and 11/12 duodenal EctVB had been treated endoscopically before TIPSS, while local 
endoscopic or other procedures were performed in only 2/21 cases with stomal EctVB 
(p<0.001).(Supplement 1)
 TIPSS dysfunction was diagnosed in 6/8 patients with bare metal stents (75%) 
compared to 10/45 with e-PTFE–covered stents (22%) (p=0.011). In 7 patients shunt 
dysfunction was diagnosed at an elective follow-up visit and in 9 patients after a rebleed. 
Most shunt dysfunctions were diagnosed in the first 6 months after TIPSS creation; in 7 
patients in the first month (13%), in 6 after 1 – 6 months (11%), and in 3 after 6 months 
(6%). The estimated cumulative TIPSS dysfunction rate significantly differed (p=0.003) for 
bare metal stents (1 year: 76%; 3 years: 100%) compared to e-PTFE–covered stents (1 year: 
23%; 3 years: 24%; 5 years: 31%).(Figure 4)
 A total of 31 shunt revisions were performed in the first two years after TIPSS 
creation in 13 patients. An additional stent was placed in 8 patients, in 4 patients 
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Figure 2. Rebleeding, stent patency and clinical outcome in  patients with bare 
metal stents and e-PTFE–covered stents.  
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angioplasty was performed followed in two cases by additional stent placements, 
and in 1 patient local thrombolysis was accomplished. Three patients with shunt 
dysfunction and rebleeding died.
Figure 2. Rebleeding, stent patency and clinical outcome in patients with bare metal stents and 
e-PTFE–covered ste ts. 
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Post-TIPSS hepatic encephalopathy (HE) manifested or worsened in 16/53 patients (30%). 
HE could be managed medically in 12 patients, however, in 4 patients radiological re-
intervention was performed reducing the TIPSS diameter and improving or resolving in all 
cases the symptoms of hepatic encephalopathy. In no cases a complete shunt occlusion 
was performed.
Table 3. Univariable analysis of ectopic variceal rebleeding.
HR 95% CI p-value
MELD score (per point) 1.081 1.012 – 1.153 0.020
Location of ectopic varices†
Enterostomal
Other site 
1
9.770 1.241 – 76.917
0.030
Previous local therapy† 5.710 1.211 – 26.922 0.028
Early placement of TIPSS†
≤ 72 hours after EctVB episode 
(reference)
> 72 hours after EctVB episode 
1
0.737 0.195 – 2.787
0.653
Type of TIPSS†
Bare (reference)
e-PTFE–covered
1
0.9894 0.193 - 4.148
0.887
Post-TIPSS PSG†
≤ 12 mmHg (reference)
> 12 mmHg
1
1.171 0.141 – 9.735
0.884
Concomitant embolization† 1.133 0.304 – 4.221 0.852
 ┼ Hazard ratio adjusted with propensity score for MELD score at TIPSS placement. 
Abbreviations: CI: confidence interval; e-PTFE: expanded polytetrafluoroethylene; EctVB: ectopic variceal 
bleeding; HR: hazard ratio; MELD: model for end-stage liver disease; PSG: portosystemic gradient; TIPSS: 
transjugular intrahepatic portosystemic stent shunt.
In this cohort, 41 patients died, 5 underwent liver transplantation, 6 were alive at the end 
of follow-up and 1 was lost to follow up. The causes of death were liver disease-related 
in 12 patients (29.3%) including 3 patients dying of EctVB, not liver disease-related in 12 
patients (29.3%), and unknown in 17 patients (41.4%).(Figure 2) The estimated 30-day, 
1-year, and 5-year mortality rates were 11%, 41% and 75%, respectively.(Supplement 2)
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Figure 3. Actuarial probability (black solid line) with 95% confidence interval (grey dashed lines)  of 
remaining free of rebleeding following TIPSS.
 
Abbreviations: TIPSS: transjugular intrahepatic portosystemic stent shunt.
Figure 4. Actuarial probability of being free of shunt dysfunction: shunt 
dysfunction was diagnosed more often in patients with bare metal stents (grey line) 
compared to patients with e-PTFE–covered stents (black line) (log rank p=0.003). 
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Figure 3. Actuarial probability (black line) with 95% confidence interval (grey 
dashed lines) of remaining free of rebleeding following TIPSS. 
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Concomitant embolization during TIPSS
Concomitant embolization during the TIPSS procedure was performed in 13 patients: 
4 patients had varices located near enterocutaneous stomas, 4 had duodenal varices, 2 
had rectal varices, 2 had intraperitoneal varices, and 1 had varices in the ascending colon. 
Concomitant embolization was performed in 4/9 patients with an acute bleeding and in 
9/44 patients as a secondary prophylactic measure. There were no statistically significant 
differences between patients receiving embolization and TIPSS alone with respect to age, 
gender, MELD score, location of varices, presentation with acute bleeding, or treatment 
center. After propensity score adjustment, the hazard ratio for rebleeding of concomitant 
embolization compared to TIPSS alone was 0.701 (95% CI: 0.145 – 3.390; p=0.659) and the 
hazard ratio for mortality was 0.776 (95% CI: 0.281 – 2.148; p=0.626).
DISCUSSION
This multicenter cohort study evaluated the efficacy of TIPSS with predominantly 
e-PTFE–covered stents in subgroups of patients with bleeding from ectopic varices. The 
present study confirms that TIPSS was an effective treatment by completely preventing 
rebleeding in the large majority (77%) of cases. TIPSS was particularly effective in patients 
with less severe liver disease and with varices located at enterostomas. In contrast, the 
rebleeding risk in patients with duodenal varices was unexpectedly high.
 The observed cumulative 23% rebleeding rate at 1 year is comparable with 
previously reported rates varying from 23% to 39%,(11-13) while the 26% rate at 2 
years was considerably lower than previously reported.(12) It seems likely that the 
superior long-term bleeding control is attributable to the use of e-PTFE–covered stents 
in the large majority of cases. The actuarial risk of remaining free from rebleeding 
in the present series in comparison with the risk observed in TIPSS-treated gastro-
oesophageal bleeding reported in two recently published studies originating from 
the participating centers was 77% vs. 94-100% at 1 year, 74% vs. 92-94% at 3 years, 
and 68% vs. 90-92% at 5 years, respectively.(22, 23) Thus, the overall rebleeding risk in 
TIPSS-treated EctVB appears to be higher than that in gastro-oesophageal bleeding. 
Our data indicate that this seems attributable to the relevant high rebleeding risk in 
TIPSS-treated duodenal EctVB.
 In our cohort, shunt dysfunction was diagnosed in three-quarter of the patients 
with rebleeding and occurred three times more often in bare metal stents compared to 
e-PTFE–covered stents. In total, TIPSS dysfunction occurred in 23% at 1-year follow-up 
compared to approximately 20% in the study from Kochar et al. and 49% in the study 
from Vidal et al.(12, 13) Although these rates vary notably, the trend that e-PTFE–covered 
stents have improved shunt patency is in line with widely reported experience.(24, 25)
 In our series the efficacy of TIPSS in patients with duodenal EctVB, who had a 
disappointing 50% rebleeding risk, was relatively poor. A potential explanatory 
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factor may be that local, but ultimately unsuccessful endoscopic therapies frequently 
preceded TIPSS. In our experience endoscopic treatment, in particular repeated 
tissue glue injections, may lead to significant duodenal ulcerations that can be the 
cause of repeated bleeding in their own right. In such cases it may be very difficult to 
distinguish portal hypertensive related bleeding from other causes, and management 
may be troublesome. Another possibility is that local tumorous vascular ingrowth or 
thrombosis could cause (re)bleeding unrelated to portal hypertension. However, in 
our two cases with duodenal variceal bleeding and a previous diagnosis of pancreatic 
cancer, there was no evidence for residual or recurrent tumour. Also with respect to 
other malignancies there was no indication that these were of etiological importance. 
Further studies in this type of EctVB are required to further address the timing of 
TIPSS and whether alternative therapeutic approaches, in particular balloon-occluded 
retrograde-transvenous-obliteration (BRTO) may be a preferable strategy.(26) 
 The efficacy of TIPSS has to be balanced against the risk of serious side effects, in 
particular hepatic encephalopathy. Post-TIPSS HE manifested or worsened in 30% 
of our patients, which was comparable with other reported experience.(18, 23, 27, 
28) The majority of post-TIPSS HE could be managed medically, but in some cases a 
stent diameter reduction was necessary. A recent report suggests that there might be 
an optimum of 8 mm TIPSS diameter to effectively decompress the portal system in 
relation to the encephalopathy risk.(29) With the knowledge that the diameter of TIPSS 
can passively increase after placement, improved results regarding post-TIPSS HE may 
be expected in the future for diameter controlled expansion stents.(30, 31)
 A recent meta-analysis found a non-significant trend towards a beneficial effect of 
variceal embolization in addition to TIPSS.(14) Our data are in line with these results 
as embolization did not significantly improve the probability of remaining free of 
rebleeding or survival. However, considering the potential selection bias occurring 
when embolization of the culprit varix is not feasible and the limited number of 
patients treated, we were unable to reliably assess the value of embolization as an 
adjunctive measure.
 To the best of our knowledge, we report the largest multicenter cohort of patients 
with TIPSS for EctVB with predominantly e-PTFE–covered stents and our data reflect real 
life practice in three university hospitals. Despite the retrospective study design, only 1 
patient was lost to follow-up. This is the first study allowing a preliminary assessment of 
the efficacy of TIPSS in subgroups of EctVB, although the results should be interpreted 
cautiously considering the size of the patient population. Ideally, prospective trials 
could provide more clarity about the role of TIPSS in subgroups of EctVB as well as on 
the role of concomitant embolization. However, such studies may never be performed 
considering the low prevalence of the disease, the heterogeneity in varices location, 
and the technical inability to embolize all culprit collateral vessels. 
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 In conclusion, our study demonstrates that TIPSS effectively prevents rebleeding in 
the majority of patients presenting with EctVB. TIPSS is particularly effective in bleeding 
from enterostomas, the most frequent type of EctVB. However, the results in duodenal 
EctVB, with a 50 percent rebleeding rate, were disappointing and highlight the need for 
alternative therapeutic approaches.
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Supplement 1. Potential risk factors associated with rebleeding present at time op TIPSS placement 
in different subgroups: enterostomal EctVB (1 rebleeding in 21 cases), duodenal EctVB (6 rebleedings 
in 12 cases), and EctVB at other sites (5 rebleedings in 20 cases).
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Supplement 2. Actuarial probability (solid line) with 95% confidence interval (dashed lines) of 
transplant free-survival following TIPSS.
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Abbreviations: TIPSS: transjugular intrahepatic portosystemic stent shunt.
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ABSTRACT
Background: Five years after rifaximin-α registration as secondary prophylaxis for overt 
hepatic encephalopathy (HE) in the Netherlands, we aimed to evaluate the use of hospital 
resources and safety of rifaximin-α treatment in a real-world setting. 
 
Methods: Prospective identification of all patients using rifaximin-α for overt HE. 
Assessment of hospital resource use, bacterial infections, and adverse events during 
6-month episodes before and after rifaximin-α initiation. 
 
Results: During 26 months we included 127 patients (71.7% male; median age 60.8 years 
(IQR 56.2-66.1); median MELD score 15.0 (IQR 12.1-20.4); 98% using lactulose treatment). 
When comparing the first 6 months after rifaximin-α initiation to the prior 6 months, HE-
related hospital admissions decreased (0.86 to 0.41 admissions/patient; p<0.001), as well 
as the mean length of stay (8.85 to 3.79 bed days/admission; p<0.001). No significant 
differences were found regarding HE-related intensive care unit admissions (0.09 to 
0.06 admission/patient; p=0.253), stay on the intensive care unit (0.43 to 0.57 bed days/
admission; p=0.661), emergency department visits (0.66 to 0.51 visit/patient; p=0.220), 
outpatient clinic visits (2.49 to 3.30 bed visit/patient; p=0.240), or bacterial infections (0.41 
to 0.35 infection/patient; p=0.523). Adverse events were recorded in 2.4% of patients.
 
Conclusions: The addition of rifaximin-α to lactulose treatment was associated with a 
significant reduction in the number and length of HE-related hospitalizations for overt 
HE. Rifaximin-α treatment was safe and well tolerated.
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INTRODUCTION
Hepatic encephalopathy (HE) is a neuropsychiatric complication of advanced liver disease 
characterized by indiscernible changes (covert HE) to clinically obvious changes (overt HE) in 
intellect, behaviour, motor function and consciousness.(1) Overt HE affects approximately 30 
– 40% of patients with cirrhosis,(2) is the most lethal cirrhosis complication with a survival rate 
between 40 – 55% at 6 months after diagnosis,(3, 4) and negatively affects quality of life.(5, 6)
 Rifaximin-α is a poorly adsorbed antimicrobial agent and has been registered since 
2013 as secondary prophylaxis for overt HE in the Netherlands.(7) The pharmacological 
effect of rifaximin-α has been attributed to a reduction in gut absorption and production 
of ammonia.(8) A meta-analysis of randomized controlled trials of rifaximin-α treatment in 
HE found that rifaximin-α had a beneficial effect on the secondary prevention of overt HE, 
increased the proportion of patients who recovered from HE, and reduced mortality.(9)
 At present, the impact of rifaximin-α has not been extensively studied in a real-world 
setting (i.e. medical data outside controlled research study protocols in a heterogenous 
patient population). Recently, a cohort study of 114 patients concluded that rifaximin-α 
significantly reduced hospitalizations, critical care admissions, and accident and 
emergency (A&E) department attendances in patients using rifaximin-α for at least 6 
months.(10) However, a potential beneficial effect of rifaximin-α on liver transplantation 
waiting list mortality or overall mortality has not been clearly established. 
 The primary aim of this study was to assess the impact of rifaximin-α treatment by 
evaluating the effect on hospitalizations, A&E department visits, outpatient clinic visits, 
and bacterial infections in the first 6 months after initiation compared to the prior 6 
months. Secondarily, we evaluated the treatment duration and safety profile of rifaximin-α.
METHODS
Study design and patients
We aimed to identify all individuals who were treated with rifaximin-α between the 1st of 
September 2015 and the 1st of November 2017 at Erasmus MC, University Medical Center, 
Rotterdam, the Netherlands. The researchers were immediately informed the electronic 
medical record computer software via email when rifaximin-α was prescribed in the 
Erasmus MC or when a patient using this agent was registered in the hospital. All patients 
using rifaximin-α as secondary prophylaxis for overt HE, irrespective of the use of lactulose 
at that time, were prospectively included in the study. Patients were excluded when 
rifaximin-α was prescribed in absence of (a history of ) HE, clinical data was incomplete, or 
when non-adherence to rifaximin-α treatment was reported. The study protocol conforms 
to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in approval by 
the institution’s human research committee (MEC-2015-394) with the determination that 
written or oral informed consent was not required considering the design of the study.
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Data collection
Data regarding demographics (age; gender), clinical characteristics (aetiology of liver disease; 
presence of hepatocellular carcinoma; presence of HE; presence of ascites; concomitant 
lactulose and norfloxacin use; and blood serum values), rifaximin-α use (duration of 
exposure; dosage; temporary and permanent discontinuation; (serious) adverse events), 
and clinical outcome (number of HE-related hospital admissions and bed days on a general 
ward and the intensive care unit; number of liver-related hospitalizations and bed days; 
number of A&E department and outpatient clinic visits; number and type of infections) were 
retrospectively collected from electronic patient hospital records. Patients were followed for 
at least 6 months after rifaximin-α initiation (last data collection on 1st of May 2018), or until 
death, liver transplantation, or permanent discontinuation of rifaximin-α occurred.
Definitions
The model for end-stage liver disease (MELD) and the model for end-stage liver disease 
including sodium (MELDNa) scores were calculated with formulas used by the OPTN 
and Eurotransplant.(11, 12) Ascites was classified as diuretic responsive or refractory, 
and HE was graded according to West Haven criteria.(13, 14) The Child Pugh score and 
classification were calculated with the HE West Haven grade, severity of ascites, bilirubin 
level (μmol/L), INR and albumin level (g/L).(15) A liver-related hospital admission was 
defined as a hospitalization with the primary reason of admission being related to the 
chronic liver disease: HE, variceal bleeding, new-onset or worsening of ascites, infection, 
hepatorenal syndrome, hepatocellular carcinoma, or general deterioration. Infection 
diagnosis and determination of infection type were determined following definitions 
formulated by the Centers for Disease Control.(16-19) All liver-related hospital admission 
comprises of both HE-related and liver-related non-HE hospital admissions.
Statistical analysis
Continuous variables were reported as mean with standard deviation (SD), after visual 
confirmation of approximate normality. A median and interquartile range (IQR), the 
range between the 25th to the 75th percentile, was computed for continuous variables 
with a non-normal distribution. Continuous variables were analysed using a paired t-test. 
Categorical variables were reported as count with proportion and compared using the 
Chi-square test, or the McNemar’s test when comparing paired outcomes. A two-sided 
p-value <0.05 was considered significant.
 The actuarial probabilities of rifaximin-α use after therapy initiation were estimated 
using Kaplan-Meier analysis. Death, liver transplantation, and rifaximin-α discontinuation 
were counted as event in these analyses. All data analyses were performed using IBM 
SPSS statistics for Windows, Version 24.0. 
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RESULTS
Patient characteristics 
Between 1st of September 2015 and 1st of November 2017, 151 patients were identified 
with rifaximin-α treatment in the Erasmus MC. A total of 24 patients were excluded: 14 
patients were prescribed rifaximin-α for other indications than HE; data regarding clinical 
endpoints was incomplete in 6, non-adherence to rifaximin-α was reported in 3 and 1 
received rifaximin-α as primary prophylaxis. The remaining 127 patients using rifaximin-α 
as secondary prophylaxis for overt HE were included in the study analysis.(Figure 1) The 
study cohort included 91 males and 36 females with a median age of 60.8 years (IQR 56.2 
– 66.1). The median MELD score among patients was 15.0 (IQR 12.1 – 20.4). At time of 
rifaximin-α initiation, 49.6% of patients were classified as having HE West Haven grade 
1, 31.5% with West Haven grade 2, 13.4% with West Haven grade 3, and 5.5% with West 
Haven grade 4. Lactulose was used by 124 (97.6%) patients and norfloxacin by 33 (26.0%) 
patients.(Table 1)
Figure 1. Flow chart of study inclusion.
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Table 1. Patient baseline clinical characteristics at the time of rifaximin-α initiation.
Patients
(n = 127)
Male gender, n (%) 91 (71.7%)
Age in years, median (IQR) 60.8 (IQR 56.2 – 66.1)
Etiology of liver disease, n (%)
Alcoholic liver disease
Viral hepatitis
NASH
Cryptogenic
PSC/PBC/auto-immune hepatitis
Other
Unknown
43 (33.9%)
25 (19.7%)
17 (13.4%)
15 (11.8%)
15 (11.8%)
5 (3.9%)
2 (1.6%)
HCC, n (%) 27 (21.3%)
Liver disease severity scores
MELD score, median (IQR)
MELDNa score, median (IQR)
Child-Pugh number, median (IQR)
Child-Pugh class, n (%)
A
B
C
15.0 (IQR 12.1 – 20.4)
16.8 (IQR 12.4 – 24.2)
8.0 (IQR 7.0 – 10.0)
20 (15.7%)
45 (35.4%)
37 (29.1%)
HE severity classification, n (%)
West Haven grade 1
West Haven grade 2
West Haven grade 3
West Haven grade 4
63 (49.6%)
40 (31.5%)
17 (13.4%)
7 (5.5%)
Ascites, n (%)
None
Diuretic responsive
Refractory
21 (16.5%)
36 (28.3%)
70 (55.1%)
Blood serum parameters
Creatinin (mmol/L), median (IQR)
Ammonia (μmol/L), median (IQR)†
Sodium (mmol/L), median (IQR)
Albumin (g/L), median (IQR)‡
CRP (mg/L), median (IQR)§
ASAT (U/L), median (IQR)
ALAT (U/L), median (IQR)
Gamma-GT (U/L), median (IQR)¶
Alkaline phosphatase (U/L), median (IQR)
Total bilirubin (μmol/L), median (IQR)
Haemoglobin (mmol/L), median (IQR)
Platelet count (x109/L), median (IQR)
Leukocyte count (x109/L), median (IQR)
INR, median (IQR)
86.5 (IQR 70.7 – 126.0)
84.0 (IQR 64.0 – 121.7)
138.5 (IQR 134.0 – 142.0)
32.0 (SD 28.0 – 36.0)
16.0 (IQR 8.0 – 32.5)
58.0 (IQR 43.5 – 87.5)
40.0 (IQR 26.5 – 62.0)
88.0 (IQR 52.5 – 163.5)
144.0 (IQR 108.0 – 210.5)
35.0 (IQR 19.0 – 69.5)
6.8 (IQR 5.9 – 8.0)
100.0 (IQR 65.5 – 146.0)
6.0 (IQR 4.2 – 8.3)
1.5 (IQR 1.3 – 1.7)
Lactulose use, n (%) 124 (97.6%)
Norfloxacin use, n (%)
None
400 mg, once daily
400 mg, twice daily
94 (74.0%)
31 (24.4%)
2 (1.6%)
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Table 1. Patient baseline clinical characteristics at the time of rifaximin-α initiation. (continued)
† Data was missing for 65 patients; ‡ Data was missing for 7 patients; § Data was missing for 39 patients; ¶ Data was 
missing for 10 patients.
Abbreviations: ALAT: alanine transaminase; ASAT: aspartate transaminase; CRP: C-reactive protein; Gamma-GT: 
gamma-glutamyl transferase; HCC: hepatocellular carcinoma; HE: hepatic encephalopathy; INR: International 
Normalized Ratio; IQR: interquartile range; MELD: Model For End-Stage Liver Disease; MELDNa: Model For End-
Stage Liver Disease Sodium; NASH: non-alcoholic steatohepatitis; PBC: primary biliary cholangitis; PSC: primary 
sclerosing cholangitis.
Clinical parameters and resource use in the 6 months prior to and after rifax-
imin-α initiation
Figure 2 shows the proportion of patients having a hospital admission or visit in the 6 
months prior to and after rifaximin-α initiation. The proportion of patients with HE-related 
hospital admissions to a general ward decreased from 67.7% patients prior to rifaximin-α 
initiation to 26.8% patients after rifaximin-α initiation (p<0.001). Similarly, the proportion 
of patients with liver-related hospital admissions to a general ward decreased (81.1% to 
53.5%; p<0.001), as well as all liver-related non-HE hospital admissions to a general ward 
(59.8% to 43.3%; p=0.006). There were no significant changes in HE-related intensive care 
unit admissions (9.4% to 5.5%; p=0.359), A&E department visits (39.4% to 26.0%; p=0.220), 
or outpatient clinic visits (74.0% to 78.0%; p=0.240) between the 6 months prior to and 
after rifaximin-α initiation.
Figure 2. Differences in proportion of patients with at least one hospital visit or hospitalization 
during 6-month episodes before and after initiation of rifaximin-α treatment
 
 
 
 
 
68
81
60
9
39
74
27
54
43
6
26
78
0
10
20
30
40
50
60
70
80
90
100
HE-related
admission
general ward
p < 0.001
Liver-related
admission
general ward
p < 0.001
Liver-related
non-HE
admissions
p = 0.006
HE-related
admission
intensive care
p = 0.359
A&E department
visits
p = 0.220
Outpatient clinic
visits
p = 0.240
Pr
op
or
ti
on
 o
f p
at
ie
nt
s 
ha
vi
ng
 a
t l
ea
st
 o
ne
 v
is
it
/h
os
pi
ta
liz
at
io
n 
(%
) 
6 months prior to rifaximin-α initiation 6 months after rifaximin-α initiation
*** ***
nsnsns
**
Chapter 11
188
The total mean number of HE-related hospital admission to the general ward decreased 
from 0.86 admission/patient (SD 0.81) to 0.41 (SD 0.80) (p<0.001). Also, the mean length 
of stay shortened from 8.85 bed days/admission (SD 11.20) to 3.79 (SD 9.37) (p<0.001). The 
total mean number bed days during liver-related admissions decreased from 17.18 bed 
days/patient (SD 18.68) to 10.16 (SD 14.81) (p=0.021) and the total mean number of bed 
days during non-liver related hospital admissions did not differ with 0.55 bed days/patient 
(SD 2.27) to 0.40 (SD 1.44) (p=0.585).
 No significant differences were found in the mean number of HE-related intensive care 
unit admissions (0.09 to 0.06 admission/patient; p=0.253), or the mean length of stay on 
the intensive care unit (0.43 to 0.57 bed days/admission; p=0.661).(Table 2)
Table 2. Hospital visits, admissions and length of stay during 6-month episodes before and after 
rifaximin-α initiation
  6 months prior to rifaximin-α initiation
6 months after 
rifaximin-α  
inittion
p-value
HE-related admissions on the general 
ward per patient in 6 months, mean 
(SD)
0.86 (0.81) 0.41 (0.80) <0.001
HE-related hospital bed days on the 
general ward per admission in 6 
months, mean (SD)
8.85 (11.20) 3.79 (9.37) <0.001
HE-related admissions on the inten-
sive care unit per patient in 6 months, 
mean (SD)
0.09 (0.29) 0.06 (0.23) 0.253
HE-related hospital bed days on the 
intensive care unit per admission in 6 
months, mean (SD)
0.43 (1.64) 0.57 (3.17) 0.661
Liver-related hospital bed days in 6 
months, mean (SD) 17.18 (18.68) 10.15 (14.81) 0.021
Non liver-related hospital bed days in 
6 months, mean (SD) 0.55 (2.27) 0.40 (1.44) 0.585
A&E department visits per patient in 
6 months, mean (SD) 0.66 (1.06) 0.51 (1.11) 0.220
Outpatient clinic visits per patient in 
6 months, mean (SD) 2.94 (2.64) 3.30 (3.21) 0.240
Abbreviations: A&E: accident and emergency; HE: hepatic encephalopathy; SD: standard deviation. 
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 There were no significant changes in the proportion of patients having a bacterial 
infection in the 6 months before or after the initiation of rifaximin-α for patients without 
systemic antibiotic use (25.5% to 22.3%; p=0.690) or patients using norfloxacin prophylaxis 
(39.4% to 30.3%; p=0.629).(Table 3)
Table 3. Bacterial infections during 6-month episodes before and after rifaximin-α initiation 
 
Patients in 
analysis
Bacterial infections 
in 6 months prior 
to rifaximin-α initi-
ation
Bacterial infections 
in 6 months after 
rifaximin-α-initi-
ation
p-value
All study patients 127
Number of infections per patient 
in 6 months, mean (SD) 0.41 (0.75) 0.35 (0.76)
0.523
Patients not using norfloxacin 94
Number of infections per patient 
in 6 months, mean (SD) 0.41 (0.75) 0.35 (0.76)
0.751
Number of infections, n (%)
Bacteremia, n (%)
SBP, n (%)
Respiratory, n (%)
Urogenital, n (%)
24 (25.5%)
9 (9.6%)
6 (6.4%)
3 (3.2%)
9 (9.6%)
21 (22.3%)
8 (8.5%)
6 (6.4%)
4 (4.3%)
4 (4.3%)
0.690
Patients using norfloxacin 33
Number of infections per patient 
in 6 months, mean (SD) 0.39 (0.79) 0.30 (0.70)
0.320
Number of infections, n (%)
Bacteremia, n (%)
SBP, n (%)
Respiratory, n (%)
Urogenital, n (%)
13 (39.4%)
1 (3.0%)
12 (36.4%)
-
1 (3.0%)
10 (30.3%)
2 (6.1%)
7 (21.2%)
1 (3.0%)
-
0.629
Abbreviations: SBP: spontaneous bacterial peritonitis; SD: standard deviation.
Rifaximin-α treatment duration and safety profile
The median treatment duration of rifaximin-α was 232 days (IQR 65.0 - 579.0). Figure 3 
shows the estimated rifaximin-α users’ rate until discontinuation. The rifaximin-α users 
rate after initiation was 74% at 3 months, 63% at 6 months, 55% at 1 year, and 44% at 
18 months. The reasons for stopping rifaximin-α treatment in the first 6 months were: 
death in 24 (18.9%) patients, liver transplantation in 16 (12.6%) patients, and temporarily 
or permanently discontinuation in 8 (6.3%) patients for other reasons.
 In the long-term follow up (until end of study observation, death, liver transplantation, 
or rifaximin-α discontinuation), rifaximin-α was temporarily discontinued in 7 (5.5%) 
patients: due to long-term HE resolution in 5 patients, adverse events in 1 patient and 
without any documented reason in 1 patient, but re-initiated after recurrence of overt HE. 
Rifaximin-α treatment was permanently discontinued in 8 (6.3%) patients: in 3 patients 
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prescription was discontinued without a documented reason, 2 patients had adverse 
events, in 2 patients treatment was withdrawn in the terminal phase of the underlying 
disease and in one case due to non-adherence. In total 3 patients reported an adverse 
event: nausea assumed to be related to rifaximin-α, rash assumed to be related to 
rifaximin-α, and polyneuropathy assumed to be non-related to rifaximin-α. Rifaximin-α 
dosage was raised to 1650 mg per day in 11 (8.7%) patients due to recurrence of overt HE 
while on 1100 mg per day.
Figure 3. Kaplan-Meier curve showing the proportion (solid line) of patients using rifaximin-α after 
initiation of treatment
 
 
 
 
 
 
 
 
 
 
DISCUSSION
The present study shows that treatment with rifaximin-α was associated with a reduction 
in the number of HE- and liver-related hospitalizations on the general ward and the 
median length of hospitalization. No evidence was found for a significant impact on 
intensive care unit hospitalizations, A&E department and outpatient clinic visits, or 
bacterial infections in the first 6 months after initiation compared to the prior 6 months. 
Treatment with rifaximin-α was well tolerated and rarely discontinued for other reasons 
than liver transplantation or death.
 This study confirms earlier reports that rifaximin-α can reduce the number of 
HE- and liver-related hospitalisations and bed days.(10, 20) However, the finding 
that this treatment was associated with a significant reduction in intensive care unit 
hospitalizations or bed days, or A&E department visits could not be confirmed in the 
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present study.(10) Factors that could potentially explain these contrasting results may 
include differences in local treatment protocols, varying criteria for intensive care unit 
admissions and differences in study population characteristics, especially with respect 
to liver disease aetiology and severity.(10)
 We found no evidence for an effect of rifaximin-α treatment on the incidence of 
bacterial infections, neither in patients not receiving antibiotic treatment nor in patients 
using continuous antibiotic treatment for the prophylaxis of spontaneous bacterial 
peritonitis (SBP). Previous studies have shown that rifaximin-α is an effective antibiotic 
prophylaxis for spontaneous bacterial peritonitis (SBP).(21) This infection is the most 
common precipitating factor for overt HE.(22) Although there was a non-significant 
decrease in SBP in our population, the power of the data might not be sufficient to draw 
conclusions regarding bacterial infections.
 The safety profile of rifaximin-α was considered to be excellent with only 2.4% 
patients experiencing an adverse event of which none was considered to be serious. This 
is comparable to other observational cohort studies reporting adverse events in 4% of 
rifaximin-α users; however, these were mainly Clostridium difficile infections, an important 
clinical problem.(10, 23, 24)
 This is the first study evaluating the efficacy of rifaximin-α with a pre-post study design 
that did not select solely patients that were alive and without a liver transplantation at 6 
months. Approximately one-third of the patients dies or undergoes liver transplantation 
in the first 6 months after rifaximin-α initiation. Therefore, this study better reflects the 
efficacy of rifaximin-α in general practice. However, the pre-post observational study 
design has several limitations, as it is not possible to control all elements in the clinical 
course, such as the natural progression of the underlying liver disease or for instance a 
change in diuretic treatment. This is a general difficulty when evaluating the efficacy of 
treatment for overt HE, as the disease has often an episodic character and does not always 
present in the same severity. Therefore, hard endpoints as hospitalizations, bed days, and 
hospital visits were chosen.
 Future studies in overt HE management are necessary to individualize treatment 
strategy. For example, it has not been determined which factors influence rifaximin-α 
treatment success, the effectiveness of high dose rifaximin-α treatment as previous shown 
for acute HE, and in which patients treatment can be safely withdrawn.(25)
 In conclusion, this study found an association between a reduction in the number and 
length of HE and liver-related hospitalizations and the initiation of rifaximin-α treatment. 
The benefit of rifaximin-α on other types of hospital resources was less clear. Our data 
support the additional use of rifaximin-α in patients with recurrent overt HE already 
receiving standard (lactulose) treatment. No evidence was found for an adverse effect on 
the risk of bacterial infections and treatment was very well tolerated.
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SUMMARY AND DISCUSSION
The aim of this thesis was to study clinical, diagnostic and therapeutic aspects of 
frequent complications in patients with severely advanced liver disease, including 
spontaneous bacterial peritonitis, bacterascites, other infections, (ectopic) variceal 
bleeding, hepatic encephalopathy and malnutrition, with the general aim to evaluate 
current and new diagnostic and therapeutic strategies and with the ultimate aim to 
optimize patient management.
A general introduction to advanced chronic liver disease is presented in Chapter 1. The 
natural course, pathophysiology, frequent complications, and management are discussed.
The second part of this thesis – Ascites and infections – addresses general aspects of 
ascites, shows the results of studies evaluating etiological, diagnostic and therapeutic 
aspects of ascitic infections, and the clinical significance and impact of these and other 
infections in patients listed for liver transplantation.
 
Chapter 2 provides a review of the initial evaluation, differential diagnosis, and diagnostic 
approach of patients presenting with new-onset ascites. Measuring the serum ascites 
albumin gradient (SAAG) is the recommended initial diagnostic step when the cause of 
ascites is unknown. Additional ascitic biochemical, cytological and microbiologic testing, 
in particular determination of the polymorphonuclear white blood cell count, is usually 
indicated, but should take into account the clinical background, the results of other 
diagnostic studies and the likelihood of potential causes. This chapter also discusses a 
number of novel biomarkers in ascitic fluid such as bacterial DNA and proteins involved 
in the inflammatory response. Although some studies have found associations between 
bacterial translocation markers and inflammatory state or rate of complications, data 
on diagnostic accuracy and cost-effectiveness regarding this and other potential new 
biomarkers are yet insufficient or missing.(1-4)
Chapter 3. Reagent dipstick strips are widely used as a bedside tool to detect leukocyte 
esterase in urine for the diagnosis of urinary tract infection. This chapter presents the 
results of a prospective cross-sectional study evaluating the accuracy of leukocyte 
esterase reagent strips for diagnosing spontaneous bacterial peritonitis (SBP). In 157 
ascites samples of patients with cirrhosis, the diagnostic accuracy of the reagent strip 
was comparable to the gold standard test (manual polymorphonuclear neutrophil 
count) with regard to the negative predictive value and sensitivity. Therefore, the 
leukocyte esterase reagent strip was considered to be an excellent tool to exclude SBP. 
The reagent strips used in this study were not specifically designed for ascitic fluid 
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analysis indicating different cut-off levels for leukocyte concentration and possible 
interference of proteins present in ascites. More recently, a large French multicenter 
study has shown that a strip with specific characteristics for ascitic fluid analysis, the 
Periscreen strip, has a 100% sensitivity and negative predictive value in 803 ascitic fluid 
samples of outpatients.(5) Although data support the reagent strip as a valuable and 
cheap tool to exclude SBP in patients with a low pre-test probability (outpatients), the 
use of reagents strips is currently not included in international guidelines, probably 
mainly due to reported variability in diagnostic accuracy.(6-8)
In Chapter 4, changes in the causative pathogens of SBP in our center were assessed. In 
several countries changes in microbiology have been reported and attributed to long-
term widespread quinolone use and increased prevalence of hospital admissions.(9-14) 
These findings have raised doubts about the currently recommended prophylactic and 
therapeutic antibiotic strategy in SBP. In the current study, a comparison was made 
between the results of ascitic bacterial cultures in two cohorts of patients diagnosed with 
SBP in the years 2003–2005 and 2013–2014, respectively. We found a modest but non-
significant increase of Gram-positive bacteria and multidrug-antibiotic–resistant bacteria 
causing SBP, which differs from data reported in other geographical areas. We concluded 
that microbiology and susceptibility patterns’ differences can be region dependent and 
empiric antibiotic prophylaxis and treatment of SBP should be based on national or 
regional microbiological data. The latest European guideline emphasizes that antibiotic 
treatment for SBP should be guided by regional microbiological data, together with the 
mode of acquisition (community-acquired, healthcare-associated, or nosocomial), and 
the infection severity.(6)
The clinical characteristics, microbiological findings and prognosis of 123 patients 
with bacterascites are described and compared to patients with SBP in Chapter 5. It is 
remarkable that bacterascites has remained a relatively infrequently studied clinical 
entity. Bacterascites is a different clinical entity than SBP and defined by an ascitic fluid 
polymorphonuclear neutrophil count below 250/μL and a positive ascitic fluid culture.
(15) Bacterascites was more often caused by Gram-positive bacteria in comparison to SBP, 
however, patients with bacterascites and SBP were highly comparable with respect to 
severity of liver disease and mortality rate. Bacterascites was likely to persist or to evolve 
to SBP in a significant proportion of patients if left untreated. We found that discrimination 
between asymptomatic and symptomatic patients, as proposed in current guidelines, 
was not an optimal indicator to predict clinical outcome.(6, 7) Our results suggest that 
the threshold to initiate antibiotic treatment should be low, particularly in patients with 
severely advanced liver disease. Other recent studies have reported that the relative 
ascites PMN count (the absolute PMN count divided by the absolute leukocyte count) and 
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clinical characteristics, particularly presence of hepatocellular carcinoma and MELD-scores 
above 17, provide information with respect to the risk of progression of bacterascites to 
SBP.(16, 17) Future studies are urgently required to establish with more certainty clinical 
and/or biochemical markers enabling reliable identification of patients with bacterascites 
who may benefit from antibiotic treatment, in order to minimize antibiotic under- and 
overtreatment in this population.
Chapter 6 reports a cohort study evaluating the frequency of infections in 327 patients 
awaiting liver transplantation and assessing the impact of infections on clinical 
outcome. Infections occurred in 44% of patients. The results of our study indicate that 
infection is the leading cause for delisting from the liver transplantation waiting list, 
increasing the chance by 5.2 times to become delisted from the waiting list compared 
to non-infected patients. In particular patients with advanced age, severely advanced 
liver disease, or receiving inappropriate antibiotic therapy were susceptible for delisting 
due to infection. The results of this study underline the importance of appropriate and 
timely antimicrobial therapy once more in order to prevent and treat infections before 
patients lose their suitability for liver transplantation. Similarly, a multicenter North 
American consortium found that patients with infections are at a much higher risk to 
become delisted.(18) In addition, an association was found between delisting and the 
number and type of organ failures caused by the infection. These data support the 
importance to recognize acute-on-chronic liver failure, a relatively recent distinguished 
clinical identity, in which the type and number of organ failures is directly associated 
with an increased risk of short-term mortality.(6, 19)
The third part – Findings and implications of diagnostic assessments during liver 
transplantation screening – covers studies assessing the results and impact of colorectal 
cancer screening and nutritional evaluation during liver transplantation screening.
In Chapters 7 and 8, the results of colonoscopy during pre-liver transplantation 
screening in 808 patients were presented. The main finding of this study was that 
colorectal cancer (CRC) screening in this subpopulation was associated with a relatively 
low prevalence of colorectal cancer (0.2%) and advanced adenomas (5.4%). Patients 
had an increased post-procedural risk of complications, such as acute renal failure and 
gastrointestinal bleeding, especially patients with severely advanced liver disease. 
The indication for standard pre-liver transplantation screening colonoscopy may be 
questioned considering the balance between the yield and associated risks and costs, 
also taking important competing mortality risks, such as the substantial waiting list 
and perioperative mortality, into account. Alternative strategies for colorectal cancer 
screening should be considered. Future research projects regarding CRC screening in 
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transplant candidates could focus on the assessment of factors relevant for more refined 
risk stratification in this population. It may be equally important to prospectively assess 
the results of alternative CRC screening strategies.
Chapter 9 presents a study reporting the results from 102 patients during liver 
transplantation screening undergoing detailed nutritional assessment. Sarcopenia, 
characterized by a reduction in muscle mass and function, is a major component 
of malnutrition and is associated with a higher rate of complications and mortality. 
Identification of nutrition-related disorders can be beneficial in order to be able to optimize 
patient condition before liver transplantation.(20-24) Our study confirms that two-thirds 
of patients had muscle mass depletion and/or impaired muscle function. The clinical 
screening tool, as proposed in a recent international guideline, had a poor efficacy in 
discriminating patient with low or high risk on malnutrition in this subpopulation.(25) 
Until there is a discriminative parameter identifying, which patients should undergo 
detailed nutritional assessment, we propose all patients screened for liver transplantation 
should be screened for malnutrition with a detailed nutritional assessment. Furthermore, 
data of this study suggests that impaired muscle function might be clinically more relevant 
than muscle mass depletion. This is in line with several other studies indicating that 
impaired muscle function has a stronger correlation with clinical outcome in advanced 
liver disease than muscle mass or volume.(26, 27) Consequently, for prognostication 
measuring muscle function, such as with the simple handgrip strength test, seems more 
relevant than CT-based muscle volumetry.
 Future prospective studies in this population are necessary to investigate whether 
reversibility of impaired muscle function and muscle mass depletion is possible, which 
nutritional and exercise programs are effective, and whether this subsequently positively 
influences clinical outcome. In addition, although oncologic and geriatric studies found 
sarcopenia is a measure of frailty (i.e. the physiological condition to have a reduced 
capacity to withstand environmental stresses), knowledge of the exact pathophysiologic 
mediators of this reduced capacity and worse clinical outcome is missing.(27-29)
In the fourth part – Treatment evaluation of ectopic variceal bleeding and hepatic 
encephalopathy – of this thesis, the efficacy of treatment strategies for ectopic variceal 
bleeding and hepatic encephalopathy were assessed.
Chapter 10 includes a multicenter retrospective cohort study evaluating the long-term 
control of bleeding in 53 patients with ectopic variceal bleeding using transjugular 
intrahepatic port-systemic shunt (TIPSS). We found that TIPSS provides long-term control 
of bleeding in the majority of patients with ectopic variceal bleeding with a rebleeding 
rate of 23% at 1 year, 26% at 3 years and 32% at 5 years. The efficacy of shunt placement 
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to avoid rebleeding seemed to differ for the location of the bleeding ectopic varices. 
Patients with stomal variceal bleeding had a 95% success rate, but patients with duodenal 
variceal bleeding a 50% success rate. A potential explanatory factor may be that local, 
but ultimately unsuccessful endoscopic therapies, in particular repeated tissue glue 
injections, may lead to significant duodenal ulcerations that can be the cause of repeated 
bleeding in their own right. Further studies in duodenal variceal bleeding are required 
to further address the timing of TIPSS and whether alternative therapeutic approaches 
might be a more preferable strategy. The efficacy of TIPSS has to be balanced against the 
risk of serious side effects, in particular hepatic encephalopathy, manifesting or worsening 
in 30% of our patients, which was comparable with other reported experience.(30-33) 
We found a non-significant trend towards a beneficial effect of variceal embolization in 
addition to TIPSS. This was in line with the results of a recent meta-analysis that showed 
concomitant embolization did not significantly improve the probability of remaining free 
of rebleeding or survival.(34)
In Chapter 11, the addition of rifaximin to lactulose treatment in the secondary prevention 
of hepatic encephalopathy was evaluated in 127 patients in a pre-post study design. In the 
six months following initiation of rifaximin, patients had a significantly lower number of 
hospitalizations for hepatic encephalopathy and a reduced length of admission, compared 
with the preceding six months. This study confirms results from earlier reports, however, 
we did not find a significant reduction in intensive care unit hospitalizations or emergency 
room department visits.(35, 36) Previous studies have shown that rifaximin is an effective 
antibiotic prophylaxis for SBP.(37, 38) Although there was a non-significant decrease in SBP 
in our population, the power of the data was not sufficient to draw conclusions regarding 
bacterial infections. Lastly, we found the safety profile of rifaximin to be excellent with a low 
number of reported adverse events. Future studies in hepatic encephalopathy management 
are necessary to individualize treatment strategy. For example, it has not been determined 
which factors influence rifaximin treatment success, the effectiveness of off-label high dose 
rifaximin treatment, and in which patients treatment can be safely withdrawn.(39)
General conclusion
This thesis focuses on various deleterious complications of chronic advanced liver disease. 
The vulnerability of the patient with chronic advanced liver disease is reflected by the 
significant risk of developing (further) complications and death. Not only the disease 
itself, but also the implications of diagnostic and therapeutic interventions can potentially 
be harmful for the patient, such as colorectal cancer screening in patients with advanced 
chronic liver disease or TIPSS in the management of ectopic variceal bleeding. Furthermore, 
the landscape in which the patient presents is dynamic: microbiologic patterns change, 
antibiotic resistance emerges, and biotechnology and laboratory research advances.
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 Our understanding of the complex problems and many threats encountered in patients 
with advanced chronic liver disease gradually deepens. Complications may involve any 
organ system, may occur consecutively or simultaneously and are often clearly related, 
such as variceal bleeding and renal failure complicating infections and encephalopathy 
and ascites following gastrointestinal bleeding. Current evidence suggests that addressing 
or strongly focus on individual complications, for instance prophylaxis of variceal 
bleeding or detection and early treatment of hepatocellular carcinoma, is unlikely to have 
a major effect on overall prognosis. Therefore, a multi-focussed approach is essential. 
However, much uncertainty exists with respect to the potential impact of certain specific 
interventions. For instance, whether (early) detection and attempts to treat malnutrition 
will ultimately influence prognosis is unclear. Also, much has to be learned about the 
potential importance of complications, such as variceal bleeding, SBP or malnutrition, in 
risk stratification. In this thesis, the importance of mainly individual patient strategies is 
considered, such as the approach to a patient with ectopic variceal bleeding from the 
duodenum versus bleeding originating from stomal varices, or the antibiotic strategy in 
bacterascites as compared to SBP.
 Taken together, the results of the presented studies shed light on certain aspects in the 
complex management of patients with advanced chronic liver disease, and will hopefully 
contribute to improve outcome in this population at high risk for fatal and non-fatal 
complications.
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SAMENVATTING EN DISCUSSIE
Dit proefschrift is gewijd aan klinische, diagnostische en therapeutische aspecten van 
veel voorkomende complicaties bij patiënten met gedecompenseerde levercirrose, 
waaronder infecties, met name spontane bacteriële peritonitis (SBP) en bacterascites, 
(ectopische) varicesbloedingen, hepatische encefalopathie en ondervoeding. Het doel 
van de opgenomen studies was om huidige en nieuwe diagnostische en therapeutische 
strategieën te evalueren teneinde de patiëntenzorg te optimaliseren.
Hoofdstuk 1 geeft een algemene inleiding tot gedecompenseerde levercirrose. 
De pathofysiologie en het natuurlijk beloop, veel voorkomende complicaties en de 
behandeling van deze ziekte worden geïntroduceerd en toegelicht.
Het tweede deel van het proefschrift – Ascites en infecties – betreft studies naar 
etiologische, diagnostische en therapeutische facetten van ascites, met de nadruk op 
infecties in ascites (bacterascites en spontane bacteriële peritonitis) en de klinische 
impact van het infecties bij patiënten op de levertransplantatie wachtlijst.
Hoofdstuk 2 bevat een literatuur synopsis van de initiële evaluatie, differentiaal diagnose 
en de diagnostische benadering van patiënten met ascites. Het meten en berekenen 
van de serum ascites albumine gradiënt (SAAG) is de eerste aanbevolen diagnostische 
stap wanneer de oorzaak van ascites onduidelijk is. Additionele biochemische, 
cytologische en microbiologische analyses van ascites, met name het bepalen van het 
aantal polymorfonucleaire leukocyten (PMN’s), is vaak geïndiceerd, maar moet worden 
afgewogen tegen de klinische achtergrond, zoals de resultaten van andere diagnostiek 
en de waarschijnlijkheid van de mogelijke oorzaken. In dit hoofdstuk worden nieuwe 
biomarkers in ascites besproken, zoals de detectie van bacterieel DNA en eiwitten 
betrokken bij de inflammatoire respons. Hoewel sommige studies een verband hebben 
gevonden tussen deze markers van bacteriële translocatie en inflammatie of het 
aantal complicaties, zijn er onvoldoende data over de diagnostische accuratesse en 
kosteneffectiviteit van deze biomarkers.(1-4)
Hoofdstuk 3. Teststroken, ook wel dipsticks of teststrips genoemd, worden in de 
alledaagse medische praktijk gebruikt als eenvoudig screenend onderzoek van urine 
voor het diagnosticeren van een urineweginfectie middels de detectie van onder andere 
leukocyten esterase. Dit hoofdstuk toont de resultaten van een prospectieve cross-
sectionele studie naar de diagnostische accuratesse van teststroken in ascites voor het 
diagnosticeren van spontane bacteriële peritonitis (SBP). De diagnostische accuratesse 
van de teststroken was vergelijkbaar met de gouden standaard (handmatige PMN telling) 
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met betrekking tot de negatief voorspellende waarde en sensitiviteit, gemeten in 157 
ascites monsters van patiënten met levercirrose. Derhalve werd de teststrook geacht een 
excellent middel te zijn om SBP te excluderen. De teststrip in deze studie is ontworpen 
voor urine en niet specifiek voor het gebruik in ascites. Het toont andere afkapwaarden 
voor leukocyten concentraties dan gebruikelijk zijn voor de diagnose SBP en mogelijk 
interfereren eiwitten in ascites met de test. Onlangs heeft een groot Frans multicenter 
onderzoek aangetoond dat de Periscreen strip, een teststrook specifiek ontworpen voor 
analyse van ascites, een 100% sensitiviteit en negatief voorspellende waarde had in 803 
ascites monsters van poliklinische patiënten.(5) Alhoewel data tonen dat teststroken 
een waardevol en goedkoop hulpmiddel zijn om SBP te excluderen in patiënten met een 
lage pre-test waarschijnlijkheid van ziekte (poliklinische patiënten), is het gebruik van 
teststroken niet geïncludeerd in internationale richtlijnen, waarschijnlijk door de hoge 
variëteit in diagnostische accuratesse.(6-8)
In Hoofdstuk 4 wordt onze studie weergegeven die erop gericht was na te gaan in 
hoeverre in ons centrum de aard van de micro-organismen, die ten grondslag ligt aan 
SBP, in de loop van de tijd is veranderd. In verschillende landen zijn er verschuivingen in 
type SBP-ziekteverwekkers gerapporteerd en dit verschijnsel wordt toegeschreven aan 
het langdurig en wijdverspreid gebruik van (fluoro)quinolone antibiotica en een toename 
van ziekenhuisopnames.(9-14) Deze bevindingen doen de vraag rijzen of het huidige 
aanbevolen profylactische en therapeutische antibiotische beleid voor SBP accuraat is. In 
de beschreven studie werd een vergelijking gemaakt tussen de microbiologische resultaten 
van asciteskweken in patiënten met SBP in de jaren 2003–2005 en 2013–2014. Er werd 
een milde niet-significante toename van Gram-positieve en multiresistente bacteriën die 
SBP veroorzaakten waargenomen, een bevinding die verschilt van andere geografische 
gebieden. We concludeerden dat microbiologische en antibioticumresistentie patronen 
tussen regio’s kunnen verschillen en empirisch antibiotisch beleid voor SBP gebaseerd 
moet zijn op nationale of regionale microbiologische data. De laatst gepubliceerde 
Europese richtlijn benadrukt dat de keuze van antibiotische behandeling van SBP 
gefundeerd moet zijn op regionale microbiologische data, samengaand met waar de 
infectie is verworven (gemeenschap of ziekenhuis) en de ernst van de infectie.(6)
De klinische kenmerken, microbiologische bevindingen en de prognose van 123 
patiënten met bacterascites werden in Hoofdstuk 5 beschreven en vergeleken met 
patiënten met SBP. Het is opmerkelijk dat bacterascites een relatief weinig bestudeerd 
ziektebeeld is gebleven. Bacterascites is anders dan SBP en wordt gekenmerkt door een 
laag aantal PMN’s (<250/μL) in ascites, maar een positieve asciteskweek.(15) Bacterascites 
werd vaker veroorzaakt door Gram-positieve bacteriën vergeleken met SBP, maar 
patiënten met bacterascites en SBP waren zeer vergelijkbaar met betrekking tot de ernst 
van de cirrose en het mortaliteitsrisico. Bacterascites bleef voortbestaan of ontwikkelde 
Chapter 13
212
zich vaak tot SBP wanneer er geen antibiotische behandeling werd ingesteld. We 
vonden dat het discrimineren tussen patiënten met en zonder symptomen, zoals in 
de huidige internationale richtlijn staat beschreven, geen optimale indicator is om de 
klinische uitkomst te voorspellen.(6, 7) Onze resultaten suggereren dat de drempel om 
antibiotische behandeling te starten laag zou moeten zijn, zeker bij patiënten met ernstige 
gedecompenseerde cirrose. Andere recente studies rapporteerden dat het relatieve PMN 
aantal in ascites (het totale PMN aantal gedeeld door het totale leukocyten aantal) en 
klinische kenmerken, waaronder de aanwezigheid van levercelkanker en een MELD-score 
boven de 17, goede voorspellers waren voor de progressie van bacterascites naar SBP.(16, 
17) Toekomstige studies naar klinische en/of biochemische voorspellende kenmerken 
voor patiënten met bacterascites die baat hebben bij antibiotische behandeling zijn hard 
nodig, met als doel om antibiotische onder- of overbehandeling te minimaliseren.
Hoofdstuk 6 bevat een studie naar het optreden van infecties bij 327 patiënten op de 
levertransplantatiewachtlijst en de impact van de infecties op het klinisch beloop. Infecties 
deden zich voor in 44% van deze patiënten. De resultaten van onze studie lieten zien 
dat infecties de meest voorkomende oorzaak waren van uitval op de levertransplantatie 
wachtlijst. Het relatief risico op uitval van de wachtlijst nam toe met een factor 5.2 ten 
opzichte van patiënten zonder een infectie. Met name patiënten met een hogere leeftijd, 
ernstige cirrose, of patiënten die empirisch antibiotica ontvingen waar de verwekker van de 
infectie niet gevoelig voor was, liepen risico op uitval van de levertransplantatie wachtlijst 
door infectie. De resultaten van deze studie benadrukken het belang van tijdige en 
geschikte antibiotische behandeling om infectie te voorkomen en te behandelen, voordat 
patiënten hun geschiktheid om een levertransplantaat te ontvangen verliezen. Een Noord-
Amerikaanse multicenter studie vond dezelfde associatie dat patiënten met infecties een 
groter risico liepen om uit te vallen van de levertransplantatie wachtlijst.(18) Tevens werd 
er een associatie gevonden tussen uitval van de levertransplantatie wachtlijst en het aantal 
en type orgaanfalen veroorzaakt door de infectie. Deze data ondersteunen het belang om 
acuut op chronisch leverfalen te herkennen, een relatief nieuwe ziekte entiteit, waarbij het 
aantal en type orgaanfalen direct geassocieerd zijn met het mortaliteitrisico.(6, 19)
Het derde deel van het proefschrift – Bevindingen en implicaties van diagnostische 
onderzoeken tijdens screening voor levertransplantatie – bevat studies met resultaten 
van de darmkankerscreening en de evaluatie van de voedingsstatus ter beoordeling van 
de geschiktheid voor het ontvangen van een levertransplantaat.
In Hoofdstuk 7 en 8, worden de resultaten en complicaties van protocollaire colonoscopie 
in het kader van levertransplantatie screening gepresenteerd. De belangrijkste bevinding 
van deze studie, waarin 808 patiënten waren opgenomen,  was dat darmkankerscreening 
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in deze subpopulatie een relatief lage prevalentie van darmkanker (0.2%) en advanced 
adenomen (5.4%) toonde. Patiënten hadden na colonoscopie een groter risico op 
complicaties, zoals acute nierinsufficiëntie en gastro-intestinale bloedingen, met name 
patiënten met ernstige cirrose. De indicatie voor het standaard uitvoeren van een 
colonoscopie tijdens levertransplantatie screening is daarom betwistbaar, in ogenschouw 
nemende de opbrengst en de geassocieerde risico’s en kosten. Alternatieve strategieën 
voor darmkankerscreening moeten worden overwogen. Toekomstige studies betreffende 
darmkankerscreening bij levertransplantatiekandidaten zijn gewenst en zouden zich 
moeten richten op het identificeren van factoren op grond waarvan een betrouwbare 
risicostratificatie in deze populatie mogelijk is. Tevens is het minstens zo belangrijk om 
prospectief alternatieve darmkankerscreening strategieën te evalueren.
In Hoofdstuk 9 zijn de resultaten van een gedetailleerde voedingsevaluatie opgetekend 
die verricht werd bij 102 patiënten tijdens protocollaire evaluatie voor levertransplantatie. 
Sarcopenie, gekenmerkt door een reductie in spiermassa en –functie, is een belangrijke 
component van ondervoeding en wordt geassocieerd met een toename van complicaties 
en mortaliteit. Het identificeren van voedingsgerelateerde ziekte kan bevorderlijk zijn om 
de conditie van de patiënt te verbeteren voordat zij een levertransplantatie ondergaan.(20-
24) Onze studie toonde dat twee derde van de patiënten een verminderde spiermassa en/
of –functie had. Het screenende algoritme, zoals recent voorgesteld in een internationale 
richtlijn, was weinig efficiënt voor het identificeren van patiënten met een laag of hoog 
risico op ondervoeding in onze populatie.(25) Totdat er een efficiënter algoritme is 
gevonden, stellen wij voor om bij alle levertransplantatie kandidaten een gedetailleerde 
voedingsevaluatie te verrichten. Onze studie toont tevens dat spierfunctie een klinisch 
meer relevante voorspellende parameter is dan spiermassa. Ook andere studies vonden 
dat een verminderde spierkracht een sterkere correlatie had met klinische uitkomsten van 
gedecompenseerde cirrose dan spiermassa of –volume.(26, 27) Derhalve lijkt het meten 
van spierfunctie, bijvoorbeeld met de handgriptest, relevanter voor het voorspellen van 
het klinisch beloop dan spiervolumetrie middels CT. Toekomstige prospectieve studies zijn 
noodzakelijk om vast te stellen of een verminderde spierfunctie/-massa reversibel is, welke 
voedings- en oefentherapieën efficiënt zijn, en of reversibiliteit ook de klinische uitkomst 
positief kan beïnvloeden. Alhoewel er binnen de oncologie en geriatrie overeenstemming 
is bereikt dat sarcopenie een maatstaf is voor ‘frailty’ (i.e. de fysiologische conditie van een 
verminderde capaciteit om zich stand te houden bij stressoren uit de omgeving), is er 
vraag naar kennis over de exacte pathofysiologische mediatoren van deze verminderde 
capaciteit en slechtere klinische uitkomsten.(27-29)
In het vierde deel van dit proefschrift – De evaluatie van de behandeling naar 
ectopische varicesbloedingen en hepatische encefalopathie – wordt de effectiviteit 
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van enkele behandelstrategieën bij deze ziektebeelden geëvalueerd.
Hoofdstuk 10 bevat een multicenter retrospectieve cohortstudie naar het beloop 
van 53 patiënten met ectopische varicesbloedingen die behandeld werden met 
een transjugulaire intrahepatische portosytemische shunt (TIPSS). TIPSS was in het 
merendeel van de patiënten met ectopische varicesbloedingen langdurig succesvol in 
het voorkomen van bloedingen met een recidief risico van 23% na 1 jaar, 26% na 3 jaar 
en 32% na 5 jaar. De effectiviteit van TIPSS leek afhankelijk van de aard van de ectopische 
varicesbloeding. Bij patiënten met stomabloedingen trad in slechts 5% van de gevallen 
een recidief bloeding op tegen 50% bij patiënten met duodenum varicesbloedingen. 
Een potentiele verklaring hiervoor is dat plaatselijke endoscopische therapieën, die op 
lange termijn onsuccesvol blijken te zijn, bijvoorbeeld recidiverende cyano-acrylaatlijm 
injecties, kunnen leiden tot significante duodenale ulcera, welke zelf opnieuw een 
bloeding kunnen veroorzaken. Verdere studies naar duodenale varicesbloedingen zijn 
nodig om de timing van TIPSS behandeling te onderzoeken en na te gaan of andere 
behandelstrategieën de voorkeur verdienen. De effectiviteit van TIPSS moet worden 
afgewogen tegen de serieuze bijwerkingen van de behandeling, met name hepatische 
encefalopathie, welke zich klinisch manifesteerde of verergerde bij 30% van de patiënten. 
Dit percentage is vergelijkbaar met ervaringen van andere studies.(30-33) Als laatste 
werd er een gunstige, maar niet statistisch significante, trend waargenomen wanneer 
de varices gelijktijdig werden geëmboliseerd. Dit resultaat komt overeen met een recent 
gepubliceerde meta-analyse welke aantoonde dat gelijktijdige varicesembolisatie 
geen significante meerwaarde had bij het voorkomen van nieuwe bloedingen of het 
verbeteren van de overleving.(34)
In Hoofdstuk 11 zijn de resultaten van een studie weergegeven betreffende karakteristieken 
en beloop van 127 patiënten met hepatische encefalopathie die naast lactulose behandeld 
werden met rifaximine. In de zes maanden na start van rifaximine hadden patiënten 
een significant lager aantal opnames voor hepatische encefalopathie en een kortere 
opnameduur, vergeleken met de zes maanden voorafgaand aan de start met rifaximine. Deze 
studie bevestigt de bevindingen van eerdere studies, echter vonden we geen significante 
daling van intensive care opnames of spoedeisende hulp presentaties.(35, 36) Eerdere 
studies hebben aangetoond dat rifaximine een effectief antibioticum is als SBP profylaxe.
(37, 38) Alhoewel er een niet-significante vermindering was van SBP in onze populatie, had 
onze studie te weinig power om hier betrouwbare uitspraken over te doen. Ten slotte had 
rifaximine een goed veiligheidsprofiel met een laag aantal gerapporteerde bijwerkingen. 
Toekomstige studies bij patiënten met hepatische encefalopathie zijn noodzakelijk om 
de behandeling te kunnen individualiseren. Het is tot op heden niet duidelijk door welke 
factoren de behandeling met rifaximine succesvol is, wat de effectiviteit van rifaximine in 
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hogere doseringen is en bij welke patiënten veilig gestopt kan worden met rifaximine.(39)
Algemene conclusie
Dit proefschrift is gewijd aan verschillende complicaties van gedecompenseerde 
levercirrose. De kwetsbaarheid van de patiënt met gedecompenseerde cirrose ziet 
men gereflecteerd in het significante risico om verdere complicaties te ontwikkelen 
of te overlijden. Niet alleen de ziekte zelf, maar ook invasieve diagnostische en 
therapeutische interventies kunnen potentieel schadelijk zijn voor de patiënt, 
bijvoorbeeld darmkankerscreening bij levertransplantatie kandidaten of TIPSS voor 
de behandeling van ectopische varicesbloedingen. Daarnaast bevindt de patiënt met 
gedecompenseerde levercirrose zich in een dynamisch landschap: microbiologische 
patronen veranderen, antibiotica resistentie is wereldwijd een toenemend probleem en 
nieuwe biotechnologische ontwikkelingen vragen om evaluatie en validatie.
 Ons begrip van de complexe problematiek en de vele bedreigingen die patiënten met 
gedecompenseerde levercirrose treffen wordt geleidelijk groter. Complicaties kunnen 
zich voordoen in elk orgaan, opeenvolgend of tegelijkertijd, en zijn vaak evident aan 
elkaar gerelateerd, zoals varicesbloedingen en acute nierinsufficiëntie tijdens een infectie 
of hepatische encefalopathie en ascites na een gastro-intestinale bloeding. Huidig 
wetenschappelijk bewijs suggereert dat de behandeling van individuele complicaties, 
bijvoorbeeld profylaxe van varicesbloedingen, zeer waarschijnlijk geen groot effect 
heeft op de algehele prognose. Derhalve is een multifactoriële benadering essentieel. 
Echter, of (vroege) detectie en pogingen om bijvoorbeeld ondervoeding te behandelen 
uiteindelijk de prognose beïnvloeden is onduidelijk. Verdere studies zijn noodzakelijk 
om tot een betere risicostratificatie te komen, zoals bij patiënten met bacterascites of ten 
aanzien van invasieve procedures als screenings colonoscopie bij kandidaat patiënten 
voor levertransplantatie. 
 De resultaten van de gepresenteerde studies hebben licht geworpen op enkele 
aspecten van de complexe behandeling van patiënten met gedecompenseerde 
levercirrose, en zullen hopelijk bijdragen aan het verbeteren van de klinische uitkomst in 
deze populatie die bedreigd wordt door multipele fatale en niet-fatale complicaties.
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ABBREVIATIONS
A&E accident and emergency
AASLD American association for the study of the liver
ADA adenosine deaminase activity 
AFP α-fetoprotein
ALAT alanine transaminase
ASAT aspartate transaminase
BIA bioelectrical impedance analysis
BMI body mass index
BRTO balloon-occluded retrograde-transvenous-obliteration
CA-125 cancer antigen 125
CA19-9 cancer antigen 19-9
CDC centers for disease control
CEA carcinoembryonic antigen
CI confidence interval
CP Child-Pugh
CRC colorectal cancer
CRP C-reactive protein
CT computed tomography
CVVH continuous veno-venous hemofiltration 
DNA deoxyribonucleic acid
EASL European association for the study of the liver
EctVB ectopic variceal bleeding
e-PTFE expanded polytetrafluoroethylene
ESBL extended-spectrum beta-lactamase
ESPEN European society of clinical nutrition and metabolism
FIT fecal immunochemical test
FOBT fecal occult blood test
Gamma-GT gamma-glutamyl transferase
GI gastrointestinal
Hb hemoglobin
HCC hepatocellular carcinoma
HE hepatic encephalopathy
HIV human immunodeficiency virus
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A
HR hazard ratio
IBD inflammatory bowel disease
ICU intensive care unit
INR international normalized ratio
IQR interquartile range
LT liver transplantation
MARS molecular adsorbent recirculating system
MDR multidrug-antibiotic–resistant
MELD model for end-stage liver disease
MELDNa model for end-stage liver disease including sodium
MRSA methicillin-resistant Staphylococcus aureus
NASH non-alcoholic steatohepatitis
NSBB non-selective beta-blocker
OPTN organ procurement and transplantation network
OR odds ratio
PBC primary biliary cholangitis
PCR polymerase chain reaction
PEG polyethylene electrolyte glycol
PMN polymorphonuclear neutrophil
PPI proton-pump inhibitor
PSC primary sclerosing cholangitis
PSG portosystemic gradient
ROC receiver operating characteristic
SBP spontaneous bacterial peritonitis
SSA/P sessile serrated adenoma/polyp
TIPS/TIPSS transjugular intrahepatic portosystemic shunt placement
SAAG serum-ascites albumin gradient
SD standard deviation
TSA traditional serrated adenoma
US ultrasound
VEGF vascular endothelial growth factor
VRE vancomycin-resistant Enterococci
WBC white blood cell
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PhD student: Rosalie Christine Oey
PhD period: 2015 – 2020
Department: Gastroenterology & Hepatology, Erasmus MC
Supervisors: dr. H.R. van Buuren and prof. dr. R.A. de Man
PhD Training Year
Workload 
(hours)
Courses
Introduction to data-analysis (NIHES) 2015 28
Introduction to SPSS (MolMed) 2015 28
Workshop EndNote (Eramus MC) 2015 6
Good clinical practice – ‘BROK’ (NFU) 2015 42
Survival Analysis Course (MolMed) 2015 17
Weekly research group meeting ‘Journal Club’ 2015-2018 60
Biomedical Writing Course (MolMed) 2016 56
Indesign CS6 Workshop (MolMed) 2016 6
Writing Grant Proposals Workshop (MolMed) 2016 14
Scientific Integrity course (Erasmus MC) 2017 8
Attendance at conferences and seminars
Digestive Disease Days (NVGE/NVH) 2015-2019 72
International Liver Congress (EASL) 2016-2019 80
Diner pensant hepatologie 2015-2019 24
Erasmus Liver day 2015-2019 32
Liver meeting (AASLD) 2016 28
Transplantation Congress (NTV-BTS) 2018 8
Digestive Disease Week (AGA) 2018 20
Lagerhuisdebat hepatologie 2018 4
Presentations
Changes in microbiological flora causing spontaneous 
bacterial  (poster) – International Liver Congress EASL.
2016 12
Bacterascites is associated with poor clinical outcome in 
decompensated cirrhosis (oral) – Digestive Disease Days.
2016 36
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APhD Training Year
Workload 
(hours)
Bacterascites is associated with poor clinical outcome 
in decompensated cirrhosis (poster) –  Annual meeting 
AASLD.
2016 12
Infection with a multi-drug resistant organism is 
associated with increased mortality in patients listed for 
liver transplantation (poster) –  Annual meeting AASLD.
2016 12
Bacterascites, is it spontaneous bacterial peritonitis? (oral) 
– Diner pensant hepatologie.
2016 24
Ectopische varicesbloedingen (oral) – Diner pensant 
hepatologie.
2017 36
New Insights to Hepatic Encephalopathy (oral)– 
Onderwijsavond MDL Erasmus MC.
2017 36
Get involved in education (oral) – PhD day MDL. 2017 36
Risks and benefits of colonoscopy in pre-liver 
transplantation screening (oral) – Transplantation 
Congress NTV-BTS.
2018 36
The efficacy and clinical outcome of transjugular 
intrahepatic portosystemic shunts in the management 
of ectopic variceal bleeding: a multicenter retrospective 
study (poster) – International Liver Congress EASL.
2018 12
Risks and benefits of colonoscopy in pre-liver 
transplantation screening (oral) - Digestive Disease Week.
2018 36
Yield and safety of colonoscopy in patients evaluated for 
liver transplantation (oral) - Digestive Disease Days.
2018 24
The efficacy and safety of rifaximin: a 2-year observational 
study of overt hepatic encephalopathy (poster) – 
International Liver Congress EASL.
2019 12
The efficacy and safety of rifaximin: a 2-year observational 
study of overt hepatic encephalopathy (oral) – Digestive 
Disease Days.
2019 36
Ectopic varices in patients with portal hypertension (oral) 
– Erasmus Liver Day.
2019 36
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PhD Training Year Workload(hours)
Teaching
Tutor first year Bachelor student group 2016-2017 84
Coach Bachelor students 2016-2018 56
Supervising part-time science project David de Jong 2016 56
Supervising masterthesis of Pim Aarts 2017 112
Supervising masterthesis of Laurèlle van Tilburg 2017 112
Supervising part-time science project of Tugce Atalik 2017 56
Supervising masterthesis of Lennart Buck 2018 112
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